curriculum vitae: brooke l. fridley page | 1 · curriculum vitae: brooke l. fridley page | 1 . ......

Curriculum vitae: Brooke L. Fridley P a g e | 1

UNIVERSITY OF KANSAS SCHOOL OF MEDICINE Faculty Curriculum Vitae

Date: August 24, 2015

I. PERSONAL DATA: 1. Applicant Information:

First Name: Brooke Middle Initial: L. Last Name: Fridley Suffix: Degree(s): B.S., M.S., Ph.D. Current Academic Rank: Associate Professor Primary Department: Department of Biostatistics Secondary Department: Office Address: 5032B Robinson, 3901 Rainbow Blvd., Mailstop 1026 Phone: 913-945-5039 Fax: 913-588-2052 Email: [email protected]

2. Professional Development:

UNDERGRADUTE AND GRADUDATE EDUCTION:

Year Degree Institution 1997 B.S., Mathematics Truman State University 2000 M.S., Statistics Iowa State University 2003 Ph.D., Statistics Iowa State University

POST-GRADUATE EDUCTION:

Year Degree Institution 1999 Summer Internship in Biostatistics Quintiles

2001, 2002, 2005 Summer Internship in Biostatistics Mayo Clinic 2006 Statistical Genetics Short Course UCLA

2006 Advance Gene Mapping Course Max Delbrück Center (MDC), Berlin, Germany

ACADEMIC AND PROFESSOIONAL APPOINTMENTS AND ACTIVITIES:

Year Position Institution

2012 - Present Director, Biostatistics and Informatics Shared Resource University of Kansas Cancer Center

2012 - Present Site Director, K-INBRE Bioinformatics Core University of Kansas Medical Center

2012 - Present Associate Professor of Biostatistics, College of Medicine

University of Kansas Medical Center

2010-2012 Associate Professor of Biostatistics Mayo Clinic

University of Kansas School of Medicine Promotion and Tenure Curriculum Vitae


Year Position Institution

2008-2012 Associate Consultant, Department of Health Sciences Research Mayo Clinic

2006-2010 Assistant Professor of Biostatistics, College of Medicine Mayo Clinic

2006-2008 Research Associate, Department of Health Sciences Research Mayo Clinic

2003-2006 Assistant Professor, Department of Mathematics University of Wisconsin – La Crosse

2002-2003 Statistical Consultant, College of Family and Consumer Sciences Iowa State University

1998-2002 Instructor, Department of Statistics Iowa State University 1998 Lab Instructor, Department of Statistics Iowa State University

PROFESSIONAL SOCIETIES AND AFFILIATIONS:

Year Organization

2008 - Present American Association for Cancer Research (AACR) 2008 - Present American Society of Human Genetics (ASHG) 2006 - Present 2007 - 2010

American Statistical Association (ASA) Publication Officer, Graphics Section

2005 - 2007 Council on Undergraduate Research 2006 - Present International Biometrics Society, Eastern North American Region (ENAR) 2006 - Present 2011 - 2013

2012 2013

International Genetic Epidemiology Society (IGES) Program Committee Member Chair of the Program Committee Nominated for the Board of Directors

2011 Statistical, Computational and Visualization Methods in Medical Informatics Conference Program Committee

HONORS AND AWARDS:

Year Award 1993 - 1997 President’s Combined Ability Scholarship, Truman State University

1997 Magna Cum Laude, Truman State University 1999 Vera David Graduate Fellowship, Department of Statistics, Iowa State University 1999 Teaching Excellence Award, Iowa State University

2000 - 2001 Rebecca Klemm Fellowship, Department of Statistics, Iowa State University 2000 - 2001 Holly & Beth Fryer Fellowship, Department of Statistics, Iowa State University 2001 - 2003 NSF VIGRE Fellowship, Department of Statistics, Iowa State University

2007 Nominee for the Health Sciences Research Educator of the Year, Mayo Clinic 2008 – 2012 Schulze Stewardship Scholar, The Richard M. Schulze Family Foundation, Mayo Clinic

2009 Highly rated paper at 100th Annual American Association for Cancer Research Meeting

2014 Invited by the National Academy of Sciences to attend Kavli Frontiers of Science symposium (meeting by invitation only for 80-100 leading researchers less than 45 yrs).



II. TEACHING ACTIVITIES:

I have received consistently high teaching evaluations over the course of my teaching career. I have been awarded or nominated for two teaching excellent awards and have advised/mentored more than 30 students (undergraduates, graduates, post-graduates). Excluding independent studies, over the last 17 years, I have taught 99 credit hours involving 31 classes/sections of statistics/biostatistics courses at both the undergraduate and graduate level. In addition to college credit related courses, I have also developed statistical genomic eduational materials and taught multiple hour-long to multiple-day long workshops involving faculty, staff, research fellows (post-docs) and students. Please see addition document summarizing the evaluations (student and peer) and student comments. Below is one example from an email a student sent to Dr. Isaacson (chair of the statistics department at Iowa State University): “Dr. Isaacson:

I would just like to take a second of your time to tell you how much I appreciated the teaching style of Brooke Fridley. I can safely say that this was one of the most well taught class that I have ever taken at Iowa State University. Brooke brought enthusiasm and a commanding knowledge of the subject to each and every class. I would be unable to say one negative thing about the way Brooke taught this class. I only wish all my classes could be as good as Stat 101”.

Philosophy of Teaching: My teaching style is focused on incorporating numerous teaching modes into the education of students. As students learn in different ways, with some being visual and others being more verbal, I believe that meeting the learning needs of the students is essential. I also firmly believe that the use of real data examples to motivate statistical ideas and problem-solving skills, along with hands–on computing assignments with real data and group learning activities. Use of group learning activities, such as group projects, enable students to learn to communicate and work within a team structure to complete a task/assignment; a skill that will be invaluable to them in their future careers in the workforce. As a mentor for future statisticians, biostatisticians and bioinformatics researchers, I feel that it is very important that PhD students and post-doctoral research fellows get exposure and additional experience in both collaborative and (statistical) methodological research. This will allow them to see how two types of research (e.g., cancer genomics and statistical genomics) can co-exist synergistically, where interesting problems encountered in the collaborative research project can lead to computational/statistical research projects, which in turn could be used in the collaborative project. A clear example of this was in the development of method and R package PurBayes, which was published in Bioinformatics (2013). I was leading the bioinformatics and statistical analysis team for a large sequencing study involving DNA and RNA extracted from breast tumor biopsies. In the processing and quality control of the data, we became aware that the samples were highly contaminated with normal tissue cells resulting in a mixture of DNA from tumor and “normal” tissue being sequence. As part of his post-doctoral training in my lab, Dr. Larson sat in on these analyses meetings to observe and learn about next-generation sequence data analysis, during which he became interested in developing an accurate method to estimate tumor purity. This research resulted in the development of the program PurBayes published in Bioinformatics.

1. Instruction:

DIDACTIC:

Academic Year

Title and Course Number

Institution Instruction Learner

Type Hours Number of Learners

Type of Learner(s)

1998 – 2002 Principals of

Statistics (STAT101)

Iowa State University Lecture 40 100 Undergraduate

students



Academic Year

Title and Course Number



Type of Learner(s)

2003 Survey

Sampling (MTH444)

University of Wisconsin-La

Crosse Lecture 40 6 Undergraduate

students

2003 – 2006 Elementary

Statistics (MTH145)


Crosse

Lecture; 2 sections each

semester

56 x 2 sections

40 x 2 sections

Undergraduate students

2004 – 2005 Statistical Methods

(MTH305)



students

2004 – 2005

Probability and Statistics

(MTH250/ MTH341)



students

2006 – 2008 Biostatistics (CORE 6650)

Mayo Clinic College of Medicine

Lecture 30 30 Graduate

students in PhD programs

2007

Statistical Methods for

Genetic Association

Studies

Mayo Clinic College of Medicine

Independent study 15 1

MD working on MS degree in

clinical research (CTSA)

2014 Linear Models (BIOS 900)

University of Kansas Medical

Center Lecture 40 4

Graduate Students in Biostatistics

2015 Statistical Genomics

(BIOS 799/855)


Center

Lecture (block format) 40 3

Graduate Students at

KUMC

NONDIDATIC:

Year Title and Course Number



Type of Learner(s)

2007

Statistical Methods for

Genetic Association

Studies

Mayo Clinic Independent study 15 1

MD working on MS degree in

clinical research (CTSA)

2007 – 2012 Genetic Epidemiology Mayo Clinic Journal Clubs 1 hour a

month 20

Faculty and Staff interested

in Genetic Studies

2012 – Present

K-INBRE Bioinformatics Journal Club


Center Journal Clubs 1 hour a

week 10

Faculty, Staff and Students interested in

Bioinformatics



Year Title and Course Number



Type of Learner(s)

2012-2014 Computational

Genomics Working Group


Center

Presentations, discussion

group

1 hour a month 20

Faculty and Staff interested

in analysis methods for

‘Omic studies

2013

Independent Study (BIOS

906) – Statistical Genomics


Center

One-on-one meetings 40 1

Graduate Student in

Biostatistics

2015 Independent Study (BIOS

906)


Center

One-on-one meetings 40 1

Graduate Student in

Biostatistics MASTER’S THESES AND PHD DISSERTATIONS DIRECTED:

Year Student Name Thesis Title Degree

2014 Whitney Michaels

Correlation of SNPs with fine needle aspiration cytology and HRT in post-menopausal women at high risk for breast cancer

Master’s in clinical research (MS-CR).

2014 Bridgette Jones Genetic Variation along the histamine pathway in children with allergic vs non-allergic asthma.


2015 Stacey Keller-Cassat

Influence of ontogeny and genetic variation on molecular and clinical elements of dyslipidemia in children


2015 Jasmin Nwachokor

The use of a blood-based microRNA test to diagnose Gastroesophageal Reflux Disease (GERD), Barrett’s Esophagus, and Esophageal Adenocarcinoma


2013-Present Janelle Noel Strategies for the Analysis of RNA-seq Data (tentative title)

PhD in biostatistics (anticipated defense in Spring 2016)

SUPERVISION OF POSTDOCTORAL FELLOWS:

Year Fellow Name Area of Study

2009 – 2011 Prabhakar Chalise PhD, Mayo Clinic

Statistical Genetics; went on to a position as a research assistant professor at KUMC

2010 – 2012 Abra Brisbin PhD, Mayo Clinic

Statistical Genetics; went on to a tenure track faculty position at University of Wisconsin-Eau Claire

2012 Nicholas Larson PhD, Mayo Clinic

Statistical Genetics; went on to an Assistant Professor / Research Associate Professor at Mayo Clinic

2014-Present Joseph Usset, PhD Statistical Genomics



ADVISING: Year Student or Group Name Type of Student/Group

2003 David Bazett-Jones Undergraduate student research project, University of Wisconsin – La Crosse

2003 Courtney Widdahl Undergraduate student research project, University of Wisconsin – La Crosse

2004 Matthew Cleaver Undergraduate student research project, University of Wisconsin – La Crosse

2005 Jeffrey Taverna Undergraduate student research project, University of Wisconsin – La Crosse

2007 – 2009 Kaye Reid-Lombardo MD NIH KL2 Scholar, Mayo Clinic College of Medicine

2007 – 2012 Kaye Reid-Lombardo MD Masters in clinical research thesis committee, Mayo Clinic College of Medicine

2008 – 2011 Adelaide Olson MD Masters in clinical research thesis committee, Mayo Clinic College of Medicine

2008 – 2011 Scott Hebbring PhD Thesis Committee, Mayo Clinic College of Medicine

2009 Matthew Deyo-Svendsen Statistical genetics graduate student intern, Mayo Clinic (from University of Minnesota)

2009 Steven Lund Statistical genetics graduate student intern, Mayo Clinic (from Iowa State University)

2010 – 2012 Ryan Abo PhD Statistical Genomics and Bioinformatics post-doctoral research fellow, Mayo Clinic

2013-2014 Amanda Brinker Member, PhD Committee, PhD Student 2013 Maria Iliakova MD/PhD student; mentored summer research project

2013 – Present Janelle Noel Advisor; PhD student in Dept of Biostatistics

2013 – Present Janelle Noel Graduate Research Assistant

2013-2015 Velda Gonzalez Member, PhD Committee 2013-2014 Marina Sorokina Advisor; MS student in Dept of Biostatistics

2014 Junqiang (Eric) Dai 2014 KUCC Summer Student Research Training Program; Project: “Sequence Based Gene Expression Signatures and Ovarian Cancer Histological Subtypes”

2014-2016 Devin Koestler, PhD KL2 Scholar; Primary Mentor 2014-2016 Ziyan Pessetto, PhD KL2 Scholar; Scientific Adviser 2014-2016 Jill Hamilton-Reeves KL2 Scholar; Secondary Mentor

2014 Wei Wang Advisor; MS student in Dept of Biostatistics 2014-2015 Brandon Hidaka Member, PhD committee; MD/PhD student

2014-Present Junqiang (Eric) Dai Graduate Research Assistant 2015-Present Richard Meier Graduate Research Assistant 2015-Present Stefan Graw Graduate Research Assistant 2015-Present Richard Meier Advisor; PhD student in Dept of Biostatistics 2015-Present Stefan Graw Advisor; PhD student in Dept of Biostatistics

2015 Ashlea Chapman 2015 K-INBRE Undergraduate Bioinformatics Research Summer Scholarship; Project: “Metabolomics and Age: A Study of Metabolite Changes in Pediatric Liver Samples”



OTHER TEACHING ACTIVITIES:

Date Title of Presentation Location Teaching Function Type of Learner

Summer 2004 Design of Experiments La Crosse, WI Girls in Science Workshop

Approx Size: 20 Middle-school girls

Summer 2006

Teaching Statistics Workshop St. Louis, MO

Annual Meeting of National Council of Teachers of Mathematics Approx. Size: 50

Middle School and High School Math Teacher

2007 Genetic Analysis Workshop

Mayo Clinic, Rochester, MN

Educational Workshop Approx. Size: 50

Faculty and staff at Mayo Clinic

August 2013

Statistical Genomics and Bioinformatics Workshop: GWAS and RNA-Seq Studies

University of Kansas Medical Center

Educational Workshop Approx. Size: 100

Faculty, students, fellows at KUMC, KU, KSU, UMKC, Stowers, Children’s Mercy

November 2014

Introduction to Pharmacogenomics and Precision Medicine: Some Tools of the Trade

University of Kansas Cancer Center

KUCC/FightCRC Research Advocate Training and Support (RATS) Size: 5

Colon cancer research avocates and survivors

Feburary 2015

Population Genetics & Genetic Association Studies for Drug Response Phenotypes

Children’s Mercy Hospital, Kansas City MO

Pediatrics Clinical Pharmacology Education Seminar Size: 10

Graduate students, residents and faculty in pharmacology

2. Development of Educational Materials:

Year Title/Description Intended Audience 1998 Development of teaching materials for STAT101 Undergraduate students at Iowa State University

2003 Development of teaching materials for MATH145 (Elementary Statistics)

Undergraduate students at University of Wisconsin – La Crosse

2003 Development of teaching materials for MATH444 (Survey Sampling)

Undergraduate students at University of Wisconsin – La Crosse

2004 Development of teaching materials for MATH305/505 (Statistical Methods)

Undergraduate /graduate students at University of Wisconsin – La Crosse

2005 Development of teaching materials for MATH341 (Probability and Statistics)

Undergraduate mathematics students at University of Wisconsin – La Crosse

2006 Development of teaching materials for CORE 6650 Graduate students at Mayo Clinic College of Medicine

2007 Genetic Association Workshop – Development of the teaching materials for the workshop, including lecture notes, example problems and analysis code

Faculty and Staff within the Department of Health Sciences Research, Mayo Clinic

2008 Linkage Analysis Resource – Development of educational materials for the Department in how to complete a genetic linkage analysis

Faculty and Staff within the Department of Health Sciences Research, Mayo Clinic

2013 BIOS 799/855: Statistical Genomics - Course Development and Syllabus

Non-Biostatistics Graduate Students (BIOS799) and Biostatistics Graduate Students (BIOS855)



Year Title/Description Intended Audience

2014 NIGMS R25 Grant Application: Workshop in Statistical Genomics and Bioinformatics (unfunded)

Quantitative and non-quantitative students and researchers interested in ‘omic based research

2014 Development of lecture notes and homework assignments for BIOS 900 (Linear Models). MS / PhD Biostatistics Graduate Students.

2015 NCI R25 Grant Application: Introduction to Statistical and Bioinformatics Methods Used in Cancer Research

Quantitative and non-quantitative students and researchers interested in ‘omic based research

2015 Development of course materials for BIOS 799/855: Statistical Genomics. Course running for first time at KUMC

Non-Biostatistics Graduate Students (BIOS799) and Biostatistics Graduate Students (BIOS855)

III. SERVICE ACTIVITIES:

1. Academic Service:

INSTITUTIONAL & DEPARTMENTAL COMMITTEES:

Year Committee

2001 - 2002 Graduate Student Senate, Iowa State University 2000 - 2002 President of the Iowa STAT-ers, Department of Statistics, Iowa State University 2000 - 2002 Statistics Department’s Student Faculty Committee on Instruction 2004 - 2006 Math Club Advisor, University of Wisconsin-La Crosse 2004 - 2005 Seminar Coordinator, Department of Mathematics, University of Wisconsin-La Crosse 2006 - 2007 Undergraduate Research Committee, University of Wisconsin-La Crosse

2006 - 2007 Executive Committee, Division of Biostatistics, Department of Health Sciences Research, Mayo Clinic

2007 - 2012 Genetic Epidemiology Journal Club, Organizer

2007 - 2008 Genomics and Bioinformatics Education Subcommittee, Department of Health Sciences Research, Mayo Clinic

2013-Present Member, KUMC School of Medicine Faculty Council 2013 Chair, Search Committee for tenure-track faculty in bioinformatics, KUMC

2013-Present Department of Biostatistics Curriculum Committee 2013-2014 Computational Genomics Working Group, Organizer 2013-2014 University of Kansas Cancer Center IIT Task Force

2013 Co-Chair, Strategic Planning Committee, Department of Biostatistics 2015-Present Member, KUMC School of Medicine Research Committee

2015 Chair, Search Committee for Research Assistant Professor in cancer informatics, KUMC

2015-Present Member, Research Computing Executive Advisory Committee for KU-Lawrence and Advance Compute Facility (ACF)

2014-Present Member, Internal Advisor Board for Biospecimen Repository at KUMC 2015-Present Member, Molecular Tumor Board at KUMC / KU-Med



NON-INSTITUTIONAL COMMITTEE MEMBERSHIP:

Year Committee

2013-Present Member, KCALSI Bioinformatics Steering Committee

2015 Member, October 2015 Regional Bioinformatics Conference Planning Committee GRANT REVIEW & STUDY SECTIONS:

Year Study Section 2009 NIH, ARRA Grant Review 2009 Breast Cancer Campaign Grant Review Committee 2010 Minnesota Partnership Research Grant Review 2011 NIH/NIMH, RFA R01 Grant Review 2011 The Netherlands Organization for Scientific Research 2010 BioMed Central Cancer, United Kingdom

2012-2015 American Cancer Society Institutional Research Grant Review Committee, University of Kansas Medical Center

2013 NIH/NCI, Member Conflicts: Epidemiology and Genetics of Cancer (EPIC) 2013 Reviewer for Internal Next-Generation Sequencing Proposals for K-INBRE

2013 Reviewer for Mayo Clinic SPORE in Ovarian Cancer Developmental Research Project Proposals

2013 NIH/NIEHS, K99 applications

2014-Present Cancer Prevention Research Institute of Texas (CPRIT) Peer Review Committee (standing member)

2014 NIH/NCI, R01 grants in response to NCI’s Provocative Questions Initiative 2014 NIH R15 (AREA) applications (study section ZRG1 PSEQ 80S)

2015 NIH, R01 grants Pharmacogenetics, Pharmacoepigenetics and Personalized Medicine in Children.

2015 United Arab Emirates University; The UAEU Program for advanced research grant competition

2015 NIH/NIMH: R01 grants in response to RFA: Psychiatric Gene Networks: Solving the Molecular Puzzle of Psychiatric Disorders.

JOURNAL & BOOK REVIEWER: I review on average 12 articles a year. The journal impact factors are given in parentheses.

Journal/Book Journal/Book American Journal of Epidemiology (5.632) Human Genetics (4.521)

American Journal of Human Genetics (11.174) Human Heredity (1.654) Annals of Human Genetics (2.211) IEEE Journal of Biomedical and Health Informatics (1.44)

Bioinformatics (8.136) JAMA Oncology Biometrics (2.01) Journal of Carcinogenesis & Mutagenesis (1.90)

BMC Cancer (3.770) Journal of Statistics Education BMC Genetics (2.896) Journal of the National Cancer Institute (13.584)

BMC Medical Genetics (2.409) Medical Oncology (2.366) Cancer Research (9.115) Molecular Biology Reports (1.908)



Clinical Pharma. & Therap. Stat. in Medicine Molecular Cancer Therapeutics (5.895) Computers in Biology and Medicine (1.459) Nature Communications (11.904)

Endocrine-related Cancer (5.217) Pharmacogenetics and Genomics (3.561) Gene (2.185) Proceedings from GAW15, BMC Proceedings

Genetic Epidemiology (3.289) Stat. Applications in Genetics & Molecular Biology (1.537) Genome Research (15.567) The Pharmacogenomics Journal (3.306)

Genomics (2.847) Textbook: 5th ed. “Introduction to the Practice of Statistics” EDITORIAL BOARDS:

Year Boards

2012-Present Frontiers in Statistical Genetics 2013-Present Frontiers in Pharmacogenetics and Pharmacogenomics 2013-Present Journal of the National Cancer Institute JNCI (Statistical Editor) 2013-Present BMC Medical Genetics (Associate Editor)

IV. RESEARCH AND SCHOLARLY ACTIVITIES:

Opening Statement: As a statistical geneticist, I have two long term research goals: 1) To develop on-going, long-term collaborations with researchers looking at genetics of complex traits/diseases, pharmacogenomics and precision medicine;

2) To develop a statistical research program with the focus of developing novel methods for high-dimensional ‘omic studies of complex disease phenotypes and pharmacogenomics.

As a statistical genomicist and bioinformatician, my collaborative research interests are focused on the genomic basis of complex diseases (primarily cancer), pharmacogenomics and precision medicine. In particular, I am actively involved in genomic, transcriptomic, epigenomic and biomarker studies dealing with breast cancer, colon cancer / GIST, glioma, ovarian cancer, and childhood diseases/cancers (in collaboration with researchers at Children’s Mercy Hospital), in addition to multiple drug screening/repurposing studies. These collaborations involve both candidate genes and genome-wide approaches, in addition to multiple types of genomic data (e.g., genotypic, methylation, mRNA expression, copy number). Recently, with the advancements in sequencing technology, I have also gained extensive experience in the analysis of RNA and DNA sequencing data. My statistical research focuses on the development of new statistical methods to analyze high-dimensional ‘omic data, including methods for genomic clustering, Bayesian models and integrative analysis methods, for which I have received three NIH grant awards. The need to develop new statistical methods is closely integrated with my collaborations with multidisciplinary scientific teams, as the new methods and software tools are developed in response to new scientific questions brought about through these collaborations. 1. Grants and Contracts:

PREVIOUS GRANTS AND CONTRACTS AWARDED (* indicates grants for which I have Notice of Grant Award, Abstract and front page of the grant application):

Principal

Investigator Title of Grant/Contract Funding Source

Direct Costs

Inclusive Years of Award

Fridley Teaching of confidence intervals and interpretations in an introductory statistics course. Lesson Study Grant.

UW-L $10,000 2004



Principal Investigator Title of Grant/Contract

Funding Source

Direct Costs


Fridley Robustness of Data Augmentation for the Analysis of Censored Spatial Data. UW-L $10,000 7/2004 - 6/2005

Fridley Missing Phenotype Imputation in Pedigree Analysis. Mayo Clinic $10,000 6/2005 - 9/2005

Fridley Bayesian Variable Selection for Genetic Association Studies. Mayo Clinic $10,000 6/2006 - 5/2007

Goode* Potter

Genetic Linkage in Colorectal Cancer Families. R01 CA104667

NIH/NCI $2,533,890 (total direct

cost) 01/2005-08/2011

Weinshilboum* Pharmacogenetics of Phase II Drug Metabolizing Enzymes. U01 GM 61388

NIH/NIGMS $1,299,586 (FY direct

cost) 7/2005-6/2010

Fridley

Novel Methods for the Analysis of Pharmacogenomic Cytotoxicity Data: Bayesian Hierarchical Nonlinear Models. EAGLES #252

Mayo Clinic Cancer

Center’s Eagles Fund

$50,000 8/2007 - 7/2008

Fridley Genetic Association Workshop HSR ED 10 Mayo Clinic $10,000 2007

Sellers* (Goode PI of subaward)

Haplotype-Based Genome Screen for Ovarian Cancer Loci. R01 CA 114343.

NIH/NCI $1,078,062 (FY Total Cost 2011)

7/2007 - 2/2012

Weinshilboum* Inherited Variations in Drug Metabolizing Enzymes. R01 GM 28157

NIH/NIGMS $325,234 (FY direct

costs) 8/2007 – 5/2012

Goode* Genetic Variation in the NF-kappaB Pathway and Ovarian Cancer Etiology. R01 CA122443

NIH/NCI $1,780,885 (total direct

costs) 9/2007-7/2012

Fridley Linkage Analysis Resource HSR ED 10 Mayo Clinic $10,000 2008

Fridley Comparison of Methods to Incorporate Prior Linkage or Association Results in Current Studies.

Mayo Clinic Cancer Center

$5,000 5/2008 - 12/2008

Saito A candidate gene association study of irritable bowel syndrome. R03 DK 76797

NIH/NIDDK $100,000 4/2008 - 3/2011

Wang* Pharmacogenomics of a Cytidine Analogue, Gemcitabine. K22 CA130828

NIH/NCI $150,817 09/2008-8/2011

Weinshilboum*

Pharmacogenomics of cytosine arabinoside (Ara-C) and acute myelogenous leukemia. R01 CA 132780

NIH/NCI $207,567 (FY direct

cost) 4/2008 - 5/2013

Olsen Genetics of Inflammation in Post Myocardial Infarction Heart Failure. R03 AG 31347

NIH/NIA $100,000 3/2008-2/2011

Fridley* Integrative genomic models for analysis of pharmacogenomic studies. R21 CA 140879

NIH/NCI $105,397 (Annual

direct cost) 8/2009-7/2011



Principal Investigator Title of Grant/Contract

Funding Source

Direct Costs


Wang* Pharmacogenomics and Mechanisms of Cytidine Analogues. R01 CA 138461

NIH/NCI $192,851 (FYdirect

cost) 3/2009 - 1/2014

Fridley

University of Minnesota – Mayo Pharmacogenomics Partnership (MMPGx) project. H001525601

State of Minnesota $250,000 6/2010 - 5/2012

Sellers* (Goode PI of subaward)

Follow-up of Ovarian Cancer genetic association and Interaction studies. U19 CA 148112 NIH/NCI

Sub-award $108,676 (FY direct

cost)

7/2010 - 6/2014

Weinshilboum* Pharmacogenetics of Phase II Drug Metabolizing Enzymes. U19 GM 61388

NIH/NIGMS $2,253,873 (FY direct

cost) 7/2010 - 6/2015

Fridley* Bayesian hierarchical nonlinear models for pharmacogenomic cytotoxicity studies. R21 GM 86689

NIH/NIGMS $150,000 8/2011-7/2013

O’Neill Mayo Clinic SPORE in Brain Cancer P50 CA108961 NIH/NCI

$2,084,586 (FY total

cost) 11/2011-03/2016

Fridley Integrative Analysis of the Ovarian TCGA Data

KUCC Pilot Project

$35,000 12/2012-11/2013

Wright*

Kansas IDeA Network of Biomedical Research Excellence P20 GM103418 Role: Site Director Bioinformatics Core

NIH/NIGMS $2,664,620 5/2012-4/2013

CURRENT GRANTS AND CONTRACTS AWARDED:

Principal Investigator Title of Grant/Contract Funding

Source Direct Costs


Wright*


NIH/NIGMS $2,988,613 05/2014-04/2019

Jensen*

Cancer Center Support Grant P30 CA168524 Role: Director, Biostatistics and Informatics Shared Resource

NIH/NCI $925,414 7/2012-6/2017

Chien*

Integrated Genomics and Proteomics to Uncover Novel Mechanisms of Resistance to Chemotherapy in Ovarian Cancer Role: Co-Investigator

US Dept of Defense $182,857 8/2013 - 6/2015




Source Direct Costs


Wright*


NIH/NIGMS $2,988,613 05/2014-04/2019

Fridley*

Bayesian Integrative Clustering for Determining Molecular Based Cancer Subtypes. R21 CA182715 Role: Principal Investigator

NIH/NCI $250,000 12/2013-11/2015

Chien Mechanism of Carboplatin Resistance in Ovarian Cancer Role: Co-Investigator

Am Cancer Society $165,000 7/2014 - 6/2018

Flatt*

Determining the Feasibility of International Specimen Procurement to Assess the Role of Ethnicity in Pediatric ALL Outcomes Role: Statistical Geneticist

Midwest Cancer

Alliance (MCA)

$123,757 9/2014-8/2016

Fridley Investigation of multifactor gene-environment interactions in ovarian cancer Role: Principal Investigator

KUCC Pilot Project $31,040 01/2015-12/2015

Usset Assessment of Biases in Xenograft Mouse Models used in Cancer Research Role: Primary Mentor

K-INBRE Post-Doctoral Award

$24,780 05/2015-04/2016

GRANTS AND CONTRACTS PENDING:

Principal

Investigator Title of Grant/Contract Funding Source

Direct Costs


Dixon HuR in Colorectal Cancer Role: Co-Investigator NIH/NCI $250,000 9/2015 - 8/2020

Godwin The Molecular Actions of Imatinib Mesylate in GISTs Role: Co-Investigator

NIH/NCI $384,782 07/2015-06/2020

Chien

Peritoneal Mouse Models of High-grade Serous Ovarian Cancer Role: Co-Investigator Subcontract from Univ South Dakota

NIH $28,724 07/2016-6/2017

Chien

Peritoneal Dormancy After Chemotherapy in Ovarian Cancer Role: Co-Investigator Subcontract from Univ South Dakota

NIH $21,830 03/2015-2/2017

Chien Defining the p53-FoxM1 axis in Ovarian Cancer Role: Co-Investigator

NIH $150,000 4/2016-3/2018




Source Direct Costs


Krieg

Hypoxia, Histone Demethylases, and Peritoneal Dissemination of Ovarian Cancer Role: Co-Investigator

NIH $250,000 4/2016-3/2021

Hagan Progesterone Receptor Promotes Inflammation in Breast Cancer Role: Co-Investigator

DOD $120,673 10/2015-09/2018

Fridley

Introduction to statistical and bioinformatics methods used in cancer research Role: Principal Investigator

NIH/NCI $190,552 01/2016-12/2020

Godwin

Multi-pronged approvals approach for the early detection of ovarian cancer based on circulating exosomes Role: Co-Investigator

DOD $107,253 04/2016-03/2019

Godwin

Reversing Platinum Resistance in High Grade Serous Ovarian Cancer by targeting SMAD3 Role: Co-Investigator

DOD $80,915 04/2016-03/2019

Godwin The achilles' heel and novel targeted therapies of ewing sarcoma Role: Co-Investigator

Braden’s Hope

Foundation $100,000 09/2015-08/2016

Dunn

Factors Responsible for Liver Recovery After Successful Treatment of Hepatitis C and NASH Role: Mentor

NIH $168,800 04/2016-3/2021

Krieg

Targeting histone demethylase mediated pathways to prevent ovarian cancer metastasis Role: Co-Investigator

DOD $113,683 4/2015-3/2017

Krieg Histone Demethylases and Ovarian Cancer Metastasis Role: Co-Investigator

NIH $250,000 4/2015-3/2020

2. Scholarly Publications:

Below is a list of my scholarly publications that have been published, in press, or submitted for peer review. Of these 169 publications, I have first authored 24 manuscripts and have been the senior author on 14 publications. This includes a co-first authored paper published in Nature Communications (impact factor of 10.015) and an invited editorial for The Journal of the National Cancer Institute (impact factor of 14.336). My publications have been cited 2759 times (as of May 12, 2015) and I have an h-Index of 29 (the largest number h such that h publications have at least h citations), with an average citation of 13.73 per article. and an i10-index of 66 (the number of publications with at least 10 citations). My highest cited first authored paper (49 citations) is “Gene set analysis of SNP data: benefits, challenges, and future directions” (PMCID: PMC3172936) and highest cited senior authored paper (13 citations) is “PurBayes: estimating tumor cellularity and subclonality in next-generation sequencing data” (PMCID: PMC3712213).

List of Published Work can be found at Web of Science: http://www.researcherid.com/rid/D-8315-2015


http://www.researcherid.com/rid/D-8315-2015

Curriculum vitae: Brooke L. Fridley P a g e | 15 PEER REVIEWED JOURNAL ARTICLES (* publications with 20 or more citations; impact factors are also presented):

PRA1. de Andrade, M, Fridley, B, Boerwinkle, E, & Turner, S. (2003). Diagnostic tools in linkage analysis for quantitative traits. Genet Epidemiol, 24(4), 302-308. Impact factor = 4.015

PRA2. Fridley, B, Rabe, K, & de Andrade, M. (2003). Imputation methods for missing data for polygenic models. BMC Genet, 4 Suppl 1, S42.

PRA3. Sloan, JA, Vargas-Chanes, D, Kamath, CC, Sargent, DJ, Novotny, PJ, Atherton, P, Almer, C, Fridley, BL, Frost, MH, & Loprinzi, CL. (2003). Detecting worms, ducks, and elephants: A Simple Approach for Defining Clinically Relevant Effects in Quality of Life Measures. Journal of Cancer Integrative Medicine, 1(1).

PRA4. Fridley, BL, DeCook, R, & Butler, H. (2005). Expanding your statistical computing toolbox with Python. Statistical Computing & Statistical Graphics Newsletter, 16(1), 4-8.

PRA5. Arruda-Olson, AM, Weston, SA, Fridley, BL, Killian, JM, Koepsell, EE, & Roger, VL. (2007). Participation bias and its impact on the assembly of a genetic specimen repository for a myocardial infarction cohort. Mayo Clin Proc, 82(10), 1185-1191.

PRA6. Atkinson, EJ, Fridley, BL, Goode, EL, McDonnell, SK, Liu-Mares, W, Rabe, KG, Sun, Z, Slager, SL, & de Andrade, M. (2007). Linkage analysis using principal components of gene expression data. BMC Proc, 1 Suppl 1, S79.

PRA7. de Andrade, M, Atkinson, EJ, Fridley, BL, Goode, EL, McDonnell, S, Liu-Mares, W, Rabe, KG, Sun, Z, & Slager, SL. (2007). The genetics of gene expression: comparison of linkage scans using two phenotype normalization methods. BMC Proc, 1 Suppl 1, S151.

PRA8. Fridley, BL, & Dixon, P. (2007). Data augmentation for a Bayesian spatial model involving censored observations. Environmetrics, 18, 107-123. Impact factor = 1.096

PRA9. Goode, EL, Fridley, BL, Sun, Z, Atkinson, EJ, Nord, AS, McDonnell, SK, Jarvik, GP, de Andrade, M, & Slager, SL. (2007). Comparison of tagging single-nucleotide polymorphism methods in association analyses. BMC Proc, 1 Suppl 1, S6.

PRA10. Liu-Mares, W, Sun, Z, Bamlet, WR, Atkinson, EJ, Fridley, BL, Slager, SL, de Andrade, M, & Goode, EL. (2007). Analysis of variation in NF-kappaB genes and expression levels of NF-kappaB-regulated molecules. BMC Proc, 1 Suppl 1, S126.

PRA11. Nordman, D, Lahiri, S, & Fridley, B. (2007). Optimal block size for variance estimation by a spatial block bootstrap method. Sankhya, 69(3), 468-493.

PRA12. Swartz, MD, Thomas, DC, Daw, EW, Albers, K, Charlesworth, JC, Dyer, TC, Fridley, BL, Govil, M, Kraft, P, Kwon, S, Logue, MW, Oh, C, Pique-Regi, R, Saba, L, Schumacher, FR, & Uh, HW. (2007). Model selection and Bayesian methods in statistical genetics: summary of group 11 contributions to Genetic Analysis Workshop 15. Genet Epidemiol, 31 Suppl 1, S96-102.

PRA13. Thomas, HR, Ezzeldin, HH, Guarcello, V, Mattison, LK, Fridley, BL, & Diasio, RB. (2007). Genetic regulation of dihydropyrimidinase and its possible implication in altered uracil catabolism. Pharmacogenet Genomics, 17(11), 973-987.* Impact factor = 3.608

PRA14. Ye, Z, Atkinson, EJ, Fridley, BL, & de Andrade, M. (2007). Comparison of variable and model selection methods for genetic association studies using the GAW15 simulated data. BMC Proc, 1 Suppl 1, S34.

PRA15. Edwards, AO, Chen, D, Fridley, BL, James, KM, Wu, Y, Abecasis, G, Swaroop, A, Othman, M, Branham, K, Iyengar, SK, Sivakumaran, TA, Klein, R, Klein, BE, & Tosakulwong, N. (2008). Toll-like receptor polymorphisms and age-related macular degeneration. Invest Ophthalmol Vis Sci, 49(4), 1652-1659.*Impact factor = 3.441.


Curriculum vitae: Brooke L. Fridley P a g e | 16 PRA16. Edwards, AO, Fridley, BL, James, KM, Sharma, AK, Cunningham, JM, & Tosakulwong, N. (2008).

Evaluation of clustering and genotype distribution for replication in genome wide association studies: the age-related eye disease study. PLoS One, 3(11), e3813.* Impact factor = 3.73

PRA17. Edwards, AO, Lee, SJ, Fridley, BL, & Tosakulwong, N. (2008). Density of common complex ocular traits in the aging eye: analysis of secondary traits in genome-wide association studies. PLoS One, 3(6), e2510. Impact factor = 3.73

PRA18. Fridley, BL, & de Andrade, M. (2008). Missing phenotype data imputation in pedigree data analysis. Genet Epidemiol, 32(1), 52-60. Impact factor = 4.015

PRA19. Fridley, BL, Turner, ST, Chapman, A, Rodin, A, Boerwinkle, E, & Bailey, K. (2008). Reproducibility of Genotypes as Measured by the Affymetrix GeneChip(R) 100K Human Mapping Array Set. Comput Stat Data Anal, 52(12), 5367-5374. Impact factor = 1.30

PRA20. Ji, Y, Snyder, EM, Fridley, BL, Salavaggione, OE, Moon, I, Batzler, A, Yee, VC, Schaid, DJ, Joyner, MJ, Johnson, BD, & Weinshilboum, RM. (2008). Human phenylethanolamine N-methyltransferase genetic polymorphisms and exercise-induced epinephrine release. Physiol Genomics, 33(3), 323-332. Impact factor = 2.81

PRA21. Juran, BD, Atkinson, EJ, Schlicht, EM, Fridley, BL, & Lazaridis, KN. (2008). Primary biliary cirrhosis is associated with a genetic variant in the 3' flanking region of the CTLA4 gene. Gastroenterology, 135(4), 1200-1206.* Impact factor = 12.821.

PRA22. Juran, BD, Atkinson, EJ, Schlicht, EM, Fridley, BL, Petersen, GM, & Lazaridis, KN. (2008). Interacting alleles of the coinhibitory immunoreceptor genes cytotoxic T-lymphocyte antigen 4 and programmed cell-death 1 influence risk and features of primary biliary cirrhosis. Hepatology, 47(2), 563-570.*Impact factor = 12.003

PRA23. Li, L, Fridley, B, Kalari, K, Jenkins, G, Batzler, A, Safgren, S, Hildebrandt, M, Ames, M, Schaid, D, & Wang, L. (2008). Gemcitabine and Cytosine Arabinoside Cytotoxicity: Association with Lymphoblastoid Cell Expression. Cancer Res, 68(17), 7050-7058.* Impact factor = 8.650

PRA24. Pardanani, A, Fridley, BL, Lasho, TL, Gilliland, DG, & Tefferi, A. (2008). Host genetic variation contributes to phenotypic diversity in myeloproliferative disorders. Blood, 111(5), 2785-2789.* Impact factor = 9.898

PRA25. Thomas, HR, Ezzeldin, HH, Guarcello, V, Mattison, LK, Fridley, BL, & Diasio, RB. (2008). Genetic regulation of beta-ureidopropionase and its possible implication in altered uracil catabolism. Pharmacogenet Genomics, 18(1), 25-35. Impact factor = 3.608

PRA26. Turner, ST, Bailey, KR, Fridley, BL, Chapman, AB, Schwartz, GL, Chai, HS, Sicotte, H, Kocher, JP, Rodin, AS, & Boerwinkle, E. (2008). Genomic association analysis suggests chromosome 12 locus influencing antihypertensive response to thiazide diuretic. Hypertension, 52(2), 359-365.* Impact factor = 6.873

PRA27. Wang, L, Kumar, S, Fridley, BL, Kalari, KR, Moon, I, Pelleymounter, LL, Hildebrandt, MA, Batzler, A, Eckloff, BW, Wieben, ED, & Greipp, PR. (2008). Proteasome beta subunit pharmacogenomics: gene resequencing and functional genomics. Clin Cancer Res, 14(11), 3503-3513. Impact factor = 7.837

PRA28. Biernacka, JM, Tang, R, Li, J, McDonnell, SK, Rabe, KG, Sinnwell, JP, Rider, DN, de Andrade, M, Goode, EL, & Fridley, BL. (2009). Assessment of genotype imputation methods. BMC Proc, 3 Suppl 7, S5.

PRA29. Cunningham, JM, Vierkant, RA, Sellers, TA, Phelan, C, Rider, DN, Liebow, M, Schildkraut, J, Berchuck, A, Couch, FJ, Wang, X, Fridley, BL, Gentry-Maharaj, A, Menon, U, Hogdall, E, Kjaer, S, Whittemore, A, DiCioccio, R, Song, H, Gayther, SA, Ramus, SJ, Pharaoh, PD, & Goode, EL. (2009). Cell cycle genes and ovarian cancer susceptibility: a tagSNP analysis. Br J Cancer, 101(8), 1461-1468.* Impact factor = 5.082

PRA30. Fridley, BL. (2009). Bayesian variable and model selection methods for genetic association studies. Genet Epidemiol, 33(1), 27-37.* Impact factor = 4.015

PRA31. Fridley, BL, Jenkins, G, Schaid, DJ, & Wang, L. (2009). A Bayesian hierarchical nonlinear model for assessing the association between genetic variation and drug cytotoxicity. Stat Med, 28(21), 2709-2722. Impact factor = 2.044


Curriculum vitae: Brooke L. Fridley P a g e | 17 PRA32. Fridley, BL, McDonnell, SK, Rabe, KG, Tang, R, Biernacka, JM, Sinnwell, JP, Rider, DN, & Goode, EL.

(2009). Single versus multiple imputation for genotypic data. BMC Proc, 3 Suppl 7, S7. PRA33. Goode, EL, Fridley, BL, Vierkant, RA, Cunningham, JM, Phelan, CM, Anderson, S, Rider, DN, White, KL,

Pankratz, VS, Song, H, Hogdall, E, Kjaer, SK, Whittemore, AS, DiCioccio, R, Ramus, SJ, Gayther, SA, Schildkraut, JM, Pharaoh, PP, & Sellers, TA. (2009). Candidate gene analysis using imputed genotypes: cell cycle single-nucleotide polymorphisms and ovarian cancer risk. Cancer Epidemiol Biomarkers Prev, 18(3), 935-944.* Impact factor = 4.559

PRA34. Goode, EL, Szabo, C, Prokunina-Olsson, L, Vierkant, RA, Fredericksen, ZS, Collins, FS, White, KL, Schmidt, M, Fridley, BL, & Couch, FJ. (2009). No association between a candidate TCF7L2 variant and risk of breast or ovarian cancer. BMC Cancer, 9, 312. Impact factor = 3.33

PRA35. Li, L, Fridley, BL, Kalari, K, Jenkins, G, Batzler, A, Weinshilboum, RM, & Wang, L. (2009). Gemcitabine and arabinosylcytosin pharmacogenomics: genome-wide association and drug response biomarkers. PLoS One, 4(11), e7765.* Impact factor = 3.73

PRA36. Park, KH, Fridley, BL, Ryu, E, Tosakulwong, N, & Edwards, AO. (2009). Complement component 3 (C3) haplotypes and risk of advanced age-related macular degeneration. Invest Ophthalmol Vis Sci, 50(7), 3386-3393.* Impact factor = 3.441

PRA37. Peedicayil, A, Vierkant, RA, Shridhar, V, Schildkraut, JM, Armasu, S, Hartmann, LC, Fridley, BL, Cunningham, JM, Phelan, CM, Sellers, TA, & Goode, EL. (2009). Polymorphisms in TCEAL7 and risk of epithelial ovarian cancer. Gynecol Oncol, 114(2), 260-264. Impact factor = 3.929

PRA38. Pei, H, Li, L, Fridley, BL, Jenkins, GD, Kalari, KR, Lingle, W, Petersen, G, Lou, Z, & Wang, L. (2009). FKBP51 affects cancer cell response to chemotherapy by negatively regulating Akt. Cancer Cell, 16(3), 259-266.* Impact factor = 24.755

PRA39. Rule, AD, Fridley, BL, Hunt, SC, Asmann, Y, Boerwinkle, E, Pankow, JS, Mosley, TH, & Turner, ST. (2009). Genome-wide linkage analysis for uric acid in families enriched for hypertension. Nephrol Dial Transplant, 24(8), 2414-2420. Impact factor = 3.371

PRA40. Song, H, Ramus, SJ, Tyrer, J, Bolton, KL, Gentry-Maharaj, A, Wozniak, E, Anton-Culver, H, Chang-Claude, J, Cramer, DW, DiCioccio, R, Dork, T, Goode, EL, Goodman, MT, Schildkraut, JM, Sellers, T, Baglietto, L, Beckmann, MW, Beesley, J, Blaakaer, J, Carney, ME, Chanock, S, Chen, Z, Cunningham, JM, Dicks, E, Doherty, JA, Durst, M, Ekici, AB, Fenstermacher, D, Fridley, BL, Giles, G, Gore, ME, De Vivo, I, Hillemanns, P, Hogdall, C, Hogdall, E, Iversen, ES, Jacobs, IJ, Jakubowska, A, Li, D, Lissowska, J, Lubinski, J, Lurie, G, McGuire, V, McLaughlin, J, Medrek, K, Moorman, PG, Moysich, K, Narod, S, Phelan, C, Pye, C, Risch, H, Runnebaum, IB, Severi, G, Southey, M, Stram, DO, Thiel, FC, Terry, KL, Tsai, YY, Tworoger, SS, Van Den Berg, DJ, Vierkant, RA, Wang-Gohrke, S, Webb, PM, Wilkens, LR, Wu, AH, Yang, H, Brewster, W, Ziogas, A, Houlston, R, Tomlinson, I, Whittemore, AS, Rossing, MA, Ponder, BA, Pearce, CL, Ness, RB, Menon, U, Kjaer, SK, Gronwald, J, Garcia-Closas, M, Fasching, PA, Easton, DF, Chenevix-Trench, G, Berchuck, A, Pharoah, PD, & Gayther, SA. (2009). A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. Nat Genet, 41(9), 996-1000.* Impact factor = 35.209

PRA41. Srinivasan, BS, Chen, J, Cheng, C, Conti, D, Duan, S, Fridley, BL, Gu, X, Haines, JL, Jorgenson, E, Kraja, A, Lasky-Su, J, Li, L, Rodin, A, Wang, D, Province, M, & Ritchie, MD. (2009). Methods for analysis in pharmacogenomics: lessons from the Pharmacogenetics Research Network Analysis Group. Pharmacogenomics, 10(2), 243-251. Impact factor = 5.134

PRA42. White, KL, Vierkant, RA, Phelan, CM, Fridley, BL, Anderson, S, Knutson, KL, Schildkraut, JM, Cunningham, JM, Kelemen, LE, Pankratz, VS, Rider, DN, Liebow, M, Hartmann, LC, Sellers, TA, & Goode, EL. (2009). Polymorphisms in NF-kappaB inhibitors and risk of epithelial ovarian cancer. BMC Cancer, 9, 170. Impact factor = 3.33


Curriculum vitae: Brooke L. Fridley P a g e | 18 PRA43. Bolton, KL, Tyrer, J, Song, H, Ramus, SJ, Notaridou, M, Jones, C, Sher, T, Gentry-Maharaj, A, Wozniak, E,

Tsai, YY, Weidhaas, J, Paik, D, Van Den Berg, DJ, Stram, DO, Pearce, CL, Wu, AH, Brewster, W, Anton-Culver, H, Ziogas, A, Narod, SA, Levine, DA, Kaye, SB, Brown, R, Paul, J, Flanagan, J, Sieh, W, McGuire, V, Whittemore, AS, Campbell, I, Gore, ME, Lissowska, J, Yang, HP, Medrek, K, Gronwald, J, Lubinski, J, Jakubowska, A, Le, ND, Cook, LS, Kelemen, LE, Brook-Wilson, A, Massuger, LF, Kiemeney, LA, Aben, KK, van Altena, AM, Houlston, R, Tomlinson, I, Palmieri, RT, Moorman, PG, Schildkraut, J, Iversen, ES, Phelan, C, Vierkant, RA, Cunningham, JM, Goode, EL, Fridley, BL, Kruger-Kjaer, S, Blaeker, J, Hogdall, E, Hogdall, C, Gross, J, Karlan, BY, Ness, RB, Edwards, RP, Odunsi, K, Moyisch, KB, Baker, JA, Modugno, F, Heikkinenen, T, Butzow, R, Nevanlinna, H, Leminen, A, Bogdanova, N, Antonenkova, N, Doerk, T, Hillemanns, P, Durst, M, Runnebaum, I, Thompson, PJ, Carney, ME, Goodman, MT, Lurie, G, Wang-Gohrke, S, Hein, R, Chang-Claude, J, Rossing, MA, Cushing-Haugen, KL, Doherty, J, Chen, C, Rafnar, T, Besenbacher, S, Sulem, P, Stefansson, K, Birrer, MJ, Terry, KL, Hernandez, D, Cramer, DW, Vergote, I, Amant, F, Lambrechts, D, Despierre, E, Fasching, PA, Beckmann, MW, Thiel, FC, Ekici, AB, Chen, X, Johnatty, SE, Webb, PM, Beesley, J, Chanock, S, Garcia-Closas, M, Sellers, T, Easton, DF, Berchuck, A, Chenevix-Trench, G, Pharoah, PD, & Gayther, SA. (2010). Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nat Genet, 42(10), 880-884.* Impact factor = 35.209

PRA44. Doherty, JA, Rossing, MA, Cushing-Haugen, KL, Chen, C, Van Den Berg, DJ, Wu, AH, Pike, MC, Ness, RB, Moysich, K, Chenevix-Trench, G, Beesley, J, Webb, PM, Chang-Claude, J, Wang-Gohrke, S, Goodman, MT, Lurie, G, Thompson, PJ, Carney, ME, Hogdall, E, Kjaer, SK, Hogdall, C, Goode, EL, Cunningham, JM, Fridley, BL, Vierkant, RA, Berchuck, A, Moorman, PG, Schildkraut, JM, Palmieri, RT, Cramer, DW, Terry, KL, Yang, HP, Garcia-Closas, M, Chanock, S, Lissowska, J, Song, H, Pharoah, PD, Shah, M, Perkins, B, McGuire, V, Whittemore, AS, Di Cioccio, RA, Gentry-Maharaj, A, Menon, U, Gayther, SA, Ramus, SJ, Ziogas, A, Brewster, W, Anton-Culver, H, & Pearce, CL. (2010). ESR1/SYNE1 polymorphism and invasive epithelial ovarian cancer risk: an Ovarian Cancer Association Consortium study. Cancer Epidemiol Biomarkers Prev, 19(1), 245-250.* Impact factor = 4.559

PRA45. Fridley, BL, Jenkins, G, Deyo-Svendsen, ME, Hebbring, S, & Freimuth, R. (2010). Utilizing genotype imputation for the augmentation of sequence data. PLoS One, 5(6), e11018. Impact factor = 3.73

PRA46. Fridley, BL, & Jenkins, GD. (2010). Localizing putative markers in genetic association studies by incorporating linkage disequilibrium into bayesian hierarchical models. Hum Hered, 70(1), 63-73. Impact factor = 1.57

PRA47. Fridley, BL, Jenkins, GD, & Biernacka, JM. (2010). Self-contained gene-set analysis of expression data: an evaluation of existing and novel methods. PLoS One, 5(9), e12693.* Impact factor = 3.73

PRA48. Fridley, BL, Serie, D, Jenkins, G, White, K, Bamlet, W, Potter, JD, & Goode, EL. (2010). Bayesian mixture models for the incorporation of prior knowledge to inform genetic association studies. Genet Epidemiol, 34(5), 418-426. Impact factor = 4.015

PRA49. Goode, EL, Chenevix-Trench, G, Song, H, Ramus, SJ, Notaridou, M, Lawrenson, K, Widschwendter, M, Vierkant, RA, Larson, MC, Kjaer, SK, Birrer, MJ, Berchuck, A, Schildkraut, J, Tomlinson, I, Kiemeney, LA, Cook, LS, Gronwald, J, Garcia-Closas, M, Gore, ME, Campbell, I, Whittemore, AS, Sutphen, R, Phelan, C, Anton-Culver, H, Pearce, CL, Lambrechts, D, Rossing, MA, Chang-Claude, J, Moysich, KB, Goodman, MT, Dork, T, Nevanlinna, H, Ness, RB, Rafnar, T, Hogdall, C, Hogdall, E, Fridley, BL, Cunningham, JM, Sieh, W, McGuire, V, Godwin, AK, Cramer, DW, Hernandez, D, Levine, D, Lu, K, Iversen, ES, Palmieri, RT, Houlston, R, van Altena, AM, Aben, KK, Massuger, LF, Brooks-Wilson, A, Kelemen, LE, Le, ND, Jakubowska, A, Lubinski, J, Medrek, K, Stafford, A, Easton, DF, Tyrer, J, Bolton, KL, Harrington, P, Eccles, D, Chen, A, Molina, AN, Davila, BN, Arango, H, Tsai, YY, Chen, Z, Risch, HA, McLaughlin, J, Narod, SA, Ziogas, A, Brewster, W, Gentry-Maharaj, A, Menon, U, Wu, AH, Stram, DO, Pike, MC, Beesley, J, Webb, PM, Chen, X, Ekici, AB, Thiel, FC, Beckmann, MW, Yang, H, Wentzensen, N, Lissowska, J, Fasching, PA, Despierre, E,



Amant, F, Vergote, I, Doherty, J, Hein, R, Wang-Gohrke, S, Lurie, G, Carney, ME, Thompson, PJ, Runnebaum, I, Hillemanns, P, Durst, M, Antonenkova, N, Bogdanova, N, Leminen, A, Butzow, R, Heikkinen, T, Stefansson, K, Sulem, P, Besenbacher, S, Sellers, TA, Gayther, SA, & Pharoah, PD. (2010). A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nat Genet, 42(10), 874-879.* Impact factor = 35.209

PRA50. Goode, EL, Maurer, MJ, Sellers, TA, Phelan, CM, Kalli, KR, Fridley, BL, Vierkant, RA, Armasu, SM, White, KL, Keeney, GL, Cliby, WA, Rider, DN, Kelemen, LE, Jones, MB, Peethambaram, PP, Lancaster, JM, Olson, JE, Schildkraut, JM, Cunningham, JM, & Hartmann, LC. (2010). Inherited determinants of ovarian cancer survival. Clin Cancer Res, 16(3), 995-1007.* Impact factor = 7.837

PRA51. Gray-McGuire, C, Guda, K, Adrianto, I, Lin, CP, Natale, L, Potter, JD, Newcomb, P, Poole, EM, Ulrich, CM, Lindor, N, Goode, EL, Fridley, BL, Jenkins, R, Le Marchand, L, Casey, G, Haile, R, Hopper, J, Jenkins, M, Young, J, Buchanan, D, Gallinger, S, Adams, M, Lewis, S, Willis, J, Elston, R, Markowitz, SD, & Wiesner, GL. (2010). Confirmation of linkage to and localization of familial colon cancer risk haplotype on chromosome 9q22. Cancer Res, 70(13), 5409-5418. Impact factor = 8.650

PRA52. Kelemen, LE, Goodman, MT, McGuire, V, Rossing, MA, Webb, PM, Kobel, M, Anton-Culver, H, Beesley, J, Berchuck, A, Brar, S, Carney, ME, Chang-Claude, J, Chenevix-Trench, G, Cramer, DW, Cunningham, JM, Dicioccio, RA, Doherty, JA, Easton, DF, Fredericksen, ZS, Fridley, BL, Gates, MA, Gayther, SA, Gentry-Maharaj, A, Hogdall, E, Kjaer, SK, Lurie, G, Menon, U, Moorman, PG, Moysich, K, Ness, RB, Palmieri, RT, Pearce, CL, Pharoah, PD, Ramus, SJ, Song, H, Stram, DO, Tworoger, SS, Van Den Berg, D, Vierkant, RA, Wang-Gohrke, S, Whittemore, AS, Wilkens, LR, Wu, AH, Schildkraut, JM, Sellers, TA, & Goode, EL. (2010). Genetic variation in TYMS in the one-carbon transfer pathway is associated with ovarian carcinoma types in the Ovarian Cancer Association Consortium. Cancer Epidemiol Biomarkers Prev, 19(7), 1822-1830. Impact factor = 4.559

PRA53. Li, F, Fridley, BL, Matimba, A, Kalari, KR, Pelleymounter, L, Moon, I, Ji, Y, Jenkins, GD, Batzler, A, Wang, L, & Weinshilboum, RM. (2010). Ecto-5'-nucleotidase and thiopurine cellular circulation: association with cytotoxicity. Drug Metab Dispos, 38(12), 2329-2338. Impact factor = 3.361

PRA54. Niu, N, Qin, Y, Fridley, BL, Hou, J, Kalari, KR, Zhu, M, Wu, TY, Jenkins, GD, Batzler, A, & Wang, L. (2010). Radiation pharmacogenomics: a genome-wide association approach to identify radiation response biomarkers using human lymphoblastoid cell lines. Genome Res, 20(11), 1482-1492.* Impact factor = 14.397

PRA55. Peedicayil, A, Vierkant, RA, Hartmann, LC, Fridley, BL, Fredericksen, ZS, White, KL, Elliott, EA, Phelan, CM, Tsai, YY, Berchuck, A, Iversen, ES, Jr., Couch, FJ, Peethamabaran, P, Larson, MC, Kalli, KR, Kosel, ML, Shridhar, V, Rider, DN, Liebow, M, Cunningham, JM, Schildkraut, JM, Sellers, TA, & Goode, EL. (2010). Risk of ovarian cancer and inherited variants in relapse-associated genes. PLoS One, 5(1), e8884. Impact factor = 3.73

PRA56. Phelan, CM, Tsai, YY, Goode, EL, Vierkant, RA, Fridley, BL, Beesley, J, Chen, XQ, Webb, PM, Chanock, S, Cramer, DW, Moysich, K, Edwards, RP, Chang-Claude, J, Garcia-Closas, M, Yang, H, Wang-Gohrke, S, Hein, R, Green, AC, Lissowska, J, Carney, ME, Lurie, G, Wilkens, LR, Ness, RB, Pearce, CL, Wu, AH, Van Den Berg, DJ, Stram, DO, Terry, KL, Whiteman, DC, Whittemore, AS, DiCioccio, RA, McGuire, V, Doherty, JA, Rossing, MA, Anton-Culver, H, Ziogas, A, Hogdall, C, Hogdall, E, Kruger Kjaer, S, Blaakaer, J, Quaye, L, Ramus, SJ, Jacobs, I, Song, H, Pharoah, PD, Iversen, ES, Marks, JR, Pike, MC, Gayther, SA, Cunningham, JM, Goodman, MT, Schildkraut, JM, Chenevix-Trench, G, Berchuck, A, & Sellers, TA. (2010). Polymorphism in the GALNT1 gene and epithelial ovarian cancer in non-Hispanic white women: the Ovarian Cancer Association Consortium. Cancer Epidemiol Biomarkers Prev, 19(2), 600-604. Impact factor = 4.559

PRA57. Ryu, E, Fridley, BL, Tosakulwong, N, Bailey, KR, & Edwards, AO. (2010). Genome-wide association analyses of genetic, phenotypic, and environmental risks in the age-related eye disease study. Mol Vis, 16, 2811-2821.* Impact factor = 1.99


Curriculum vitae: Brooke L. Fridley P a g e | 20 PRA58. Saito, YA, Petersen, GM, Larson, JJ, Atkinson, EJ, Fridley, BL, de Andrade, M, Locke, GR, 3rd, Zimmerman,

JM, Almazar-Elder, AE, & Talley, NJ. (2010). Familial aggregation of irritable bowel syndrome: a family case-control study. Am J Gastroenterol, 105(4), 833-841.* Impact factor = 7.553

PRA59. Wang, L, Ellsworth, KA, Moon, I, Pelleymounter, LL, Eckloff, BW, Martin, YN, Fridley, BL, Jenkins, GD, Batzler, A, Suman, VJ, Ravi, S, Dixon, JM, Miller, WR, Wieben, ED, Buzdar, A, Weinshilboum, RM, & Ingle, JN. (2010). Functional genetic polymorphisms in the aromatase gene CYP19 vary the response of breast cancer patients to neoadjuvant therapy with aromatase inhibitors. Cancer Res, 70(1), 319-328.* Impact factor = 8.650

PRA60. White, KL, Sellers, TA, Fridley, BL, Vierkant, RA, Phelan, CM, Tsai, YY, Kalli, KR, Berchuck, A, Iversen, ES, Hartmann, LC, Liebow, M, Armasu, S, Fredericksen, Z, Larson, MC, Duggan, D, Couch, FJ, Schildkraut, JM, Cunningham, JM, & Goode, EL. (2010). Variation at 8q24 and 9p24 and risk of epithelial ovarian cancer. Twin Res Hum Genet, 13(1), 43-56. Impact factor = 1.64

PRA61. Amankwah, EK, Kelemen, LE, Wang, Q, Song, H, Chenevix-Trench, G, Beesley, J, Webb, PM, Pearce, CL, Wu, AH, Pike, MC, Stram, DO, Chang-Claude, J, Wang-Gohrke, S, Ness, RB, Goode, EL, Cunningham, JM, Fridley, BL, Vierkant, RA, Tworoger, SS, Whittemore, AS, McGuire, V, Sieh, W, Gayther, SA, Gentry-Maharaj, A, Menon, U, Ramus, SJ, Rossing, MA, Doherty, JA, Goodman, MT, Carney, ME, Lurie, G, Wilkens, LR, Kruger Kjaer, S, Hogdall, E, Cramer, DW, Terry, KL, Garcia-Closas, M, Yang, H, Lissowska, J, Anton-Culver, H, Ziogas, A, Schildkraut, JM, Berchuck, A, & Pharoah, PD. (2011). Prostate Cancer Susceptibility Polymorphism rs2660753 Is Not Associated with Invasive Ovarian Cancer. Cancer Epidemiol Biomarkers Prev, 20(5), 1028-1031. Impact factor = 4.559

PRA62. Amankwah, EK, Wang, Q, Schildkraut, JM, Tsai, YY, Ramus, SJ, Fridley, BL, Beesley, J, Johnatty, SE, Webb, PM, Chenevix-Trench, G, Dale, LC, Lambrechts, D, Amant, F, Despierre, E, Vergote, I, Gayther, SA, Gentry-Maharaj, A, Menon, U, Chang-Claude, J, Wang-Gohrke, S, Anton-Culver, H, Ziogas, A, Dork, T, Durst, M, Antonenkova, N, Bogdanova, N, Brown, R, Flanagan, JM, Kaye, SB, Paul, J, Butzow, R, Nevanlinna, H, Campbell, I, Eccles, DM, Karlan, BY, Gross, J, Walsh, C, Pharoah, PD, Song, H, Kruger Kjaer, S, Hogdall, E, Hogdall, C, Lundvall, L, Nedergaard, L, Kiemeney, LA, Massuger, LF, van Altena, AM, Vermeulen, SH, Le, ND, Brooks-Wilson, A, Cook, LS, Phelan, CM, Cunningham, JM, Vachon, CM, Vierkant, RA, Iversen, ES, Berchuck, A, Goode, EL, Sellers, TA, & Kelemen, LE. (2011). Polymorphisms in stromal genes and susceptibility to serous epithelial ovarian cancer: a report from the ovarian cancer association consortium. PLoS One, 6(5), e19642. Impact factor = 3.73

PRA63. Brisbin, AG, Asmann, YW, Song, H, Tsai, YY, Aakre, JA, Yang, P, Jenkins, RB, Pharoah, P, Schumacher, F, Conti, DV, Duggan, DJ, Jenkins, M, Hopper, J, Gallinger, S, Newcomb, P, Casey, G, Sellers, TA, & Fridley, BL. (2011). Meta-analysis of 8q24 for seven cancers reveals a locus between NOV and ENPP2 associated with cancer development. BMC Med Genet, 12(1), 156. Impact factor = 2.536

PRA64. Feng, Q, Kalari, K, Fridley, BL, Jenkins, G, Ji, Y, Abo, R, Hebbring, S, Zhang, J, Nye, MD, Leeder, JS, & Weinshilboum, RM. (2011). Betaine-homocysteine methyltransferase: human liver genotype-phenotype correlation. Mol Genet Metab, 102(2), 126-133.Impact factor = 2.83

PRA65. Fridley, BL, Batzler, A, Li, L, Li, F, Matimba, A, Jenkins, GD, Ji, Y, Wang, L, & Weinshilboum, RM. (2011). Gene set analysis of purine and pyrimidine antimetabolites cancer therapies. Pharmacogenet Genomics. Impact factor = 3.608

PRA66. Fridley, BL, & Biernacka, JM. (2011). Gene set analysis of SNP data: benefits, challenges, and future directions. Eur J Hum Genet, 19(8), 837-843.* Impact factor = 4.319

PRA67. Fridley, BL, Iversen, E, Tsai, YY, Jenkins, GD, Goode, EL, & Sellers, TA. (2011). A Latent Model for Prioritization of SNPs for Functional Studies. PLoS One, 6(6), e20764. Impact factor = 3.73

PRA68. Goode, EL, Chenevix-Trench, G, Hartmann, LC, Fridley, BL, Kalli, KR, Vierkant, RA, Larson, MC, White, KL, Keeney, GL, Oberg, TN, Cunningham, JM, Beesley, J, Johnatty, SE, Chen, X, Goodman, KE, Armasu, SM, Rider, DN, Sicotte, H, Schmidt, MM, Elliott, EA, Hogdall, E, Kjaer, SK, Fasching, PA, Ekici, AB,



Lambrechts, D, Despierre, E, Hogdall, C, Lundvall, L, Karlan, BY, Gross, J, Brown, R, Chien, J, Duggan, DJ, Tsai, YY, Phelan, CM, Kelemen, LE, Peethambaram, PP, Schildkraut, JM, Shridhar, V, Sutphen, R, Couch, FJ, & Sellers, TA. (2011). Assessment of hepatocyte growth factor in ovarian cancer mortality. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 20(8), 1638-1648. Impact factor = 4.559

PRA69. Goode, EL, White, KL, Vierkant, RA, Phelan, CM, Cunningham, JM, Schildkraut, JM, Berchuck, A, Larson, MC, Fridley, BL, Olson, JE, Webb, PM, Chen, X, Beesley, J, Chenevix-Trench, G, & Sellers, TA. (2011). Xenobiotic-Metabolizing gene polymorphisms and ovarian cancer risk. Mol Carcinog, 50(5), 397-402. Impact factor = 4.269

PRA70. Huang, RS, Johnatty, SE, Gamazon, ER, Im, HK, Ziliak, D, Duan, S, Zhang, W, Kistner, EO, Chen, P, Beesley, J, Mi, S, O'Donnell, PH, Fraiman, YS, Das, S, Cox, NJ, Lu, Y, Macgregor, S, Goode, EL, Vierkant, RA, Fridley, BL, Hogdall, E, Kjaer, SK, Jensen, A, Moysich, KB, Grasela, M, Odunsi, K, Brown, R, Paul, J, Lambrechts, D, Despierre, E, Vergote, I, Gross, J, Karlan, BY, Defazio, A, Chenevix-Trench, G, & Dolan, ME. (2011). Platinum sensitivity-related germline polymorphism discovered via a cell-based approach and analysis of its association with outcome in ovarian cancer patients. Clinical cancer research : an official journal of the American Association for Cancer Research, 17(16), 5490-5500.* Impact factor = 7.837

PRA71. Jenkins, RB, Wrensch, MR, Johnson, D, Fridley, BL, Decker, PA, Xiao, Y, Kollmeyer, TM, Rynearson, AL, Fink, S, Rice, T, McCoy, LS, Halder, C, Kosel, ML, Giannini, C, Tihan, T, O'Neill, BP, Lachance, DH, Yang, P, Wiemels, J, & Wiencke, JK. (2011). Distinct germ line polymorphisms underlie glioma morphologic heterogeneity. Cancer Genet, 204(1), 13-18.* Impact factor = 1.915

PRA72. Moyer, AM, Fridley, BL, Jenkins, GD, Batzler, AJ, Pelleymounter, LL, Kalari, KR, Ji, Y, Chai, Y, Nordgren, KK, & Weinshilboum, RM. (2011). Acetaminophen-NAPQI hepatotoxicity: a cell line model system genome-wide association study. Toxicol Sci, 120(1), 33-41. Impact factor = 4.328

PRA73. Near, AM, Wu, AH, Templeman, C, Van Den Berg, DJ, Doherty, JA, Rossing, MA, Goode, EL, Cunningham, JM, Vierkant, RA, Fridley, BL, Chenevix-Trench, G, Webb, PM, Kjaer, SK, Hogdall, E, Gayther, SA, Ramus, SJ, Menon, U, Gentry-Maharaj, A, Schildkraut, JM, Moorman, PG, Palmieri, RT, Ness, RB, Moysich, K, Cramer, DW, Terry, KL, Vitonis, AF, Pike, MC, Berchuck, A, & Pearce, CL. (2011). Progesterone receptor gene polymorphisms and risk of endometriosis: results from an international collaborative effort. Fertil Steril, 95(1), 40-45. Impact factor = 4.174

PRA74. Peethambaram, P, Fridley, BL, Vierkant, RA, Larson, MC, Kalli, KR, Elliott, EA, Oberg, AL, White, KL, Rider, DN, Keeney, GL, Cunningham, JM, Hartmann, LC, & Goode, EL. (2011). Polymorphisms in ABCB1 and ERCC2 associated with ovarian cancer outcome. Int J Mol Epidemiol Genet, 2(2), 185-195. Impact factor = 1.329

PRA75. Permuth-Wey, J, Chen, YA, Tsai, YY, Chen, Z, Qu, X, Lancaster, JM, Stockwell, H, Dagne, G, Iversen, E, Risch, H, Barnholtz-Sloan, J, Cunningham, JM, Vierkant, RA, Fridley, BL, Sutphen, R, McLaughlin, J, Narod, SA, Goode, EL, Schildkraut, JM, Fenstermacher, D, Phelan, CM, & Sellers, TA. (2011). Inherited variants in mitochondrial biogenesis genes may influence epithelial ovarian cancer risk. Cancer Epidemiol Biomarkers Prev, 20(6), 1131-1145. Impact factor = 4.559

PRA76. Permuth-Wey, J, Chen, Z, Tsai, YY, Lin, HY, Chen, YA, Barnholtz-Sloan, J, Birrer, MJ, Chanock, SJ, Cramer, DW, Cunningham, JM, Fenstermacher, D, Fridley, BL, Garcia-Closas, M, Gayther, SA, Gentry-Maharaj, A, Gonzalez Bosquet, J, Iversen, E, Jim, H, McLaughlin, J, Menon, U, Narod, SA, Phelan, CM, Ramus, SJ, Risch, H, Song, H, Sutphen, R, Terry, KL, Tyrer, J, Vierkant, RA, Wentzensen, N, Lancaster, JM, Cheng, JQ, Berchuck, A, Pharoah, PD, Schildkraut, JM, Goode, EL, & Sellers, TA. (2011). MicroRNA Processing and Binding Site Polymorphisms are not Replicated in the Ovarian Cancer Association Consortium. Cancer Epidemiol Biomarkers Prev. Impact factor = 4.559


Curriculum vitae: Brooke L. Fridley P a g e | 22 PRA77. Permuth-Wey, J, Kim, D, Tsai, YY, Lin, HY, Chen, YA, Barnholtz-Sloan, J, Birrer, MJ, Bloom, G, Chanock,

SJ, Chen, Z, Cramer, DW, Cunningham, JM, Dagne, G, Ebbert-Syfrett, J, Fenstermacher, D, Fridley, BL, Garcia-Closas, M, Gayther, SA, Ge, W, Gentry-Maharaj, A, Gonzalez-Bosquet, J, Goode, EL, Iversen, E, Jim, H, Kong, W, McLaughlin, J, Menon, U, Monteiro, AN, Narod, SA, Pharoah, PD, Phelan, CM, Qu, X, Ramus, SJ, Risch, H, Schildkraut, JM, Song, H, Stockwell, H, Sutphen, R, Terry, KL, Tyrer, J, Vierkant, RA, Wentzensen, N, Lancaster, JM, Cheng, JQ, & Sellers, TA. (2011). LIN28B Polymorphisms Influence Susceptibility to Epithelial Ovarian Cancer. Cancer Res, 71(11), 3896-3903.* Impact factor = 8.650

PRA78. Pharoah, PD, Palmieri, RT, Ramus, SJ, Gayther, SA, Andrulis, IL, Anton-Culver, H, Antonenkova, N, Antoniou, AC, Goldgar, D, Beattie, MS, Beckmann, MW, Birrer, MJ, Bogdanova, N, Bolton, KL, Brewster, W, Brooks-Wilson, A, Brown, R, Butzow, R, Caldes, T, Caligo, MA, Campbell, I, Chang-Claude, J, Chen, YA, Cook, LS, Couch, FJ, Cramer, DW, Cunningham, JM, Despierre, E, Doherty, JA, Dork, T, Durst, M, Eccles, DM, Ekici, AB, Easton, D, Fasching, PA, de Fazio, A, Fenstermacher, DA, Flanagan, JM, Fridley, BL, Friedman, E, Gao, B, Sinilnikova, O, Gentry-Maharaj, A, Godwin, AK, Goode, EL, Goodman, MT, Gross, J, Hansen, TV, Harnett, P, Rookus, M, Heikkinen, T, Hein, R, Hogdall, C, Hogdall, E, Iversen, ES, Jakubowska, A, Johnatty, SE, Karlan, BY, Kauff, ND, Kaye, SB, Chenevix-Trench, G, Kelemen, LE, Kiemeney, LA, Kjaer, SK, Lambrechts, D, Lapolla, JP, Lazaro, C, Le, ND, Leminen, A, Leunen, K, Levine, DA, Lu, Y, Lundvall, L, Macgregor, S, Marees, T, Massuger, LF, McLaughlin, JR, Menon, U, Montagna, M, Moysich, KB, Narod, SA, Nathanson, KL, Nedergaard, L, Ness, RB, Nevanlinna, H, Nickels, S, Osorio, A, Paul, J, Pearce, CL, Phelan, CM, Pike, MC, Radice, P, Rossing, MA, Schildkraut, JM, Sellers, TA, Singer, CF, Song, H, Stram, DO, Sutphen, R, Lindblom, A, Terry, KL, Tsai, YY, van Altena, AM, Vergote, I, Vierkant, RA, Vitonis, AF, Walsh, C, Wang-Gohrke, S, Wappenschmidt, B, Wu, AH, Ziogas, A, Berchuck, A, & Risch, HA. (2011). The Role of KRAS rs61764370 in Invasive Epithelial Ovarian Cancer: Implications for Clinical Testing. Clin Cancer Res, 17(11), 3742-3750.* Impact factor = 7.837

PRA79. Reid-Lombardo, KM, Fridley, BL, Bamlet, WR, Cunningham, JM, Sarr, MG, & Petersen, GM. (2011). Inflammation-related gene variants as risk factors for pancreatic cancer. Cancer Epidemiol Biomarkers Prev, 20(6), 1251-1254. Impact factor = 4.559

PRA80. Tan, XL, Moyer, AM, Fridley, BL, Schaid, DJ, Niu, N, Batzler, AJ, Jenkins, GD, Abo, RP, Li, L, Cunningham, JM, Sun, Z, Yang, P, & Wang, L. (2011). Genetic variation predicting cisplatin cytotoxicity associated with overall survival in lung cancer patients receiving platinum-based chemotherapy. Clinical cancer research : an official journal of the American Association for Cancer Research, 17(17), 5801-5811.* Impact factor = 7.837

PRA81. Wu, TY, Fridley, BL, Jenkins, GD, Batzler, A, Wang, L, & Weinshilboum, RM. (2011). Mycophenolic acid response biomarkers: A cell line model system-based genome-wide screen. Int Immunopharmacol. Impact factor = 2.417

PRA82. Abo, R, Hebbring, S, Ji, Y, Zhu, H, Zeng, ZB, Batzler, A, Jenkins, GD, Biernacka, J, Snyder, K, Drews, M, Fiehn, O, Fridley, B, Schaid, D, Kamatani, N, Nakamura, Y, Kubo, M, Mushiroda, T, Kaddurah-Daouk, R, Mrazek, DA, & Weinshilboum, RM. (2012). Merging pharmacometabolomics with pharmacogenomics using '1000 Genomes' single-nucleotide polymorphism imputation: selective serotonin reuptake inhibitor response pharmacogenomics. Pharmacogenet Genomics, 22(4), 247-253. Impact factor = 3.608

PRA83. Abo, R, Jenkins, GD, Wang, L, & Fridley, BL. (2012). Identifying the Genetic Variation of Gene Expression Using Gene Sets: Application of Novel Gene Set eQTL Approach to PharmGKB and KEGG. PLoS One, 7(8), e43301. Impact factor = 3.73

PRA84. Biernacka, JM, Jenkins, GD, Wang, L, Moyer, AM, & Fridley, BL. (2012). Use of the gamma method for self-contained gene-set analysis of SNP data. Eur J Hum Genet, 20(5), 565-571. Impact factor = 4.319

PRA85. Bolton, KL, Chenevix-Trench, G, Goh, C, Sadetzki, S, Ramus, SJ, Karlan, BY, Lambrechts, D, Despierre, E, Barrowdale, D, McGuffog, L, Healey, S, Easton, DF, Sinilnikova, O, Benitez, J, Garcia, MJ, Neuhausen, S, Gail, MH, Hartge, P, Peock, S, Frost, D, Evans, DG, Eeles, R, Godwin, AK, Daly, MB, Kwong, A, Ma, ES,



Lazaro, C, Blanco, I, Montagna, M, D'Andrea, E, Nicoletto, MO, Johnatty, SE, Kjaer, SK, Jensen, A, Hogdall, E, Goode, EL, Fridley, BL, Loud, JT, Greene, MH, Mai, PL, Chetrit, A, Lubin, F, Hirsh-Yechezkel, G, Glendon, G, Andrulis, IL, Toland, AE, Senter, L, Gore, ME, Gourley, C, Michie, CO, Song, H, Tyrer, J, Whittemore, AS, McGuire, V, Sieh, W, Kristoffersson, U, Olsson, H, Borg, A, Levine, DA, Steele, L, Beattie, MS, Chan, S, Nussbaum, RL, Moysich, KB, Gross, J, Cass, I, Walsh, C, Li, AJ, Leuchter, R, Gordon, O, Garcia-Closas, M, Gayther, SA, Chanock, SJ, Antoniou, AC, Pharoah, PD, Embrace, kConFab, I, & Cancer Genome Atlas Research, N. (2012). Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA, 307(4), 382-390.* Impact factor = 29.98

PRA86. Breheny, P, Chalise, P, Batzler, A, Wang, L, & Fridley, BL. (2012). Genetic association studies of copy-number variation: should assignment of copy number states precede testing? PLoS One, 7(4), e34262. Impact factor = 3.73

PRA87. Brisbin, A, Jenkins, GD, Ellsworth, KA, Wang, L, & Fridley, BL. (2012). Localization of association signal from risk and protective variants in sequencing studies. Front Genet, 3, 173.

PRA88. Chalise, P, Batzler, A, Abo, R, Wang, L, & Fridley, BL. (2012). Simultaneous analysis of multiple data types in pharmacogenomic studies using weighted sparse canonical correlation analysis. OMICS, 16(7-8), 363-373. Impact factor = 2.73

PRA89. Chalise, P, & Fridley, BL. (2012). Comparison of Penalty Functions for Sparse Canonical Correlation Analysis. Comput Stat Data Anal, 56(2), 245-254. Impact factor = 1.30

PRA90. Cicek, MS, Cunningham, JM, Fridley, BL, Serie, DJ, Bamlet, WR, Diergaarde, B, Haile, RW, Le Marchand, L, Krontiris, TG, Younghusband, HB, Gallinger, S, Newcomb, PA, Hopper, JL, Jenkins, MA, Casey, G, Schumacher, F, Chen, Z, DeRycke, MS, Templeton, AS, Winship, I, Green, RC, Green, JS, Macrae, FA, Parry, S, Young, GP, Young, JP, Buchanan, D, Thomas, DC, Bishop, DT, Lindor, NM, Thibodeau, SN, Potter, JD, Goode, EL, & Colon, CFR. (2012). Colorectal cancer linkage on chromosomes 4q21, 8q13, 12q24, and 15q22. PLoS One, 7(5), e38175. Impact factor = 3.73

PRA91. Fridley, BL, Chalise, P, Tsai, YY, Sun, Z, Vierkant, RA, Larson, MC, Cunningham, JM, Iversen, ES, Fenstermacher, D, Barnholtz-Sloan, J, Asmann, Y, Risch, HA, Schildkraut, JM, Phelan, CM, Sutphen, R, Sellers, TA, & Goode, EL. (2012). Germline copy number variation and ovarian cancer survival. Front Genet, 3, 142.

PRA92. Fridley, BL, Jenkins, GD, Batzler, A, Wang, L, Ji, Y, Li, F, & Weinshilboum, RM. (2012). Multivariate models to detect genomic signatures for a class of drugs: application to thiopurines pharmacogenomics. Pharmacogenomics J, 12(2), 105-110. Impact factor = 5.134

PRA93. Fridley, BL, Jenkins, GD, Tsai, YY, Song, H, Bolton, KL, Fenstermacher, D, Tyrer, J, Ramus, SJ, Cunningham, JM, Vierkant, RA, Chen, Z, Chen, YA, Iversen, E, Menon, U, Gentry-Maharaj, A, Schildkraut, J, Sutphen, R, Gayther, SA, Hartmann, LC, Pharoah, PD, Sellers, TA, & Goode, EL. (2012). Gene set analysis of survival following ovarian cancer implicates macrolide binding and intracellular signaling genes. Cancer Epidemiol Biomarkers Prev, 21(3), 529-536. Impact factor = 4.559

PRA94. Fridley, BL, Lund, S, Jenkins, GD, & Wang, L. (2012). A Bayesian integrative genomic model for pathway analysis of complex traits. Genet Epidemiol, 36(4), 352-359. Impact factor = 4.015

PRA95. Hebbring, SJ, Chai, Y, Ji, Y, Abo, RP, Jenkins, GD, Fridley, B, Zhang, J, Eckloff, BW, Wieben, ED, & Weinshilboum, RM. (2012). Serine hydroxymethyltransferase 1 and 2: gene sequence variation and functional genomic characterization. J Neurochem, 120(6), 881-890. Impact factor = 3.97

PRA96. Jenkins, RB, Xiao, Y, Sicotte, H, Decker, PA, Kollmeyer, TM, Hansen, HM, Kosel, ML, Zheng, S, Walsh, KM, Rice, T, Bracci, P, McCoy, LS, Smirnov, I, Patoka, JS, Hsuang, G, Wiemels, JL, Tihan, T, Pico, AR, Prados, MD, Chang, SM, Berger, MS, Caron, AA, Fink, SR, Halder, C, Rynearson, AL, Fridley, BL, Buckner, JC, O'Neill, BP, Giannini, C, Lachance, DH, Wiencke, JK, Eckel-Passow, JE, & Wrensch, MR. (2012). A low-



frequency variant at 8q24.21 is strongly associated with risk of oligodendroglial tumors and astrocytomas with IDH1 or IDH2 mutation. Nat Genet, 44(10), 1122-1125.* Impact factor = 35.209

PRA97. Ji, Y, Nordgren, KK, Chai, Y, Hebbring, SJ, Jenkins, GD, Abo, RP, Peng, Y, Pelleymounter, LL, Moon, I, Eckloff, BW, Chai, X, Zhang, J, Fridley, BL, Yee, VC, Wieben, ED, & Weinshilboum, RM. (2012). Human liver methionine cycle: MAT1A and GNMT gene resequencing, functional genomics, and hepatic genotype-phenotype correlation. Drug Metab Dispos, 40(10), 1984-1992. Impact factor = 3.36

PRA98. Kelemen, LE, Wang, Q, Dinu, I, Vierkant, RA, Tsai, YY, Cunningham, JM, Phelan, CM, Fridley, BL, Amankwah, EK, Iversen, ES, Berchuck, A, Schildkraut, JM, Goode, EL, & Sellers, TA. (2012). Regular Multivitamin Supplement Use, Single Nucleotide Polymorphisms in ATIC, SHMT2, and SLC46A1, and Risk of Ovarian Carcinoma. Front Genet, 3, 33.

PRA99. Li, L, Schaid, DJ, Fridley, BL, Kalari, KR, Jenkins, GD, Abo, RP, Batzler, A, Moon, I, Pelleymounter, L, Eckloff, BW, Wieben, ED, Sun, Z, Yang, P, & Wang, L. (2012). Gemcitabine metabolic pathway genetic polymorphisms and response in patients with non-small cell lung cancer. Pharmacogenet Genomics, 22(2), 105-116. Impact factor = 3.608

PRA100. Pearce, CL, Templeman, C, Rossing, MA, Lee, A, Near, AM, Webb, PM, Nagle, CM, Doherty, JA, Cushing-Haugen, KL, Wicklund, KG, Chang-Claude, J, Hein, R, Lurie, G, Wilkens, LR, Carney, ME, Goodman, MT, Moysich, K, Kjaer, SK, Hogdall, E, Jensen, A, Goode, EL, Fridley, BL, Larson, MC, Schildkraut, JM, Palmieri, RT, Cramer, DW, Terry, KL, Vitonis, AF, Titus, LJ, Ziogas, A, Brewster, W, Anton-Culver, H, Gentry-Maharaj, A, Ramus, SJ, Anderson, AR, Brueggmann, D, Fasching, PA, Gayther, SA, Huntsman, DG, Menon, U, Ness, RB, Pike, MC, Risch, H, Wu, AH, Berchuck, A, & Ovarian Cancer Association, C. (2012). Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. Lancet Oncol, 13(4), 385-394.* Impact factor = 25.117

PRA101. Poole, EM, Gates, MA, High, BA, Chanock, SJ, Cramer, DW, Cunningham, JM, Fridley, BL, Gayther, SA, Goode, EL, Iversen, ES, Lissowska, J, Weber, RT, Pharoah, PD, Phelan, CM, Ramus, SJ, Schildkraut, JM, Sutphen, R, Tsai, YY, Tyrer, J, Vierkant, RA, Wentzensen, N, Yang, HP, Terry, KL, & Tworoger, SS. (2012). ABO blood group and risk of epithelial ovarian cancer within the Ovarian Cancer Association Consortium. Cancer Causes Control, 23(11), 1805-1810. Impact factor = 3.20.

PRA102. Rajaraman, P, Melin, BS, Wang, Z, McKean-Cowdin, R, Michaud, DS, Wang, SS, Bondy, M, Houlston, R, Jenkins, RB, Wrensch, M, Yeager, M, Ahlbom, A, Albanes, D, Andersson, U, Freeman, LE, Buring, JE, Butler, MA, Braganza, M, Carreon, T, Feychting, M, Fleming, SJ, Gapstur, SM, Gaziano, JM, Giles, GG, Hallmans, G, Henriksson, R, Hoffman-Bolton, J, Inskip, PD, Johansen, C, Kitahara, CM, Lathrop, M, Liu, C, Le Marchand, L, Linet, MS, Lonn, S, Peters, U, Purdue, MP, Rothman, N, Ruder, AM, Sanson, M, Sesso, HD, Severi, G, Shu, XO, Simon, M, Stampfer, M, Stevens, VL, Visvanathan, K, White, E, Wolk, A, Zeleniuch-Jacquotte, A, Zheng, W, Decker, P, Enciso-Mora, V, Fridley, B, Gao, YT, Kosel, M, Lachance, DH, Lau, C, Rice, T, Swerdlow, A, Wiemels, JL, Wiencke, JK, Shete, S, Xiang, YB, Xiao, Y, Hoover, RN, Fraumeni, JF, Jr., Chatterjee, N, Hartge, P, & Chanock, SJ. (2012). Genome-wide association study of glioma and meta-analysis. Hum Genet.* Impact factor = 4.633

PRA103. Raska, P, Iversen, E, Chen, A, Chen, Z, Fridley, BL, Permuth-Wey, J, Tsai, YY, Vierkant, RA, Goode, EL, Risch, H, Schildkraut, JM, Sellers, TA, & Barnholtz-Sloan, J. (2012). European American stratification in ovarian cancer case control data: the utility of genome-wide data for inferring ancestry. PLoS One, 7(5), e35235. Impact factor = 3.73

PRA104. Stevens, KN, Kelemen, LE, Wang, X, Fridley, BL, Vierkant, RA, Fredericksen, Z, Armasu, SM, Tsai, YY, Berchuck, A, Narod, SA, Phelan, CM, Sutphen, R, Birrer, MJ, Schildkraut, JM, Sellers, TA, Goode, EL, Ovarian Cancer Association, C, & Couch, FJ. (2012). Common variation in Nemo-like kinase is associated with risk of ovarian cancer. Cancer Epidemiol Biomarkers Prev, 21(3), 523-528. Impact factor = 4.559



PRA105. Stevens, KN, Lindstrom, S, Scott, CG, Thompson, D, Sellers, TA, Wang, X, Wang, A, Atkinson, E, Rider, DN, Eckel-Passow, JE, Varghese, JS, Audley, T, Brown, J, Leyland, J, Luben, RN, Warren, RM, Loos, RJ, Wareham, NJ, Li, J, Hall, P, Liu, J, Eriksson, L, Czene, K, Olson, JE, Pankratz, VS, Fredericksen, Z, Diasio, RB, Lee, AM, Heit, JA, DeAndrade, M, Goode, EL, Vierkant, RA, Cunningham, JM, Armasu, SM, Weinshilboum, R, Fridley, BL, Batzler, A, Ingle, JN, Boyd, NF, Paterson, AD, Rommens, J, Martin, LJ, Hopper, JL, Southey, MC, Stone, J, Apicella, C, Kraft, P, Hankinson, SE, Hazra, A, Hunter, DJ, Easton, DF, Couch, FJ, Tamimi, RM, & Vachon, CM. (2012). Identification of a novel percent mammographic density locus at 12q24. Hum Mol Genet, 21(14), 3299-3305. Impact factor = 7.692

PRA106. White, KL, Schildkraut, JM, Palmieri, RT, Iversen, ES, Jr., Berchuck, A, Vierkant, RA, Rider, DN, Charbonneau, B, Cicek, MS, Sutphen, R, Birrer, MJ, Pharoah, PP, Song, H, Tyrer, J, Gayther, SA, Ramus, SJ, Wentzensen, N, Yang, HP, Garcia-Closas, M, Phelan, CM, Cunningham, JM, Fridley, BL, Sellers, TA, Goode, EL, & Ovarian Cancer Association, C. (2012). Ovarian cancer risk associated with inherited inflammation-related variants. Cancer Res, 72(5), 1064-1069. Impact factor = 8.65

PRA107. Xiao, Y, Decker, PA, Rice, T, McCoy, LS, Smirnov, I, Patoka, JS, Hansen, HM, Wiemels, JL, Tihan, T, Prados, MD, Chang, SM, Berger, MS, Kosel, ML, Fridley, BL, Lachance, DH, O'Neill, BP, Buckner, JC, Thompson, RC, Nabors, LB, Olson, JJ, Brem, S, Madden, MH, Browning, JE, Wiencke, JK, Egan, KM, Jenkins, RB, & Wrensch, MR. (2012). SSBP2 variants are associated with survival in glioblastoma patients. Clin Cancer Res, 18(11), 3154-3162. Impact factor = 7.837

PRA108. Biernacka, JM, Geske, J, Jenkins, GD, Colby, C, Rider, DN, Karpyak, VM, Choi, DS, & Fridley, BL. (2013). Genome-wide gene-set analysis for identification of pathways associated with alcohol dependence. Int J Neuropsychopharmacol, 16(2), 271-278. Impact factor = 8.678

PRA109. Bojesen, SE, Pooley, KA, Johnatty, SE, Beesley, J, Michailidou, K, Tyrer, JP, Edwards, SL, Pickett, HA, Shen, HC, Smart, CE, Hillman, KM, Mai, PL, Lawrenson, K, Stutz, MD, Lu, Y, Karevan, R, Woods, N, Johnston, RL, French, JD, Chen, X, Weischer, M, Nielsen, SF, Maranian, MJ, Ghoussaini, M, Ahmed, S, Baynes, C, Bolla, MK, Wang, Q, Dennis, J, McGuffog, L, Barrowdale, D, Lee, A, Healey, S, Lush, M, Tessier, DC, Vincent, D, Bacot, F, Australian Cancer, S, Australian Ovarian Cancer, S, Kathleen Cuningham Foundation Consortium for Research into Familial Breast, C, Gene Environment, I, Breast, C, Swedish Breast Cancer, S, Hereditary, B, Ovarian Cancer Research Group, N, Epidemiological study of, B, Carriers, BM, Genetic Modifiers of Cancer Risk in, BMC, Vergote, I, Lambrechts, S, Despierre, E, Risch, HA, Gonzalez-Neira, A, Rossing, MA, Pita, G, Doherty, JA, Alvarez, N, Larson, MC, Fridley, BL, Schoof, N, Chang-Claude, J, Cicek, MS, Peto, J, Kalli, KR, Broeks, A, Armasu, SM, Schmidt, MK, Braaf, LM, Winterhoff, B, Nevanlinna, H, Konecny, GE, Lambrechts, D, Rogmann, L, Guenel, P, Teoman, A, Milne, RL, Garcia, JJ, Cox, A, Shridhar, V, Burwinkel, B, Marme, F, Hein, R, Sawyer, EJ, Haiman, CA, Wang-Gohrke, S, Andrulis, IL, Moysich, KB, Hopper, JL, Odunsi, K, Lindblom, A, Giles, GG, Brenner, H, Simard, J, Lurie, G, Fasching, PA, Carney, ME, Radice, P, Wilkens, LR, Swerdlow, A, Goodman, MT, Brauch, H, Garcia-Closas, M, Hillemanns, P, Winqvist, R, Durst, M, Devilee, P, Runnebaum, I, Jakubowska, A, Lubinski, J, Mannermaa, A, Butzow, R, Bogdanova, NV, Dork, T, Pelttari, LM, Zheng, W, Leminen, A, Anton-Culver, H, Bunker, CH, Kristensen, V, Ness, RB, Muir, K, Edwards, R, Meindl, A, Heitz, F, Matsuo, K, du Bois, A, Wu, AH, Harter, P, Teo, SH, Schwaab, I, Shu, XO, Blot, W, Hosono, S, Kang, D, Nakanishi, T, Hartman, M, Yatabe, Y, Hamann, U, Karlan, BY, Sangrajrang, S, Kjaer, SK, Gaborieau, V, Jensen, A, Eccles, D, Hogdall, E, Shen, CY, Brown, J, Woo, YL, Shah, M, Azmi, MA, Luben, R, Omar, SZ, Czene, K, Vierkant, RA, Nordestgaard, BG, Flyger, H, Vachon, C, Olson, JE, Wang, X, Levine, DA, Rudolph, A, Weber, RP, Flesch-Janys, D, Iversen, E, Nickels, S, Schildkraut, JM, Silva Idos, S, Cramer, DW, Gibson, L, Terry, KL, Fletcher, O, Vitonis, AF, van der Schoot, CE, Poole, EM, Hogervorst, FB, Tworoger, SS, Liu, J, Bandera, EV, Li, J, Olson, SH, Humphreys, K, Orlow, I, Blomqvist, C, Rodriguez-Rodriguez, L, Aittomaki, K, Salvesen, HB, Muranen, TA, Wik, E, Brouwers, B, Krakstad, C, Wauters, E, Halle, MK, Wildiers, H, Kiemeney, LA, Mulot, C, Aben, KK, Laurent-Puig, P, Altena, AM,



Truong, T, Massuger, LF, Benitez, J, Pejovic, T, Perez, JI, Hoatlin, M, Zamora, MP, Cook, LS, Balasubramanian, SP, Kelemen, LE, Schneeweiss, A, Le, ND, Sohn, C, Brooks-Wilson, A, Tomlinson, I, Kerin, MJ, Miller, N, Cybulski, C, Henderson, BE, Menkiszak, J, Schumacher, F, Wentzensen, N, Le Marchand, L, Yang, HP, Mulligan, AM, Glendon, G, Engelholm, SA, Knight, JA, Hogdall, CK, Apicella, C, Gore, M, Tsimiklis, H, Song, H, Southey, MC, Jager, A, den Ouweland, AM, Brown, R, Martens, JW, Flanagan, JM, Kriege, M, Paul, J, Margolin, S, Siddiqui, N, Severi, G, Whittemore, AS, Baglietto, L, McGuire, V, Stegmaier, C, Sieh, W, Muller, H, Arndt, V, Labreche, F, Gao, YT, Goldberg, MS, Yang, G, Dumont, M, McLaughlin, JR, Hartmann, A, Ekici, AB, Beckmann, MW, Phelan, CM, Lux, MP, Permuth-Wey, J, Peissel, B, Sellers, TA, Ficarazzi, F, Barile, M, Ziogas, A, Ashworth, A, Gentry-Maharaj, A, Jones, M, Ramus, SJ, Orr, N, Menon, U, Pearce, CL, Bruning, T, Pike, MC, Ko, YD, Lissowska, J, Figueroa, J, Kupryjanczyk, J, Chanock, SJ, Dansonka-Mieszkowska, A, Jukkola-Vuorinen, A, Rzepecka, IK, Pylkas, K, Bidzinski, M, Kauppila, S, Hollestelle, A, Seynaeve, C, Tollenaar, RA, Durda, K, Jaworska, K, Hartikainen, JM, Kosma, VM, Kataja, V, Antonenkova, NN, Long, J, Shrubsole, M, Deming-Halverson, S, Lophatananon, A, Siriwanarangsan, P, Stewart-Brown, S, Ditsch, N, Lichtner, P, Schmutzler, RK, Ito, H, Iwata, H, Tajima, K, Tseng, CC, Stram, DO, van den Berg, D, Yip, CH, Ikram, MK, Teh, YC, Cai, H, Lu, W, Signorello, LB, Cai, Q, Noh, DY, Yoo, KY, Miao, H, Iau, PT, Teo, YY, McKay, J, Shapiro, C, Ademuyiwa, F, Fountzilas, G, Hsiung, CN, Yu, JC, Hou, MF, Healey, CS, Luccarini, C, Peock, S, Stoppa-Lyonnet, D, Peterlongo, P, Rebbeck, TR, Piedmonte, M, Singer, CF, Friedman, E, Thomassen, M, Offit, K, Hansen, TV, Neuhausen, SL, Szabo, CI, Blanco, I, Garber, J, Narod, SA, Weitzel, JN, Montagna, M, Olah, E, Godwin, AK, Yannoukakos, D, Goldgar, DE, Caldes, T, Imyanitov, EN, Tihomirova, L, Arun, BK, Campbell, I, Mensenkamp, AR, van Asperen, CJ, van Roozendaal, KE, Meijers-Heijboer, H, Collee, JM, Oosterwijk, JC, Hooning, MJ, Rookus, MA, van der Luijt, RB, Os, TA, Evans, DG, Frost, D, Fineberg, E, Barwell, J, Walker, L, Kennedy, MJ, Platte, R, Davidson, R, Ellis, SD, Cole, T, Bressac-de Paillerets, B, Buecher, B, Damiola, F, Faivre, L, Frenay, M, Sinilnikova, OM, Caron, O, Giraud, S, Mazoyer, S, Bonadona, V, Caux-Moncoutier, V, Toloczko-Grabarek, A, Gronwald, J, Byrski, T, Spurdle, AB, Bonanni, B, Zaffaroni, D, Giannini, G, Bernard, L, Dolcetti, R, Manoukian, S, Arnold, N, Engel, C, Deissler, H, Rhiem, K, Niederacher, D, Plendl, H, Sutter, C, Wappenschmidt, B, Borg, A, Melin, B, Rantala, J, Soller, M, Nathanson, KL, Domchek, SM, Rodriguez, GC, Salani, R, Kaulich, DG, Tea, MK, Paluch, SS, Laitman, Y, Skytte, AB, Kruse, TA, Jensen, UB, Robson, M, Gerdes, AM, Ejlertsen, B, Foretova, L, Savage, SA, Lester, J, Soucy, P, Kuchenbaecker, KB, Olswold, C, Cunningham, JM, Slager, S, Pankratz, VS, Dicks, E, Lakhani, SR, Couch, FJ, Hall, P, Monteiro, AN, Gayther, SA, Pharoah, PD, Reddel, RR, Goode, EL, Greene, MH, Easton, DF, Berchuck, A, Antoniou, AC, Chenevix-Trench, G, & Dunning, AM. (2013). Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet, 45(4), 371-384, 384e371-372.* Impact factor = 35.209

PRA110. Brisbin, A, & Fridley, BL. (2013). Bayesian genomic models for the incorporation of pathway topology knowledge into association studies. Stat Appl Genet Mol Biol, 12(4), 505-516. Impact factor = 1.717

PRA111. Cicek, MS, Koestler, DC, Fridley, BL, Kalli, KR, Armasu, SM, Larson, MC, Wang, C, Winham, SJ, Vierkant, RA, Rider, DN, Block, MS, Klotzle, B, Konecny, G, Winterhoff, BJ, Hamidi, H, Shridhar, V, Fan, JB, Visscher, DW, Olson, JE, Hartmann, LC, Bibikova, M, Chien, J, Cunningham, JM, & Goode, EL. (2013). Epigenome-wide ovarian cancer analysis identifies a methylation profile differentiating clear-cell histology with epigenetic silencing of the HERG K+ channel. Hum Mol Genet, 22(15), 3038-3047. Impact factor = 7.692

PRA112. DeRycke, MS, Gunawardena, SR, Middha, S, Asmann, YW, Schaid, DJ, McDonnell, SK, Riska, SM, Eckloff, BW, Cunningham, JM, Fridley, BL, Serie, DJ, Bamlet, WR, Cicek, MS, Jenkins, MA, Duggan, DJ, Buchanan, D, Clendenning, M, Haile, RW, Woods, MO, Gallinger, SN, Casey, G, Potter, JD, Newcomb, PA, Le Marchand, L, Lindor, NM, Thibodeau, SN, & Goode, EL. (2013). Identification of novel variants in colorectal cancer families by high-throughput exome sequencing. Cancer Epidemiol Biomarkers Prev, 22(7), 1239-1251. Impact factor = 4.559



PRA113. Earp, MA, Kelemen, LE, Magliocco, AM, Swenerton, KD, Chenevix-Trench, G, Australian Cancer, S, Australian Ovarian Cancer Study, G, Lu, Y, Hein, A, Ekici, AB, Beckmann, MW, Fasching, PA, Lambrechts, D, Despierre, E, Vergote, I, Lambrechts, S, Doherty, JA, Rossing, MA, Chang-Claude, J, Rudolph, A, Friel, G, Moysich, KB, Odunsi, K, Sucheston-Campbell, L, Lurie, G, Goodman, MT, Carney, ME, Thompson, PJ, Runnebaum, IB, Durst, M, Hillemanns, P, Dork, T, Antonenkova, N, Bogdanova, N, Leminen, A, Nevanlinna, H, Pelttari, LM, Butzow, R, Bunker, CH, Modugno, F, Edwards, RP, Ness, RB, du Bois, A, Heitz, F, Schwaab, I, Harter, P, Karlan, BY, Walsh, C, Lester, J, Jensen, A, Kjaer, SK, Hogdall, CK, Hogdall, E, Lundvall, L, Sellers, TA, Fridley, BL, Goode, EL, Cunningham, JM, Vierkant, RA, Giles, GG, Baglietto, L, Severi, G, Southey, MC, Liang, D, Wu, X, Lu, K, Hildebrandt, MA, Levine, DA, Bisogna, M, Schildkraut, JM, Iversen, ES, Weber, RP, Berchuck, A, Cramer, DW, Terry, KL, Poole, EM, Tworoger, SS, Bandera, EV, Chandran, U, Orlow, I, Olson, SH, Wik, E, Salvesen, HB, Bjorge, L, Halle, MK, van Altena, AM, Aben, KK, Kiemeney, LA, Massuger, LF, Pejovic, T, Bean, YT, Cybulski, C, Gronwald, J, Lubinski, J, Wentzensen, N, Brinton, LA, Lissowska, J, Garcia-Closas, M, Dicks, E, Dennis, J, Easton, DF, Song, H, Tyrer, JP, Pharoah, PD, Eccles, D, Campbell, IG, Whittemore, AS, McGuire, V, Sieh, W, Rothstein, JH, Flanagan, JM, Paul, J, Brown, R, Phelan, CM, Risch, HA, McLaughlin, JR, Narod, SA, Ziogas, A, Anton-Culver, H, Gentry-Maharaj, A, Menon, U, Gayther, SA, Ramus, SJ, Wu, AH, Pearce, CL, Pike, MC, Dansonka-Mieszkowska, A, Rzepecka, IK, Szafron, LM, Kupryjanczyk, J, Cook, LS, Le, ND, Brooks-Wilson, A, & On behalf of the Ovarian Cancer Association, C. (2014). Genome-wide association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNA. Hum Genet. Impact factor = 4.633

PRA114. Ellsworth, KA, Eckloff, BW, Li, L, Moon, I, Fridley, BL, Jenkins, GD, Carlson, E, Brisbin, A, Abo, R, Bamlet, W, Petersen, G, Wieben, ED, & Wang, L. (2013). Contribution of FKBP5 genetic variation to gemcitabine treatment and survival in pancreatic adenocarcinoma. PLoS One, 8(8), e70216. Impact factor = 3.73

PRA115. Ellsworth, KA, Moon, I, Eckloff, BW, Fridley, BL, Jenkins, GD, Batzler, A, Biernacka, JM, Abo, R, Brisbin, A, Ji, Y, Hebbring, S, Wieben, ED, Mrazek, DA, Weinshilboum, RM, & Wang, L. (2013). FKBP5 genetic variation: association with selective serotonin reuptake inhibitor treatment outcomes in major depressive disorder. Pharmacogenet Genomics, 23(3), 156-166. Impact factor = 3.608

PRA116. Faber, MT, Kjaer, SK, Dehlendorff, C, Chang-Claude, J, Andersen, KK, Hogdall, E, Webb, PM, Jordan, SJ, Australian Cancer, S, Australian Ovarian Cancer Study, G, Rossing, MA, Doherty, JA, Lurie, G, Thompson, PJ, Carney, ME, Goodman, MT, Ness, RB, Modugno, F, Edwards, RP, Bunker, CH, Goode, EL, Fridley, BL, Vierkant, RA, Larson, MC, Schildkraut, J, Cramer, DW, Terry, KL, Vitonis, AF, Bandera, EV, Olson, SH, King, M, Chandran, U, Kiemeney, LA, Massuger, LF, van Altena, AM, Vermeulen, SH, Brinton, L, Wentzensen, N, Lissowska, J, Yang, HP, Moysich, KB, Odunsi, K, Kasza, K, Odunsi-Akanji, O, Song, H, Pharaoh, P, Shah, M, Whittemore, AS, McGuire, V, Sieh, W, Sutphen, R, Menon, U, Gayther, SA, Ramus, SJ, Gentry-Maharaj, A, Pearce, CL, Wu, AH, Pike, MC, Risch, HA, Jensen, A, & Ovarian Cancer Association, C. (2013). Cigarette smoking and risk of ovarian cancer: a pooled analysis of 21 case-control studies. Cancer Causes Control, 24(5), 989-1004. Impact factor=3.20

PRA117. Fridley, BL, Jenkins, GD, Grill, DE, Kennedy, RB, Poland, GA, & Oberg, AL. (2013). Soft truncation thresholding for gene set analysis of RNA-seq data: application to a vaccine study. Sci Rep, 3, 2898. Impact factor = 2.927

PRA118. Goode, EL, DeRycke, M, Kalli, KR, Oberg, AL, Cunningham, JM, Maurer, MJ, Fridley, BL, Armasu, SM, Serie, DJ, Ramar, P, Goergen, K, Vierkant, RA, Rider, DN, Sicotte, H, Wang, C, Winterhoff, B, Phelan, CM, Schildkraut, JM, Weber, RP, Iversen, E, Berchuck, A, Sutphen, R, Birrer, MJ, Hampras, S, Preus, L, Gayther, SA, Ramus, SJ, Wentzensen, N, Yang, HP, Garcia-Closas, M, Song, H, Tyrer, J, Pharoah, PP, Konecny, G, Sellers, TA, Ness, RB, Sucheston, LE, Odunsi, K, Hartmann, LC, Moysich, KB, & Knutson, KL. (2013). Inherited variants in regulatory T cell genes and outcome of ovarian cancer. PLoS One, 8(1), e53903. Impact factor = 3.73



PRA119. Jiang, J, Fridley, BL, Feng, Q, Abo, RP, Brisbin, A, Batzler, A, Jenkins, G, Long, PA, & Wang, L. (2013). Genome-wide association study for biomarker identification of Rapamycin and Everolimus using a lymphoblastoid cell line system. Front Genet, 4, 166.

PRA120. Johnatty, SE, Beesley, J, Gao, B, Chen, X, Lu, Y, Law, MH, Henderson, MJ, Russell, AJ, Hedditch, EL, Emmanuel, C, Fereday, S, Webb, PM, Australian Ovarian Cancer Study, G, Goode, EL, Vierkant, RA, Fridley, BL, Cunningham, JM, Fasching, PA, Beckmann, MW, Ekici, AB, Hogdall, E, Kjaer, SK, Jensen, A, Hogdall, C, Brown, R, Paul, J, Lambrechts, S, Despierre, E, Vergote, I, Lester, J, Karlan, BY, Heitz, F, du Bois, A, Harter, P, Schwaab, I, Bean, Y, Pejovic, T, Levine, DA, Goodman, MT, Camey, ME, Thompson, PJ, Lurie, G, Shildkraut, J, Berchuck, A, Terry, KL, Cramer, DW, Norris, MD, Haber, M, MacGregor, S, deFazio, A, & Chenevix-Trench, G. (2013). ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: a comprehensive analysis from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas. Gynecol Oncol, 131(1), 8-14. Impact factor = 3.929

PRA121. Kobel, M, Kalloger, SE, Lee, S, Duggan, MA, Kelemen, LE, Prentice, L, Kalli, KR, Fridley, BL, Visscher, DW, Keeney, GL, Vierkant, RA, Cunningham, JM, Chow, C, Ness, RB, Moysich, K, Edwards, R, Modugno, F, Bunker, C, Wozniak, EL, Benjamin, E, Gayther, SA, Gentry-Maharaj, A, Menon, U, Gilks, CB, Huntsman, DG, Ramus, SJ, Goode, EL, & Ovarian Tumor Tissue Analysis, c. (2013). Biomarker-based ovarian carcinoma typing: a histologic investigation in the ovarian tumor tissue analysis consortium. Cancer Epidemiol Biomarkers Prev, 22(10), 1677-1686. Impact factor = 4.559

PRA122. Larson, NB, & Fridley, BL. (2013). PurBayes: estimating tumor cellularity and subclonality in next-generation sequencing data. Bioinformatics, 29(15), 1888-1889. Impact factor = 5.323

PRA123. Liu, M, Ingle, JN, Fridley, BL, Buzdar, AU, Robson, ME, Kubo, M, Wang, L, Batzler, A, Jenkins, GD, Pietrzak, TL, Carlson, EE, Goetz, MP, Northfelt, DW, Perez, EA, Williard, CV, Schaid, DJ, Nakamura, Y, & Weinshilboum, RM. (2013). TSPYL5 SNPs: association with plasma estradiol concentrations and aromatase expression. Mol Endocrinol, 27(4), 657-670. Impact factor = 4.746

PRA124. Olsen, CM, Nagle, CM, Whiteman, DC, Ness, R, Pearce, CL, Pike, MC, Rossing, MA, Terry, KL, Wu, AH, Australian Cancer, S, Australian Ovarian Cancer Study, G, Risch, HA, Yu, H, Doherty, JA, Chang-Claude, J, Hein, R, Nickels, S, Wang-Gohrke, S, Goodman, MT, Carney, ME, Matsuno, RK, Lurie, G, Moysich, K, Kjaer, SK, Jensen, A, Hogdall, E, Goode, EL, Fridley, BL, Vierkant, RA, Larson, MC, Schildkraut, J, Hoyo, C, Moorman, P, Weber, RP, Cramer, DW, Vitonis, AF, Bandera, EV, Olson, SH, Rodriguez-Rodriguez, L, King, M, Brinton, LA, Yang, H, Garcia-Closas, M, Lissowska, J, Anton-Culver, H, Ziogas, A, Gayther, SA, Ramus, SJ, Menon, U, Gentry-Maharaj, A, Webb, PM, & Ovarian Cancer Association, C. (2013). Obesity and risk of ovarian cancer subtypes: evidence from the Ovarian Cancer Association Consortium. Endocr Relat Cancer, 20(2), 251-262. Impact factor = 5.261

PRA125. Pearce, CL, Rossing, MA, Lee, AW, Ness, RB, Webb, PM, for Australian Cancer, S, Australian Ovarian Cancer Study, G, Chenevix-Trench, G, Jordan, SM, Stram, DA, Chang-Claude, J, Hein, R, Nickels, S, Lurie, G, Thompson, PJ, Carney, ME, Goodman, MT, Moysich, K, Hogdall, E, Jensen, A, Goode, EL, Fridley, BL, Cunningham, JM, Vierkant, RA, Weber, RP, Ziogas, A, Anton-Culver, H, Gayther, SA, Gentry-Maharaj, A, Menon, U, Ramus, SJ, Brinton, L, Wentzensen, N, Lissowska, J, Garcia-Closas, M, Massuger, LF, Kiemeney, LA, Van Altena, AM, Aben, KK, Berchuck, A, Doherty, JA, Iversen, E, McGuire, V, Moorman, PG, Pharoah, P, Pike, MC, Risch, H, Sieh, W, Stram, DO, Terry, KL, Whittemore, A, Wu, AH, Schildkraut, JM, Kjaer, SK, & Ovarian Cancer Association, C. (2013). Combined and interactive effects of environmental and GWAS-identified risk factors in ovarian cancer. Cancer Epidemiol Biomarkers Prev, 22(5), 880-890. Impact factor = 4.559

PRA126. Permuth-Wey, J, Lawrenson, K, Shen, HC, Velkova, A, Tyrer, JP, Chen, Z, Lin, HY, Chen, YA, Tsai, YY, Qu, X, Ramus, SJ, Karevan, R, Lee, J, Lee, N, Larson, MC, Aben, KK, Anton-Culver, H, Antonenkova, N, Antoniou, AC, Armasu, SM, Australian Cancer, S, Australian Ovarian Cancer, S, Bacot, F, Baglietto, L,



Bandera, EV, Barnholtz-Sloan, J, Beckmann, MW, Birrer, MJ, Bloom, G, Bogdanova, N, Brinton, LA, Brooks-Wilson, A, Brown, R, Butzow, R, Cai, Q, Campbell, I, Chang-Claude, J, Chanock, S, Chenevix-Trench, G, Cheng, JQ, Cicek, MS, Coetzee, GA, Consortium of Investigators of Modifiers of, B, Cook, LS, Couch, FJ, Cramer, DW, Cunningham, JM, Dansonka-Mieszkowska, A, Despierre, E, Doherty, JA, Dork, T, du Bois, A, Durst, M, Easton, DF, Eccles, D, Edwards, R, Ekici, AB, Fasching, PA, Fenstermacher, DA, Flanagan, JM, Garcia-Closas, M, Gentry-Maharaj, A, Giles, GG, Glasspool, RM, Gonzalez-Bosquet, J, Goodman, MT, Gore, M, Gorski, B, Gronwald, J, Hall, P, Halle, MK, Harter, P, Heitz, F, Hillemanns, P, Hoatlin, M, Hogdall, CK, Hogdall, E, Hosono, S, Jakubowska, A, Jensen, A, Jim, H, Kalli, KR, Karlan, BY, Kaye, SB, Kelemen, LE, Kiemeney, LA, Kikkawa, F, Konecny, GE, Krakstad, C, Kjaer, SK, Kupryjanczyk, J, Lambrechts, D, Lambrechts, S, Lancaster, JM, Le, ND, Leminen, A, Levine, DA, Liang, D, Lim, BK, Lin, J, Lissowska, J, Lu, KH, Lubinski, J, Lurie, G, Massuger, LF, Matsuo, K, McGuire, V, McLaughlin, JR, Menon, U, Modugno, F, Moysich, KB, Nakanishi, T, Narod, SA, Nedergaard, L, Ness, RB, Nevanlinna, H, Nickels, S, Noushmehr, H, Odunsi, K, Olson, SH, Orlow, I, Paul, J, Pearce, CL, Pejovic, T, Pelttari, LM, Pike, MC, Poole, EM, Raska, P, Renner, SP, Risch, HA, Rodriguez-Rodriguez, L, Rossing, MA, Rudolph, A, Runnebaum, IB, Rzepecka, IK, Salvesen, HB, Schwaab, I, Severi, G, Shridhar, V, Shu, XO, Shvetsov, YB, Sieh, W, Song, H, Southey, MC, Spiewankiewicz, B, Stram, D, Sutphen, R, Teo, SH, Terry, KL, Tessier, DC, Thompson, PJ, Tworoger, SS, van Altena, AM, Vergote, I, Vierkant, RA, Vincent, D, Vitonis, AF, Wang-Gohrke, S, Palmieri Weber, R, Wentzensen, N, Whittemore, AS, Wik, E, Wilkens, LR, Winterhoff, B, Woo, YL, Wu, AH, Xiang, YB, Yang, HP, Zheng, W, Ziogas, A, Zulkifli, F, Phelan, CM, Iversen, E, Schildkraut, JM, Berchuck, A, Fridley, BL, Goode, EL, Pharoah, PD, Monteiro, AN, Sellers, TA, & Gayther, SA. (2013). Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. Nat Commun, 4, 1627. *Impact factor = 10.015

PRA127. Pharoah, PD, Tsai, YY, Ramus, SJ, Phelan, CM, Goode, EL, Lawrenson, K, Buckley, M, Fridley, BL, Tyrer, JP, Shen, H, Weber, R, Karevan, R, Larson, MC, Song, H, Tessier, DC, Bacot, F, Vincent, D, Cunningham, JM, Dennis, J, Dicks, E, Australian Cancer, S, Australian Ovarian Cancer Study, G, Aben, KK, Anton-Culver, H, Antonenkova, N, Armasu, SM, Baglietto, L, Bandera, EV, Beckmann, MW, Birrer, MJ, Bloom, G, Bogdanova, N, Brenton, JD, Brinton, LA, Brooks-Wilson, A, Brown, R, Butzow, R, Campbell, I, Carney, ME, Carvalho, RS, Chang-Claude, J, Chen, YA, Chen, Z, Chow, WH, Cicek, MS, Coetzee, G, Cook, LS, Cramer, DW, Cybulski, C, Dansonka-Mieszkowska, A, Despierre, E, Doherty, JA, Dork, T, du Bois, A, Durst, M, Eccles, D, Edwards, R, Ekici, AB, Fasching, PA, Fenstermacher, D, Flanagan, J, Gao, YT, Garcia-Closas, M, Gentry-Maharaj, A, Giles, G, Gjyshi, A, Gore, M, Gronwald, J, Guo, Q, Halle, MK, Harter, P, Hein, A, Heitz, F, Hillemanns, P, Hoatlin, M, Hogdall, E, Hogdall, CK, Hosono, S, Jakubowska, A, Jensen, A, Kalli, KR, Karlan, BY, Kelemen, LE, Kiemeney, LA, Kjaer, SK, Konecny, GE, Krakstad, C, Kupryjanczyk, J, Lambrechts, D, Lambrechts, S, Le, ND, Lee, N, Lee, J, Leminen, A, Lim, BK, Lissowska, J, Lubinski, J, Lundvall, L, Lurie, G, Massuger, LF, Matsuo, K, McGuire, V, McLaughlin, JR, Menon, U, Modugno, F, Moysich, KB, Nakanishi, T, Narod, SA, Ness, RB, Nevanlinna, H, Nickels, S, Noushmehr, H, Odunsi, K, Olson, S, Orlow, I, Paul, J, Pejovic, T, Pelttari, LM, Permuth-Wey, J, Pike, MC, Poole, EM, Qu, X, Risch, HA, Rodriguez-Rodriguez, L, Rossing, MA, Rudolph, A, Runnebaum, I, Rzepecka, IK, Salvesen, HB, Schwaab, I, Severi, G, Shen, H, Shridhar, V, Shu, XO, Sieh, W, Southey, MC, Spellman, P, Tajima, K, Teo, SH, Terry, KL, Thompson, PJ, Timorek, A, Tworoger, SS, van Altena, AM, van den Berg, D, Vergote, I, Vierkant, RA, Vitonis, AF, Wang-Gohrke, S, Wentzensen, N, Whittemore, AS, Wik, E, Winterhoff, B, Woo, YL, Wu, AH, Yang, HP, Zheng, W, Ziogas, A, Zulkifli, F, Goodman, MT, Hall, P, Easton, DF, Pearce, CL, Berchuck, A, Chenevix-Trench, G, Iversen, E, Monteiro, AN, Gayther, SA, Schildkraut, JM, & Sellers, TA. (2013). GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nat Genet, 45(4), 362-370, 370e361-362.* Impact factor = 35.209



PRA128. Reid-Lombardo, KM, Fridley, BL, Bamlet, WR, Cunningham, JM, Sarr, MG, & Petersen, GM. (2013). Survival is associated with genetic variation in inflammatory pathway genes among patients with resected and unresected pancreatic cancer. Ann Surg, 257(6), 1096-1102. Impact factor = 6.329

PRA129. Rice, T, Zheng, S, Decker, PA, Walsh, KM, Bracci, P, Xiao, Y, McCoy, LS, Smirnov, I, Patoka, JS, Hansen, HM, Hsuang, G, Wiemels, JL, Tihan, T, Pico, AR, Prados, MD, Chang, SM, Berger, MS, Caron, A, Fink, S, Kollmeyer, T, Rynearson, A, Voss, J, Kosel, ML, Fridley, BL, Lachance, DH, Eckel-Passow, JE, Sicotte, H, O'Neill, BP, Giannini, C, Wiencke, JK, Jenkins, RB, & Wrensch, MR. (2013). Inherited variant on chromosome 11q23 increases susceptibility to IDH-mutated but not IDH-normal gliomas regardless of grade or histology. Neuro Oncol, 15(5), 535-541. Impact factor = 6.180.

PRA130. Shen, H*, Fridley, BL*, Song, H, Lawrenson, K, Cunningham, JM, Ramus, SJ, Cicek, MS, Tyrer, J, Stram, D, Larson, MC, Kobel, M, Consortium, P, Ziogas, A, Zheng, W, Yang, HP, Wu, AH, Wozniak, EL, Woo, YL, Winterhoff, B, Wik, E, Whittemore, AS, Wentzensen, N, Weber, RP, Vitonis, AF, Vincent, D, Vierkant, RA, Vergote, I, Van Den Berg, D, Van Altena, AM, Tworoger, SS, Thompson, PJ, Tessier, DC, Terry, KL, Teo, SH, Templeman, C, Stram, DO, Southey, MC, Sieh, W, Siddiqui, N, Shvetsov, YB, Shu, XO, Shridhar, V, Wang-Gohrke, S, Severi, G, Schwaab, I, Salvesen, HB, Rzepecka, IK, Runnebaum, IB, Rossing, MA, Rodriguez-Rodriguez, L, Risch, HA, Renner, SP, Poole, EM, Pike, MC, Phelan, CM, Pelttari, LM, Pejovic, T, Paul, J, Orlow, I, Omar, SZ, Olson, SH, Odunsi, K, Nickels, S, Nevanlinna, H, Ness, RB, Narod, SA, Nakanishi, T, Moysich, KB, Monteiro, AN, Moes-Sosnowska, J, Modugno, F, Menon, U, McLaughlin, JR, McGuire, V, Matsuo, K, Adenan, NA, Massuger, LF, Lurie, G, Lundvall, L, Lubinski, J, Lissowska, J, Levine, DA, Leminen, A, Lee, AW, Le, ND, Lambrechts, S, Lambrechts, D, Kupryjanczyk, J, Krakstad, C, Konecny, GE, Kjaer, SK, Kiemeney, LA, Kelemen, LE, Keeney, GL, Karlan, BY, Karevan, R, Kalli, KR, Kajiyama, H, Ji, BT, Jensen, A, Jakubowska, A, Iversen, E, Hosono, S, Hogdall, CK, Hogdall, E, Hoatlin, M, Hillemanns, P, Heitz, F, Hein, R, Harter, P, Halle, MK, Hall, P, Gronwald, J, Gore, M, Goodman, MT, Giles, GG, Gentry-Maharaj, A, Garcia-Closas, M, Flanagan, JM, Fasching, PA, Ekici, AB, Edwards, R, Eccles, D, Easton, DF, Durst, M, du Bois, A, Dork, T, Doherty, JA, Despierre, E, Dansonka-Mieszkowska, A, Cybulski, C, Cramer, DW, Cook, LS, Chen, X, Charbonneau, B, Chang-Claude, J, Campbell, I, Butzow, R, Bunker, CH, Brueggmann, D, Brown, R, Brooks-Wilson, A, Brinton, LA, Bogdanova, N, Block, MS, Benjamin, E, Beesley, J, Beckmann, MW, Bandera, EV, Baglietto, L, Bacot, F, Armasu, SM, Antonenkova, N, Anton-Culver, H, Aben, KK, Liang, D, Wu, X, Lu, K, Hildebrandt, MA, Australian Ovarian Cancer Study, G, Australian Cancer, S, Schildkraut, JM, Sellers, TA, Huntsman, D, Berchuck, A, Chenevix-Trench, G, Gayther, SA, Pharoah, PD, Laird, PW, Goode, EL, & Pearce, CL. (2013). Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. Nat Commun, 4, 1628.* Impact factor = 10.015

PRA131. Sieh, W, Kobel, M, Longacre, TA, Bowtell, DD, deFazio, A, Goodman, MT, Hogdall, E, Deen, S, Wentzensen, N, Moysich, KB, Brenton, JD, Clarke, BA, Menon, U, Gilks, CB, Kim, A, Madore, J, Fereday, S, George, J, Galletta, L, Lurie, G, Wilkens, LR, Carney, ME, Thompson, PJ, Matsuno, RK, Kjaer, SK, Jensen, A, Hogdall, C, Kalli, KR, Fridley, BL, Keeney, GL, Vierkant, RA, Cunningham, JM, Brinton, LA, Yang, HP, Sherman, ME, Garcia-Closas, M, Lissowska, J, Odunsi, K, Morrison, C, Lele, S, Bshara, W, Sucheston, L, Jimenez-Linan, M, Driver, K, Alsop, J, Mack, M, McGuire, V, Rothstein, JH, Rosen, BP, Bernardini, MQ, Mackay, H, Oza, A, Wozniak, EL, Benjamin, E, Gentry-Maharaj, A, Gayther, SA, Tinker, AV, Prentice, LM, Chow, C, Anglesio, MS, Johnatty, SE, Chenevix-Trench, G, Whittemore, AS, Pharoah, PD, Goode, EL, Huntsman, DG, & Ramus, SJ. (2013). Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. Lancet Oncol, 14(9), 853-862. * Impact factor = 25.117

PRA132. White, KL, Vierkant, RA, Fogarty, ZC, Charbonneau, B, Block, MS, Pharoah, PD, Chenevix-Trench, G, for, AACSg, Rossing, MA, Cramer, DW, Pearce, CL, Schildkraut, JM, Menon, U, Kjaer, SK, Levine, DA, Gronwald, J, Culver, HA, Whittemore, AS, Karlan, BY, Lambrechts, D, Wentzensen, N, Kupryjanczyk, J, Chang-Claude, J, Bandera, EV, Hogdall, E, Heitz, F, Kaye, SB, Fasching, PA, Campbell, I, Goodman, MT,



Pejovic, T, Bean, Y, Lurie, G, Eccles, D, Hein, A, Beckmann, MW, Ekici, AB, Paul, J, Brown, R, Flanagan, JM, Harter, P, du Bois, A, Schwaab, I, Hogdall, CK, Lundvall, L, Olson, SH, Orlow, I, Paddock, LE, Rudolph, A, Eilber, U, Dansonka-Mieszkowska, A, Rzepecka, IK, Ziolkowska-Seta, I, Brinton, L, Yang, H, Garcia-Closas, M, Despierre, E, Lambrechts, S, Vergote, I, Walsh, C, Lester, J, Sieh, W, McGuire, V, Rothstein, JH, Ziogas, A, Lubinski, J, Cybulski, C, Menkiszak, J, Jensen, A, Gayther, SA, Ramus, SJ, Gentry-Maharaj, A, Berchuck, A, Wu, AH, Pike, MC, Van Denberg, D, Terry, KL, Vitonis, AF, Doherty, JA, Johnatty, SE, Defazio, A, Song, H, Tyrer, J, Sellers, TA, Phelan, CM, Kalli, KR, Cunningham, JM, Fridley, BL, & Goode, EL. (2013). Analysis of over 10,000 Cases finds no association between previously reported candidate polymorphisms and ovarian cancer outcome. Cancer Epidemiol Biomarkers Prev, 22(5), 987-992. Impact factor = 4.559

PRA133. Charbonneau, B, Block, MS, Bamlet, WR, Vierkant, RA, Kalli, KR, Fogarty, Z, Rider, DN, Sellers, TA, Tworoger, SS, Poole, E, Risch, HA, Salvesen, HB, Kiemeney, LA, Baglietto, L, Giles, GG, Severi, G, Trabert, B, Wentzensen, N, Chenevix-Trench, G, for, AACSg, Whittemore, AS, Sieh, W, Chang-Claude, J, Bandera, EV, Orlow, I, Terry, K, Goodman, MT, Thompson, PJ, Cook, LS, Rossing, MA, Ness, RB, Narod, SA, Kupryjanczyk, J, Lu, K, Butzow, R, Dork, T, Pejovic, T, Campbell, I, Le, ND, Bunker, CH, Bogdanova, N, Runnebaum, IB, Eccles, D, Paul, J, Wu, AH, Gayther, SA, Hogdall, E, Heitz, F, Kaye, SB, Karlan, BY, Anton-Culver, H, Gronwald, J, Hogdall, CK, Lambrechts, D, Fasching, PA, Menon, U, Schildkraut, J, Pearce, CL, Levine, DA, Kjaer, SK, Cramer, D, Flanagan, JM, Phelan, CM, Brown, R, Massuger, LF, Song, H, Doherty, JA, Krakstad, C, Liang, D, Odunsi, K, Berchuck, A, Jensen, A, Lubinski, J, Nevanlinna, H, Bean, YT, Lurie, G, Ziogas, A, Walsh, C, Despierre, E, Brinton, L, Hein, A, Rudolph, A, Dansonka-Mieszkowska, A, Olson, SH, Harter, P, Tyrer, J, Vitonis, AF, Brooks-Wilson, A, Aben, KK, Pike, MC, Ramus, SJ, Wik, E, Cybulski, C, Lin, J, Sucheston, L, Edwards, R, McGuire, V, Lester, J, du Bois, A, Lundvall, L, Wang-Gohrke, S, Szafron, LM, Lambrechts, S, Yang, H, Beckmann, MW, Pelttari, LM, Van Altena, AM, van den Berg, D, Halle, MK, Gentry-Maharaj, A, Schwaab, I, Chandran, U, Menkiszak, J, Ekici, AB, Wilkens, LR, Leminen, A, Modugno, F, Friel, G, Rothstein, JH, Vergote, I, Garcia-Closas, M, Hildebrandt, MA, Sobiczewski, P, Kelemen, LE, Pharoah, PD, Moysich, K, Knutson, KL, Cunningham, JM, Fridley, BL, & Goode, EL. (2014). Risk of Ovarian Cancer and the NF-kappaB Pathway: Genetic Association with IL1A and TNFSF10. Cancer Res, 74(3), 852-861. Impact factor = 8.650

PRA134. Cunningham, JM, Cicek, MS, Larson, NB, Davila, J, Wang, C, Larson, MC, Song, H, Dicks, EM, Harrington, P, Wick, M, Winterhoff, BJ, Hamidi, H, Konecny, GE, Chien, J, Bibikova, M, Fan, JB, Kalli, KR, Lindor, NM, Fridley, BL, Pharoah, PP, & Goode, EL. (2014). Clinical characteristics of ovarian cancer classified by BRCA1, BRCA2, and RAD51C status. Sci Rep, 4, 4026. Impact factor = 2.927

PRA135. Niu, N, Schaid, DJ, Abo, RP, Kalari, K, Fridley, BL, Feng, Q, Jenkins, G, Batzler, A, Brisbin, AG, Cunningham, JM, Li, L, Sun, Z, Yang, P, & Wang, L. (2012). Genetic association with overall survival of taxane-treated lung cancer patients - a genome-wide association study in human lymphoblastoid cell lines followed by a clinical association study. BMC Cancer, 12, 422. Impact factor = 3.319

PRA136. Fridley, BL, Abo, R, Tan, XL, Jenkins, GD, Batzler, A, Moyer, AM, Biernacka, JM, & Wang, L. (2014). Integrative gene set analysis: application to platinum pharmacogenomics. OMICS, 18(1), 34-41. Impact factor = 2.730

PRA137. Koestler, DC, Chalise, P, Cicek, MS, Cunningham, JM, Armasu, S, Larson, MC, Chien, J, Block, M, Kalli, KR, Sellers, TA, Fridley, BL, & Goode, EL. (2014). Integrative genomic analysis identifies epigenetic marks that mediate genetic risk for epithelial ovarian cancer. BMC Med Genomics, 7(1), 8. Impact factor = 3.466

PRA138. Larson, NB, Jenkins, GD, Larson, MC, Vierkant, RA, Sellers, TA, Phelan, CM, Schildkraut, JM, Sutphen, R, Pharoah, PP, Gayther, SA, Wentzensen, N, Ovarian Cancer Association, C, Goode, EL, & Fridley, BL. (2014). Kernel canonical correlation analysis for assessing gene-gene interactions and application to ovarian cancer. Eur J Hum Genet, 22(1), 126-131. Impact factor = 4.633



PRA139. Laurie, CC, Laurie, CA, Smoley, SA, Carlson, EE, Flinn, I, Fridley, BL, Greisman, HA, Gribben, JG, Jelinek, DF, Nelson, SC, Paietta, E, Schaid, D, Sun, Z, Tallman, MS, Weinshilboum, R, Kay, NE, & Shanafelt, TD. (2014). Acquired chromosomal anomalies in chronic lymphocytic leukemia patients compared with more than 50,000 quasi-normal participants. Cancer Genet, 207(1-2), 19-30. Impact factor = 2.417.

PRA140. Li, L, Fridley, BL, Kalari, K, Niu, N, Jenkins, G, Batzler, A, Abo, RP, Schaid, D, & Wang, L. (2014). Discovery of genetic biomarkers contributing to variation in drug response of cytidine analogues using human lymphoblastoid cell lines. BMC Genomics, 15(1), 93. Impact factor = 4.397

PRA141. Matimba, A, Li, F, Livshits, A, Cartwright, CS, Scully, S, Fridley, BL, Jenkins, G, Batzler, A, Wang, L, Weinshilboum, R, & Lennard, L. (2014). Thiopurine pharmacogenomics: association of SNPs with clinical response and functional validation of candidate genes. Pharmacogenomics, 15(4), 433-447. Impact factor = 5.134

PRA142. Fridley, BL, Armasu, SM, Cicek, MS, Larson, MC, Wang, C, Winham, S, Kalli, KR, Koestler, DC, Rider, DN, Shridhar, V, Olson, JE, Cunningham, JM, and Goode, EL. (2014). Methylation of leukocyte DNA and ovarian cancer: relationships with disease status and outcome, BMC Medical Genomics, 7(1), 21. Impact factor = 3.466.

PRA143. Song, H, Cicek, MS, Dicks, E, Harrington, P, Ramus, SJ, Cunningham, JM, Fridley, BL, Tyrer, JP, Alsop, J, Jimenez-Linan, M, Gayther, SA, Goode, EL, & Pharoah, PD. (2014). The contribution of deleterious germline mutations in BRCA1, BRCA2 and the mismatch repair genes to ovarian cancer in the population. Hum Mol Genet. Online / in press. Impact factor = 7.692

PRA144. Block, MS, Charbonneau, B, Vierkant, RA, Fogarty, Z, Bamlet, WR, Pharoah, PD, Chenevix-Trench, G, Rossing, MA, Cramer, D, Pearce, CL, Schildkraut, J, Menon, U, Kjaer, SK, Levine, DA, Gronwald, J, Anton-Culver, H, Whittemore, AS, Karlan, BY, Lambrechts, D, Wentzensen, N, Kupryjanczyk, J, Chang-Claude, J, Bandera, EV, Hogdall, E, Heitz, F, Kaye, SB, Fasching, PA, Campbell, I, Goodman, MT, Pejovic, T, Bean, YT, Hays, L, Lurie, G, Eccles, DM, Hein, A, Beckmann, MW, Ekici, AB, Paul, J, Brown, R, Flanagan, JM, Harter, P, du Bois, A, Schwaab, I, Hogdall, CK, Lundvall, L, Olson, SH, Orlow, I, Paddock, LE, Rudolph, A, Eilber, U, Dansonka-Mieszkowska, A, Rzepecka, IK, Ziolkowska-Seta, I, Brinton, LA, Yang, H, Garcia-Closas, M, Despierre, E, Lambrechts, S, Vergote, I, Walsh, CS, Lester, J, Sieh, W, McGuire, V, Rothstein, JH, Ziogas, A, Lubinski, J, Cybulski, C, Menkiszak, J, Jensen, A, Gayther, SA, Ramus, SJ, Gentry-Maharaj, A, Berchuck, A, Wu, AH, Pike, MC, Van Den Berg, DJ, Terry, KL, Vitonis, AF, Ramirez, SM, Rider, DN, Knutson, KL, Sellers, TA, Phelan, CM, Doherty, JA, Johnatty, SE, Defazio, A, Song, H, Tyrer, J, Kalli, KR, Fridley, BL, Cunningham, JM, & Goode, EL. (2014). Variation in NF-kappaB Signaling Pathways and Survival in Invasive Epithelial Ovarian Cancer. Cancer Epidemiol Biomarkers Prev. Online / in press. Impact factor = 4.559

PRA145. Wang, C, Cicek, MS, Charbonneau, B, Kalli, KR, Armasu, SM, Larson, MC, Konecny, GE, Winterhoff, B, Fan, JB, Bibikova, M, Chien, J, Shridhar, V, Block, MS, Hartmann, LC, Visscher, DW, Cunningham, JM, Knutson, KL, Fridley, BL, & Goode, EL. (2014). Tumor Hypomethylation at 6p21.3 Associates with Longer Time to Recurrence of High-Grade Serous Epithelial Ovarian Cancer. Cancer Res. Online / in press. Impact factor = 8.65

PRA146. Charbonneau, B, Moysich, KB, Kalli, KR, Oberg, AL, Vierkant, RA, Fogarty, ZC, Block, MS, Maurer, MJ, Goergen, KM, Fridley, BL, Cunningham, JM, Rider, DN, Preston, C, Hartmann, LC, Lawrenson, K, Wang, C, Tyrer, J, Song, H, Defazio, A, Johnatty, SE, Doherty, JA, Phelan, CM, Sellers, TA, Ramirez, SM, Vitonis, AF, Terry, KL, Van Den Berg, D, Pike, MC, Wu, AH, Berchuck, A, Gentry-Maharaj, A, Ramus, SJ, Diergaarde, B, Shen, H, Jensen, A, Menkiszak, J, Cybulski, C, Lubilski, J, Ziogas, A, Rothstein, JH, McGuire, V, Sieh, W, Lester, J, Walsh, C, Vergote, I, Lambrechts, S, Despierre, E, Garcia-Closas, M, Yang, H, Brinton, LA, Spiewankiewicz, B, Rzepecka, IK, Dansonka-Mieszkowska, A, Seibold, P, Rudolph, A, Paddock, LE, Orlow, I, Lundvall, L, Olson, SH, Hogdall, CK, Schwaab, I, du Bois, A, Harter, P, Flanagan, JM, Brown, R, Paul, J, Ekici, AB, Beckmann, MW, Hein, A, Eccles, D, Lurie, G, Hays, LE, Bean, YT, Pejovic, T, Goodman, MT, Campbell, I, Fasching, PA, Konecny, G, Kaye, SB, Heitz, F, Hogdall, E, Bandera, EV, Chang-Claude, J,



Kupryjanczyk, J, Wentzensen, N, Lambrechts, D, Karlan, BY, Whittemore, AS, Culver, HA, Gronwald, J, Levine, DA, Kjaer, SK, Menon, U, Schildkraut, JM, Pearce, CL, Cramer, DW, Rossing, MA, Chenevix-Trench, G, group, A, Acs, Pharoah, PD, Gayther, SA, Ness, RB, Odunsi, K, Sucheston, LE, Knutson, KL, & Goode, EL. (2014). Large-scale evaluation of common variation in regulatory T cell-related genes and ovarian cancer outcome. Cancer Immunol Res, 2(4), 332-340.

PRA147. Winham, SJ, Armasu, SM, Cicek, MS, Larson, MC, Cunningham, JM, Kalli, KR, Fridley, BL, & Goode, EL. (2014). Genome-Wide Investigation of Regional Blood-Based DNA Methylation Adjusted for Complete Blood Counts Implicates BNC2 in Ovarian Cancer. Genet Epidemiol. Online / in press. Impact factor = 4.015.

PRA148. Chalise, P, Koestler, DC, Bimali, M, Yu, Q, & Fridley, BL. (2014). Integrative clustering methods for high-dimensional molecular data. Transl Cancer Res, 3(3), 202-216.

PRA149. Arruda-Olson, AM, Roger, VL, Chai, HS, de Andrade, M, Fridley, BL, Cunningham, JM, Gabriel, SE, & Bielinski, SJ. (2011). Association of TNFSF8 polymorphisms with peripheral neutrophil count. Mayo Clin Proc, 86(11), 1075-1081. Impact factor = 5.812

PRA150. Atkinson, EJ, McDonnell, SK, Witte, JS, Crawford, DC, Fan, Y, Fridley, B, Li, D, Li, L, Rodin, A, Sadee, W, Speed, T, Weiss, ST, Yang, J, Yerges, L, & Schaid, DJ. (2010). Conference Scene: Lessons learned from the 5th Statistical Analysis Workshop of the Pharmacogenetics Research Network. Pharmacogenomics, 11(3), 297-303. Impact factor = 5.134

PRA151. Beesley, J, Pickett, HA, Johnatty, SE, Dunning, AM, Chen, X, Li, J, Michailidou, K, Lu, Y, Rider, DN, Palmieri, RT, Stutz, MD, Lambrechts, D, Despierre, E, Lambrechts, S, Vergote, I, Chang-Claude, J, Nickels, S, Vrieling, A, Flesch-Janys, D, Wang-Gohrke, S, Eilber, U, Bogdanova, N, Antonenkova, N, Runnebaum, IB, Dork, T, Goodman, MT, Lurie, G, Wilkens, LR, Matsuno, RK, Kiemeney, LA, Aben, KK, Marees, T, Massuger, LF, Fridley, BL, Vierkant, RA, Bandera, EV, Olson, SH, Orlow, I, Rodriguez-Rodriguez, L, Cook, LS, Le, ND, Brooks-Wilson, A, Kelemen, LE, Campbell, I, Gayther, SA, Ramus, SJ, Gentry-Maharaj, A, Menon, U, Ahmed, S, Baynes, C, Pharoah, PD, kConFab, I, Australian Ovarian Cancer Study, G, Investigators, A, Muir, K, Lophatananon, A, Chaiwerawattana, A, Wiangnon, S, Macgregor, S, Easton, DF, Reddel, RR, Goode, EL, Chenevix-Trench, G, & Ovarian Cancer Association, C. (2011). Functional polymorphisms in the TERT promoter are associated with risk of serous epithelial ovarian and breast cancers. PLoS One, 6(9), e24987. Impact factor = 3.534

PRA152. Lachance, DH, Yang, P, Johnson, DR, Decker, PA, Kollmeyer, TM, McCoy, LS, Rice, T, Xiao, Y, Ali-Osman, F, Wang, F, Stoddard, SM, Sprau, DJ, Kosel, ML, Wiencke, JK, Wiemels, JL, Patoka, JS, Davis, F, McCarthy, B, Rynearson, AL, Worra, JB, Fridley, BL, O'Neill, BP, Buckner, JC, Il'yasova, D, Jenkins, RB, & Wrensch, MR. (2011). Associations of high-grade glioma with glioma risk alleles and histories of allergy and smoking. Am J Epidemiol, 174(5), 574-581. Impact factor = 4.975

PRA153. Hedditch, EL, Gao, B, Russell, AJ, Lu, Y, Emmanuel, C, Beesley, J, Johnatty, SE, Chen, X, Harnett, P, George, J, Australian Ovarian Cancer Study, G, Williams, RT, Flemming, C, Lambrechts, D, Despierre, E, Lambrechts, S, Vergote, I, Karlan, B, Lester, J, Orsulic, S, Walsh, C, Fasching, P, Beckmann, MW, Ekici, AB, Hein, A, Matsuo, K, Hosono, S, Nakanishi, T, Yatabe, Y, Pejovic, T, Bean, Y, Heitz, F, Harter, P, du Bois, A, Schwaab, I, Hogdall, E, Kjaer, SK, Jensen, A, Hogdall, C, Lundvall, L, Engelholm, SA, Brown, B, Flanagan, J, Metcalf, MD, Siddiqui, N, Sellers, T, Fridley, B, Cunningham, J, Schildkraut, J, Iversen, E, Weber, RP, Berchuck, A, Goode, E, Bowtell, DD, Chenevix-Trench, G, deFazio, A, Norris, MD, MacGregor, S, Haber, M, & Henderson, MJ. (2014). ABCA transporter gene expression and poor outcome in epithelial ovarian cancer. J Natl Cancer Inst, 106(7). Impact factor = 15.161

PRA154. Lamba, JK, Fridley, BL, Ghosh, TM, Yu, Q, Mehta, G, & Gupta, P. (2014). Genetic variation in platinating agent and taxane pathway genes as predictors of outcome and toxicity in advanced non-small-cell lung cancer. Pharmacogenomics, 15(12), 1565-1574. Impact factor = 5.134



PRA155. Kobel, M, Madore, J, Ramus, SJ, Clarke, BA, Pharoah, PD, Deen, S, Bowtell, DD, Odunsi, K, Menon, U, Morrison, C, Lele, S, Bshara, W, Sucheston, L, Beckmann, MW, Hein, A, Thiel, FC, Hartmann, A, Wachter, DL, Anglesio, MS, Hogdall, E, Jensen, A, Hogdall, C, Kalli, KR, Fridley, BL, Keeney, GL, Fogarty, ZC, Vierkant, RA, Liu, S, Cho, S, Nelson, G, Ghatage, P, Gentry-Maharaj, A, Gayther, SA, Benjamin, E, Widschwendter, M, Intermaggio, MP, Rosen, B, Bernardini, MQ, Mackay, H, Oza, A, Shaw, P, Jimenez-Linan, M, Driver, KE, Alsop, J, Mack, M, Koziak, JM, Steed, H, Ewanowich, C, DeFazio, A, Chenevix-Trench, G, Fereday, S, Gao, B, Johnatty, SE, George, J, Galletta, L, Group, AS, Goode, EL, Kjaer, SK, Huntsman, DG, Fasching, PA, Moysich, KB, Brenton, JD, & Kelemen, LE. (2014). Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study. Br J Cancer, 111(12), 2297-2307. Impact factor = 4.817

PRA156. Kelemen, LE, Terry, KL, Goodman, MT, Webb, PM, Bandera, EV, McGuire, V, Rossing, MA, Wang, Q, Dicks, E, Tyrer, JP, Song, H, Kupryjanczyk, J, Dansonka-Mieszkowska, A, Plisiecka-Halasa, J, Timorek, A, Menon, U, Gentry-Maharaj, A, Gayther, SA, Ramus, SJ, Narod, SA, Risch, HA, McLaughlin, JR, Siddiqui, N, Glasspool, R, Paul, J, Carty, K, Gronwald, J, Lubinski, J, Jakubowska, A, Cybulski, C, Kiemeney, LA, Massuger, LF, van Altena, AM, Aben, KK, Olson, SH, Orlow, I, Cramer, DW, Levine, DA, Bisogna, M, Giles, GG, Southey, MC, Bruinsma, F, Kjaer, SK, Hogdall, E, Jensen, A, Hogdall, CK, Lundvall, L, Engelholm, SA, Heitz, F, du Bois, A, Harter, P, Schwaab, I, Butzow, R, Nevanlinna, H, Pelttari, LM, Leminen, A, Thompson, PJ, Lurie, G, Wilkens, LR, Lambrechts, D, Van Nieuwenhuysen, E, Lambrechts, S, Vergote, I, Beesley, J, Investigators, ASGA, Fasching, PA, Beckmann, MW, Hein, A, Ekici, AB, Doherty, JA, Wu, AH, Pearce, CL, Pike, MC, Stram, D, Chang-Claude, J, Rudolph, A, Dork, T, Durst, M, Hillemanns, P, Runnebaum, IB, Bogdanova, N, Antonenkova, N, Odunsi, K, Edwards, RP, Kelley, JL, Modugno, F, Ness, RB, Karlan, BY, Walsh, C, Lester, J, Orsulic, S, Fridley, BL, Vierkant, RA, Cunningham, JM, Wu, X, Lu, K, Liang, D, Hildebrandt, MA, Weber, RP, Iversen, ES, Tworoger, SS, Poole, EM, Salvesen, HB, Krakstad, C, Bjorge, L, Tangen, IL, Pejovic, T, Bean, Y, Kellar, M, Wentzensen, N, Brinton, LA, Lissowska, J, Garcia-Closas, M, Campbell, IG, Eccles, D, Whittemore, AS, Sieh, W, Rothstein, JH, Anton-Culver, H, Ziogas, A, Phelan, CM, Moysich, KB, Goode, EL, Schildkraut, JM, Berchuck, A, Pharoah, PD, Sellers, TA, Brooks-Wilson, A, Cook, LS, & Le, ND. (2014). Consortium analysis of gene and gene-folate interactions in purine and pyrimidine metabolism pathways with ovarian carcinoma risk. Mol Nutr Food Res, 58(10), 2023-2035. Impact factor = 4.909

PRA157. Wang, Z, Zhu, B, Zhang, M, Parikh, H, Jia, J, Chung, CC, Sampson, JN, Hoskins, JW, Hutchinson, A, Burdette, L, Ibrahim, A, Hautman, C, Raj, PS, Abnet, CC, Adjei, AA, Ahlbom, A, Albanes, D, Allen, NE, Ambrosone, CB, Aldrich, M, Amiano, P, Amos, C, Andersson, U, Andriole, G, Jr., Andrulis, IL, Arici, C, Arslan, AA, Austin, MA, Baris, D, Barkauskas, DA, Bassig, BA, Beane Freeman, LE, Berg, CD, Berndt, SI, Bertazzi, PA, Biritwum, RB, Black, A, Blot, W, Boeing, H, Boffetta, P, Bolton, K, Boutron-Ruault, MC, Bracci, PM, Brennan, P, Brinton, LA, Brotzman, M, Bueno-de-Mesquita, HB, Buring, JE, Butler, MA, Cai, Q, Cancel-Tassin, G, Canzian, F, Cao, G, Caporaso, NE, Carrato, A, Carreon, T, Carta, A, Chang, GC, Chang, IS, Chang-Claude, J, Che, X, Chen, CJ, Chen, CY, Chen, CH, Chen, C, Chen, KY, Chen, YM, Chokkalingam, AP, Chu, LW, Clavel-Chapelon, F, Colditz, GA, Colt, JS, Conti, D, Cook, MB, Cortessis, VK, Crawford, ED, Cussenot, O, Davis, FG, De Vivo, I, Deng, X, Ding, T, Dinney, CP, Di Stefano, AL, Diver, WR, Duell, EJ, Elena, JW, Fan, JH, Feigelson, HS, Feychting, M, Figueroa, JD, Flanagan, AM, Fraumeni, JF, Jr., Freedman, ND, Fridley, BL, Fuchs, CS, Gago-Dominguez, M, Gallinger, S, Gao, YT, Gapstur, SM, Garcia-Closas, M, Garcia-Closas, R, Gastier-Foster, JM, Gaziano, JM, Gerhard, DS, Giffen, CA, Giles, GG, Gillanders, EM, Giovannucci, EL, Goggins, M, Gokgoz, N, Goldstein, AM, Gonzalez, C, Gorlick, R, Greene, MH, Gross, M, Grossman, HB, Grubb, R, 3rd, Gu, J, Guan, P, Haiman, CA, Hallmans, G, Hankinson, SE, Harris, CC, Hartge, P, Hattinger, C, Hayes, RB, He, Q, Helman, L, Henderson, BE, Henriksson, R, Hoffman-Bolton, J, Hohensee, C, Holly, EA, Hong, YC, Hoover, RN, Hosgood, HD, 3rd, Hsiao, CF, Hsing, AW, Hsiung, CA, Hu, N, Hu, W, Hu, Z, Huang,



MS, Hunter, DJ, Inskip, PD, Ito, H, Jacobs, EJ, Jacobs, KB, Jenab, M, Ji, BT, Johansen, C, Johansson, M, Johnson, A, Kaaks, R, Kamat, AM, Kamineni, A, Karagas, M, Khanna, C, Khaw, KT, Kim, C, Kim, IS, Kim, JH, Kim, YH, Kim, YC, Kim, YT, Kang, CH, Jung, YJ, Kitahara, CM, Klein, AP, Klein, R, Kogevinas, M, Koh, WP, Kohno, T, Kolonel, LN, Kooperberg, C, Kratz, CP, Krogh, V, Kunitoh, H, Kurtz, RC, Kurucu, N, Lan, Q, Lathrop, M, Lau, CC, Lecanda, F, Lee, KM, Lee, MP, Le Marchand, L, Lerner, SP, Li, D, Liao, LM, Lim, WY, Lin, D, Lin, J, Lindstrom, S, Linet, MS, Lissowska, J, Liu, J, Ljungberg, B, Lloreta, J, Lu, D, Ma, J, Malats, N, Mannisto, S, Marina, N, Mastrangelo, G, Matsuo, K, McGlynn, KA, McKean-Cowdin, R, McNeill, LH, McWilliams, RR, Melin, BS, Meltzer, PS, Mensah, JE, Miao, X, Michaud, DS, Mondul, AM, Moore, LE, Muir, K, Niwa, S, Olson, SH, Orr, N, Panico, S, Park, JY, Patel, AV, Patino-Garcia, A, Pavanello, S, Peeters, PH, Peplonska, B, Peters, U, Petersen, GM, Picci, P, Pike, MC, Porru, S, Prescott, J, Pu, X, Purdue, MP, Qiao, YL, Rajaraman, P, Riboli, E, Risch, HA, Rodabough, RJ, Rothman, N, Ruder, AM, Ryu, JS, Sanson, M, Schned, A, Schumacher, FR, Schwartz, AG, Schwartz, KL, Schwenn, M, Scotlandi, K, Seow, A, Serra, C, Serra, M, Sesso, HD, Severi, G, Shen, H, Shen, M, Shete, S, Shiraishi, K, Shu, XO, Siddiq, A, Sierrasesumaga, L, Sierri, S, Loon Sihoe, AD, Silverman, DT, Simon, M, Southey, MC, Spector, L, Spitz, M, Stampfer, M, Stattin, P, Stern, MC, Stevens, VL, Stolzenberg-Solomon, RZ, Stram, DO, Strom, SS, Su, WC, Sund, M, Sung, SW, Swerdlow, A, Tan, W, Tanaka, H, Tang, W, Tang, ZZ, Tardon, A, Tay, E, Taylor, PR, Tettey, Y, Thomas, DM, Tirabosco, R, Tjonneland, A, Tobias, GS, Toro, JR, Travis, RC, Trichopoulos, D, Troisi, R, Truelove, A, Tsai, YH, Tucker, MA, Tumino, R, Van Den Berg, D, Van Den Eeden, SK, Vermeulen, R, Vineis, P, Visvanathan, K, Vogel, U, Wang, C, Wang, C, Wang, J, Wang, SS, Weiderpass, E, Weinstein, SJ, Wentzensen, N, Wheeler, W, White, E, Wiencke, JK, Wolk, A, Wolpin, BM, Wong, MP, Wrensch, M, Wu, C, Wu, T, Wu, X, Wu, YL, Wunder, JS, Xiang, YB, Xu, J, Yang, HP, Yang, PC, Yatabe, Y, Ye, Y, Yeboah, ED, Yin, Z, Ying, C, Yu, CJ, Yu, K, Yuan, JM, Zanetti, KA, Zeleniuch-Jacquotte, A, Zheng, W, Zhou, B, Mirabello, L, Savage, SA, Kraft, P, Chanock, SJ, Yeager, M, Landi, MT, Shi, J, Chatterjee, N, & Amundadottir, LT. (2014). Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33. Hum Mol Genet, 23(24), 6616-6633. Impact factor = 6.677

PRA158. Candido-dos-Reis, FJ, Song, H, Goode, EL, Cunningham, JM, Fridley, BL, Larson, MC, Alsop, K, Dicks, E, Harrington, P, Ramus, SJ, de Fazio, A, Mitchell, G, Fereday, S, Bolton, KL, Gourley, C, Michie, C, Karlan, B, Lester, J, Walsh, C, Cass, I, Olsson, H, Gore, M, Benitez, JJ, Garcia, MJ, Andrulis, I, Mulligan, AM, Glendon, G, Blanco, I, Lazaro, C, Whittemore, AS, McGuire, V, Sieh, W, Montagna, M, Alducci, E, Sadetzki, S, Chetrit, A, Kwong, A, Kjaer, SK, Jensen, A, Hogdall, E, Neuhausen, S, Nussbaum, R, Daly, M, Greene, MH, Mai, PL, Loud, JT, Moysich, K, Toland, AE, Lambrechts, D, Ellis, S, Frost, D, Brenton, JD, Tischkowitz, M, Easton, DF, Antoniou, A, Chenevix-Trench, G, Gayther, SA, Bowtell, D, Pharoah, PD, for, E, kConFab, I, & Australian Ovarian Cancer Study, G. (2015). Germline mutation in BRCA1 or BRCA2 and ten-year survival for women diagnosed with epithelial ovarian cancer. Clin Cancer Res, 21(3), 652-657. Impact factor = 8.193.

PRA159. Lee, AW, Tyrer, JP, Doherty, JA, Stram, DA, Kupryjanczyk, J, Dansonka-Mieszkowska, A, Plisiecka-Halasa, J, Spiewankiewicz, B, Myers, EJ, Australian Cancer, S, Australian Ovarian Cancer Study, G, Chenevix-Trench, G, Fasching, PA, Beckmann, MW, Ekici, AB, Hein, A, Vergote, I, Van Nieuwenhuysen, E, Lambrechts, D, Wicklund, KG, Eilber, U, Wang-Gohrke, S, Chang-Claude, J, Rudolph, A, Sucheston-Campbell, L, Odunsi, K, Moysich, KB, Shvetsov, YB, Thompson, PJ, Goodman, MT, Wilkens, LR, Dork, T, Hillemanns, P, Durst, M, Runnebaum, IB, Bogdanova, N, Pelttari, LM, Nevanlinna, H, Leminen, A, Edwards, RP, Kelley, JL, Harter, P, Schwaab, I, Heitz, F, du Bois, A, Orsulic, S, Lester, J, Walsh, C, Karlan, BY, Hogdall, E, Kjaer, SK, Jensen, A, Vierkant, RA, Cunningham, JM, Goode, EL, Fridley, BL, Southey, MC, Giles, GG, Bruinsma, F, Wu, X, Hildebrandt, MA, Lu, K, Liang, D, Bisogna, M, Levine, DA, Weber, RP, Schildkraut, JM, Iversen, ES, Berchuck, A, Terry, KL, Cramer, DW, Tworoger, SS, Poole, EM, Olson, SH, Orlow, I, Bandera, EV, Bjorge, L, Tangen, IL, Salvesen, HB, Krakstad, C, Massuger, LF, Kiemeney, LA, Aben, KK, van Altena, AM, Bean, Y,



Pejovic, T, Kellar, M, Le, ND, Cook, LS, Kelemen, LE, Brooks-Wilson, A, Lubinski, J, Gronwald, J, Cybulski, C, Jakubowska, A, Wentzensen, N, Brinton, LA, Lissowska, J, Yang, H, Nedergaard, L, Lundvall, L, Hogdall, C, Song, H, Campbell, IG, Eccles, D, Glasspool, R, Siddiqui, N, Carty, K, Paul, J, McNeish, IA, Sieh, W, McGuire, V, Rothstein, JH, Whittemore, AS, McLaughlin, JR, Risch, HA, Phelan, CM, Anton-Culver, H, Ziogas, A, Menon, U, Ramus, SJ, Gentry-Maharaj, A, Harrington, P, Pike, MC, Modugno, F, Rossing, MA, Ness, RB, Pharoah, PD, Stram, DO, Wu, AH, & Pearce, CL. (2015). Evaluating the ovarian cancer gonadotropin hypothesis: a candidate gene study. Gynecol Oncol, 136(3), 542-548. Impact factor = 3.687

PRA160. Painter, JN, O'Mara, TA, Batra, J, Cheng, T, Lose, FA, Dennis, J, Michailidou, K, Tyrer, JP, Ahmed, S, Ferguson, K, Healey, CS, Kaufmann, S, Hillman, KM, Walpole, C, Moya, L, Pollock, P, Jones, A, Howarth, K, Martin, L, Gorman, M, Hodgson, S, National Study of Endometrial Cancer Genetics, G, Consortium, C, De Polanco, MM, Sans, M, Carracedo, A, Castellvi-Bel, S, Rojas-Martinez, A, Santos, E, Teixeira, MR, Carvajal-Carmona, L, Shu, XO, Long, J, Zheng, W, Xiang, YB, Australian National Endometrial Cancer Study, G, Montgomery, GW, Webb, PM, Scott, RJ, McEvoy, M, Attia, J, Holliday, E, Martin, NG, Nyholt, DR, Henders, AK, Fasching, PA, Hein, A, Beckmann, MW, Renner, SP, Dork, T, Hillemanns, P, Durst, M, Runnebaum, I, Lambrechts, D, Coenegrachts, L, Schrauwen, S, Amant, F, Winterhoff, B, Dowdy, SC, Goode, EL, Teoman, A, Salvesen, HB, Trovik, J, Njolstad, TS, Werner, HM, Ashton, K, Proietto, T, Otton, G, Tzortzatos, G, Mints, M, Tham, E, Rendocas, Hall, P, Czene, K, Liu, J, Li, J, Hopper, JL, Southey, MC, Australian Ovarian Cancer, S, Ekici, AB, Ruebner, M, Johnson, N, Peto, J, Burwinkel, B, Marme, F, Brenner, H, Dieffenbach, AK, Meindl, A, Brauch, H, Network, G, Lindblom, A, Depreeuw, J, Moisse, M, Chang-Claude, J, Rudolph, A, Couch, FJ, Olson, JE, Giles, GG, Bruinsma, F, Cunningham, JM, Fridley, BL, Borresen-Dale, AL, Kristensen, VN, Cox, A, Swerdlow, AJ, Orr, N, Bolla, MK, Wang, Q, Weber, RP, Chen, Z, Shah, M, French, JD, Pharoah, PD, Dunning, AM, Tomlinson, I, Easton, DF, Edwards, SL, Thompson, DJ, & Spurdle, AB. (2015). Fine-mapping of the HNF1B multicancer locus identifies candidate variants that mediate endometrial cancer risk. Hum Mol Genet, 24(5), 1478-1492. Impact factor = 6.677

PRA161. Kuchenbaecker, KB, Ramus, SJ, Tyrer, J, Lee, A, Shen, HC, Beesley, J, Lawrenson, K, McGuffog, L, Healey, S, Lee, JM, Spindler, TJ, Lin, YG, Pejovic, T, Bean, Y, Li, Q, Coetzee, S, Hazelett, D, Miron, A, Southey, M, Terry, MB, Goldgar, DE, Buys, SS, Janavicius, R, Dorfling, CM, van Rensburg, EJ, Neuhausen, SL, Ding, YC, Hansen, TV, Jonson, L, Gerdes, AM, Ejlertsen, B, Barrowdale, D, Dennis, J, Benitez, J, Osorio, A, Garcia, MJ, Komenaka, I, Weitzel, JN, Ganschow, P, Peterlongo, P, Bernard, L, Viel, A, Bonanni, B, Peissel, B, Manoukian, S, Radice, P, Papi, L, Ottini, L, Fostira, F, Konstantopoulou, I, Garber, J, Frost, D, Perkins, J, Platte, R, Ellis, S, Embrace, Godwin, AK, Schmutzler, RK, Meindl, A, Engel, C, Sutter, C, Sinilnikova, OM, Collaborators, GS, Damiola, F, Mazoyer, S, Stoppa-Lyonnet, D, Claes, K, De Leeneer, K, Kirk, J, Rodriguez, GC, Piedmonte, M, O'Malley, DM, de la Hoya, M, Caldes, T, Aittomaki, K, Nevanlinna, H, Collee, JM, Rookus, MA, Oosterwijk, JC, Breast Cancer Family, R, Tihomirova, L, Tung, N, Hamann, U, Isaccs, C, Tischkowitz, M, Imyanitov, EN, Caligo, MA, Campbell, IG, Hogervorst, FB, Hebon, Olah, E, Diez, O, Blanco, I, Brunet, J, Lazaro, C, Pujana, MA, Jakubowska, A, Gronwald, J, Lubinski, J, Sukiennicki, G, Barkardottir, RB, Plante, M, Simard, J, Soucy, P, Montagna, M, Tognazzo, S, Teixeira, MR, Investigators, KC, Pankratz, VS, Wang, X, Lindor, N, Szabo, CI, Kauff, N, Vijai, J, Aghajanian, CA, Pfeiler, G, Berger, A, Singer, CF, Tea, MK, Phelan, CM, Greene, MH, Mai, PL, Rennert, G, Mulligan, AM, Tchatchou, S, Andrulis, IL, Glendon, G, Toland, AE, Jensen, UB, Kruse, TA, Thomassen, M, Bojesen, A, Zidan, J, Friedman, E, Laitman, Y, Soller, M, Liljegren, A, Arver, B, Einbeigi, Z, Stenmark-Askmalm, M, Olopade, OI, Nussbaum, RL, Rebbeck, TR, Nathanson, KL, Domchek, SM, Lu, KH, Karlan, BY, Walsh, C, Lester, J, Australian Cancer, S, Australian Ovarian Cancer Study, G, Hein, A, Ekici, AB, Beckmann, MW, Fasching, PA, Lambrechts, D, Van Nieuwenhuysen, E, Vergote, I, Lambrechts, S, Dicks, E, Doherty, JA, Wicklund, KG, Rossing, MA, Rudolph, A, Chang-Claude, J, Wang-Gohrke, S, Eilber, U, Moysich, KB, Odunsi, K, Sucheston, L, Lele, S, Wilkens, LR, Goodman, MT, Thompson, PJ, Shvetsov, YB, Runnebaum, IB, Durst, M, Hillemanns, P, Dork, T,



Antonenkova, N, Bogdanova, N, Leminen, A, Pelttari, LM, Butzow, R, Modugno, F, Kelley, JL, Edwards, RP, Ness, RB, du Bois, A, Heitz, F, Schwaab, I, Harter, P, Matsuo, K, Hosono, S, Orsulic, S, Jensen, A, Kjaer, SK, Hogdall, E, Hasmad, HN, Azmi, MA, Teo, SH, Woo, YL, Fridley, BL, Goode, EL, Cunningham, JM, Vierkant, RA, Bruinsma, F, Giles, GG, Liang, D, Hildebrandt, MA, Wu, X, Levine, DA, Bisogna, M, Berchuck, A, Iversen, ES, Schildkraut, JM, Concannon, P, Weber, RP, Cramer, DW, Terry, KL, Poole, EM, Tworoger, SS, Bandera, EV, Orlow, I, Olson, SH, Krakstad, C, Salvesen, HB, Tangen, IL, Bjorge, L, van Altena, AM, Aben, KK, Kiemeney, LA, Massuger, LF, Kellar, M, Brooks-Wilson, A, Kelemen, LE, Cook, LS, Le, ND, Cybulski, C, Yang, H, Lissowska, J, Brinton, LA, Wentzensen, N, Hogdall, C, Lundvall, L, Nedergaard, L, Baker, H, Song, H, Eccles, D, McNeish, I, Paul, J, Carty, K, Siddiqui, N, Glasspool, R, Whittemore, AS, Rothstein, JH, McGuire, V, Sieh, W, Ji, BT, Zheng, W, Shu, XO, Gao, YT, Rosen, B, Risch, HA, McLaughlin, JR, Narod, SA, Monteiro, AN, Chen, A, Lin, HY, Permuth-Wey, J, Sellers, TA, Tsai, YY, Chen, Z, Ziogas, A, Anton-Culver, H, Gentry-Maharaj, A, Menon, U, Harrington, P, Lee, AW, Wu, AH, Pearce, CL, Coetzee, G, Pike, MC, Dansonka-Mieszkowska, A, Timorek, A, Rzepecka, IK, Kupryjanczyk, J, Freedman, M, Noushmehr, H, Easton, DF, Offit, K, Couch, FJ, Gayther, S, Pharoah, PP, Antoniou, AC, Chenevix-Trench, G, Consortium of Investigators of Modifiers of, B, & Brca. (2015). Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nat Genet, 47(2), 164-171. Impact factor = 29.648

PRA162. Carvajal-Carmona, LG, O'Mara, TA, Painter, JN, Lose, FA, Dennis, J, Michailidou, K, Tyrer, JP, Ahmed, S, Ferguson, K, Healey, CS, Pooley, K, Beesley, J, Cheng, T, Jones, A, Howarth, K, Martin, L, Gorman, M, Hodgson, S, National Study of Endometrial Cancer Genetics, G, Australian National Endometrial Cancer Study, G, Wentzensen, N, Fasching, PA, Hein, A, Beckmann, MW, Renner, SP, Dork, T, Hillemanns, P, Durst, M, Runnebaum, I, Lambrechts, D, Coenegrachts, L, Schrauwen, S, Amant, F, Winterhoff, B, Dowdy, SC, Goode, EL, Teoman, A, Salvesen, HB, Trovik, J, Njolstad, TS, Werner, HM, Scott, RJ, Ashton, K, Proietto, T, Otton, G, Wersall, O, Mints, M, Tham, E, Rendocas, Hall, P, Czene, K, Liu, J, Li, J, Hopper, JL, Southey, MC, Australian Ovarian Cancer, S, Ekici, AB, Ruebner, M, Johnson, N, Peto, J, Burwinkel, B, Marme, F, Brenner, H, Dieffenbach, AK, Meindl, A, Brauch, H, Network, G, Lindblom, A, Depreeuw, J, Moisse, M, Chang-Claude, J, Rudolph, A, Couch, FJ, Olson, JE, Giles, GG, Bruinsma, F, Cunningham, JM, Fridley, BL, Borresen-Dale, AL, Kristensen, VN, Cox, A, Swerdlow, AJ, Orr, N, Bolla, MK, Wang, Q, Weber, RP, Chen, Z, Shah, M, Pharoah, PD, Dunning, AM, Tomlinson, I, Easton, DF, Spurdle, AB, & Thompson, DJ. (2015). Candidate locus analysis of the TERT-CLPTM1L cancer risk region on chromosome 5p15 identifies multiple independent variants associated with endometrial cancer risk. Hum Genet, 134(2), 231-245. Impact factor = 4.522.

PRA163. Ovarian Cancer Association Consortium, BCAC, Consortium of Modifiers of, B, Brca, Hollestelle, A, van der Baan, FH, Berchuck, A, Johnatty, SE, Aben, KK, Agnarsson, BA, Aittomaki, K, Alducci, E, Andrulis, IL, Anton-Culver, H, Antonenkova, NN, Antoniou, AC, Apicella, C, Arndt, V, Arnold, N, Arun, BK, Arver, B, Ashworth, A, Australian Ovarian Cancer Study, G, Baglietto, L, Balleine, R, Bandera, EV, Barrowdale, D, Bean, YT, Beckmann, L, Beckmann, MW, Benitez, J, Berger, A, Berger, R, Beuselinck, B, Bisogna, M, Bjorge, L, Blomqvist, C, Bogdanova, NV, Bojesen, A, Bojesen, SE, Bolla, MK, Bonanni, B, Brand, JS, Brauch, H, Breast Cancer Family, R, Brenner, H, Brinton, L, Brooks-Wilson, A, Bruinsma, F, Brunet, J, Bruning, T, Budzilowska, A, Bunker, CH, Burwinkel, B, Butzow, R, Buys, SS, Caligo, MA, Campbell, I, Carter, J, Chang-Claude, J, Chanock, SJ, Claes, KB, Collee, JM, Cook, LS, Couch, FJ, Cox, A, Cramer, D, Cross, SS, Cunningham, JM, Cybulski, C, Czene, K, Damiola, F, Dansonka-Mieszkowska, A, Darabi, H, de la Hoya, M, deFazio, A, Dennis, J, Devilee, P, Dicks, EM, Diez, O, Doherty, JA, Domchek, SM, Dorfling, CM, Dork, T, Silva, ID, du Bois, A, Dumont, M, Dunning, AM, Duran, M, Easton, DF, Eccles, D, Edwards, RP, Ehrencrona, H, Ejlertsen, B, Ekici, AB, Ellis, SD, Embrace, Engel, C, Eriksson, M, Fasching, PA, Feliubadalo, L, Figueroa, J, Flesch-Janys, D, Fletcher, O, Fontaine, A, Fortuzzi, S, Fostira, F, Fridley, BL, Friebel, T, Friedman, E, Friel, G, Frost, D, Garber, J, Garcia-Closas, M, Gayther, SA, Collaborators, GS, Network, G, Gentry-Maharaj, A,



Gerdes, AM, Giles, GG, Glasspool, R, Glendon, G, Godwin, AK, Goodman, MT, Gore, M, Greene, MH, Grip, M, Gronwald, J, Gschwantler Kaulich, D, Guenel, P, Guzman, SR, Haeberle, L, Haiman, CA, Hall, P, Halverson, SL, Hamann, U, Hansen, TV, Harter, P, Hartikainen, JM, Healey, S, Hebon, Hein, A, Heitz, F, Henderson, BE, Herzog, J, MA, TH, Hogdall, CK, Hogdall, E, Hogervorst, FB, Hopper, JL, Humphreys, K, Huzarski, T, Imyanitov, EN, Isaacs, C, Jakubowska, A, Janavicius, R, Jaworska, K, Jensen, A, Jensen, UB, Johnson, N, Jukkola-Vuorinen, A, Kabisch, M, Karlan, BY, Kataja, V, Kauff, N, Investigators, KC, Kelemen, LE, Kerin, MJ, Kiemeney, LA, Kjaer, SK, Knight, JA, Knol-Bout, JP, Konstantopoulou, I, Kosma, VM, Krakstad, C, Kristensen, V, Kuchenbaecker, KB, Kupryjanczyk, J, Laitman, Y, Lambrechts, D, Lambrechts, S, Larson, MC, Lasa, A, Laurent-Puig, P, Lazaro, C, Le, ND, Le Marchand, L, Leminen, A, Lester, J, Levine, DA, Li, J, Liang, D, Lindblom, A, Lindor, N, Lissowska, J, Long, J, Lu, KH, Lubinski, J, Lundvall, L, Lurie, G, Mai, PL, Mannermaa, A, Margolin, S, Mariette, F, Marme, F, Martens, JW, Massuger, LF, Maugard, C, Mazoyer, S, McGuffog, L, McGuire, V, McLean, C, McNeish, I, Meindl, A, Menegaux, F, Menendez, P, Menkiszak, J, Menon, U, Mensenkamp, AR, Miller, N, Milne, RL, Modugno, F, Montagna, M, Moysich, KB, Muller, H, Mulligan, AM, Muranen, TA, Narod, SA, Nathanson, KL, Ness, RB, Neuhausen, SL, Nevanlinna, H, Neven, P, Nielsen, FC, Nielsen, SF, Nordestgaard, BG, Nussbaum, RL, Odunsi, K, Offit, K, Olah, E, Olopade, OI, Olson, JE, Olson, SH, Oosterwijk, JC, Orlow, I, Orr, N, Orsulic, S, Osorio, A, Ottini, L, Paul, J, Pearce, CL, Pedersen, IS, Peissel, B, Pejovic, T, Pelttari, LM, Perkins, J, Permuth-Wey, J, Peterlongo, P, Peto, J, Phelan, CM, Phillips, KA, Piedmonte, M, Pike, MC, Platte, R, Plisiecka-Halasa, J, Poole, EM, Poppe, B, Pylkas, K, Radice, P, Ramus, SJ, Rebbeck, TR, Reed, MW, Rennert, G, Risch, HA, Robson, M, Rodriguez, GC, Romero, A, Rossing, MA, Rothstein, JH, Rudolph, A, Runnebaum, I, Salani, R, Salvesen, HB, Sawyer, EJ, Schildkraut, JM, Schmidt, MK, Schmutzler, RK, Schneeweiss, A, Schoemaker, MJ, Schrauder, MG, Schumacher, F, Schwaab, I, Scuvera, G, Sellers, TA, Severi, G, Seynaeve, CM, Shah, M, Shrubsole, M, Siddiqui, N, Sieh, W, Simard, J, Singer, CF, Sinilnikova, OM, Smeets, D, Sohn, C, Soller, M, Song, H, Soucy, P, Southey, MC, Stegmaier, C, Stoppa-Lyonnet, D, Sucheston, L, Swe, B, Swerdlow, A, Tangen, IL, Tea, MK, Teixeira, MR, Terry, KL, Terry, MB, Thomassen, M, Thompson, PJ, Tihomirova, L, Tischkowitz, M, Toland, AE, Tollenaar, RA, Tomlinson, I, Torres, D, Truong, T, Tsimiklis, H, Tung, N, Tworoger, SS, Tyrer, JP, Vachon, CM, Van 't Veer, LJ, van Altena, AM, Van Asperen, CJ, van den Berg, D, van den Ouweland, AM, van Doorn, HC, Van Nieuwenhuysen, E, van Rensburg, EJ, Vergote, I, Verhoef, S, Vierkant, RA, Vijai, J, Vitonis, AF, von Wachenfeldt, A, Walsh, C, Wang, Q, Wang-Gohrke, S, Wappenschmidt, B, Weischer, M, Weitzel, JN, Weltens, C, Wentzensen, N, Whittemore, AS, Wilkens, LR, Winqvist, R, Wu, AH, Wu, X, Yang, HP, Zaffaroni, D, Pilar Zamora, M, Zheng, W, Ziogas, A, Chenevix-Trench, G, Pharoah, PD, Rookus, MA, Hooning, MJ, & Goode, EL. (2015). No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecol Oncol. Impact factor = 3.687

PRA164. Nagle, CM, Dixon, SC, Jensen, A, Kjaer, SK, Modugno, F, deFazio, A, Fereday, S, Hung, J, Johnatty, SE, Australian Ovarian Cancer Study, G, Fasching, PA, Beckmann, MW, Lambrechts, D, Vergote, I, Van Nieuwenhuysen, E, Lambrechts, S, Risch, HA, Rossing, MA, Doherty, JA, Wicklund, KG, Chang-Claude, J, Goodman, MT, Ness, RB, Moysich, K, Heitz, F, du Bois, A, Harter, P, Schwaab, I, Matsuo, K, Hosono, S, Goode, EL, Vierkant, RA, Larson, MC, Fridley, BL, Hogdall, C, Schildkraut, JM, Weber, RP, Cramer, DW, Terry, KL, Bandera, EV, Paddock, L, Rodriguez-Rodriguez, L, Wentzensen, N, Yang, HP, Brinton, LA, Lissowska, J, Hogdall, E, Lundvall, L, Whittemore, A, McGuire, V, Sieh, W, Rothstein, J, Sutphen, R, Anton-Culver, H, Ziogas, A, Pearce, CL, Wu, AH, & Webb, PM. (2015). Obesity and survival among women with ovarian cancer: results from the Ovarian Cancer Association Consortium. Br J Cancer.

PRA165. Johnatty, S, Tyrer, JP, Kar, SP, Beesley, J, Lu, Y, Gao, B, Fasching, PA, Hein, A, Ekici, AB, Beckmann, MW, Lambrechts, D, Van Nieuwenhuysen, E, Vergote, I, Lambrechts, S, Rossing, MA, Doherty, JA, Chang-Claude, J, Modugno, F, Ness, RB, Moysich, KB, Levine, DA, Kiemeney, LA, Massuger, L, Gronwald, J, Lubinski, J, Brinton, LA, Lissowska, J, Wentzensen, N, Song, H, Rhenius, V, Campbell, I, Eccles, D, Sieh, W, Whittemore,



AS, McGuire, V, Rothstein, JH, Sutphen, R, Anton-Culver, H, Ziogas, A, Gayther, SA, Gentry-Maharaj, A, Menon, U, Ramus, SJ, Pearce, CL, Pike, MC, Stram, D, Wu, AH, Kupryjanczyk, J, Dansonka-Mieszkowska, A, Rzepecka, IK, Spiewankiewicz, B, Goodman, MT, Wilkens, LR, Carney, ME, Thompson, PJ, Heitz, F, du Bois, A, Schwaab, I, Harter, P, Pisterer, J, Hillemanns, P, Karlan, BY, Walsh, C, Lester, J, Orsulic, S, Winham, SJ, Earp, M, Larson, MC, Fogarty, Z, Hogdall, E, Jensen, A, Kruger Kjaer, S, Fridley, BL, Cunningham, J, Vierkant, RA, Schildkraut, JM, Iversen, E, Terry, KL, Cramer, D, Bandera, E, Orlow, I, Pejovic, T, Bean, YT, Hogdall, C, Lundvall, L, McNeish, IA, Paul, J, Carty, K, Siddiqui, N, Glasspool, R, Sellers, TA, Kennedy, C, Chiew, YE, Berchuck, A, Macgregor, S, Pharoah, P, Goode, EL, deFazio, A, Webb, P, & Chenevix-Trench, G. (2015). Genome-wide analysis identifies novel loci associated with ovarian cancer outcomes: findings from the Ovarian Cancer Association Consortium. Clin Cancer Res.

PRA166. Chornokur, G, Lin, HY, Tyrer, JP, Lawrenson, K, Dennis, J, Amankwah, EK, Qu, X, Tsai, YY, Jim, HS, Chen, Z, Chen, AY, Permuth-Wey, J, Aben, K, Anton-Culver, H, Antonenkova, N, Bruinsma, F, Bandera, EV, Bean, YT, Beckmann, MW, Bisogna, M, Bjorge, L, Bogdanova, N, Brinton, LA, Brooks-Wilson, A, Bunker, CH, Butzow, R, Campbell, IG, Carty, K, Chang-Claude, J, Cook, LS, Cramer, DW, Cunningham, JM, Cybulski, C, Dansonka-Mieszkowska, A, du Bois, A, Despierre, E, Dicks, E, Doherty, JA, Dork, T, Durst, M, Easton, DF, Eccles, DM, Edwards, RP, Ekici, AB, Fasching, PA, Fridley, BL, Gao, YT, Gentry-Maharaj, A, Giles, GG, Glasspool, R, Goodman, MT, Gronwald, J, Harrington, P, Harter, P, Hein, A, Heitz, F, Hildebrandt, MA, Hillemanns, P, Hogdall, CK, Hogdall, E, Hosono, S, Jakubowska, A, Jensen, A, Ji, BT, Karlan, BY, Kelemen, LE, Kellar, M, Kiemeney, LA, Krakstad, C, Kjaer, SK, Kupryjanczyk, J, Lambrechts, D, Lambrechts, S, Le, ND, Lee, AW, Lele, S, Leminen, A, Lester, J, Levine, DA, Liang, D, Lim, BK, Lissowska, J, Lu, K, Lubinski, J, Lundvall, L, Massuger, LF, Matsuo, K, McGuire, V, McLaughlin, JR, McNeish, I, Menon, U, Milne, RL, Modugno, F, Moysich, KB, Ness, RB, Nevanlinna, H, Eilber, U, Odunsi, K, Olson, SH, Orlow, I, Orsulic, S, Weber, RP, Paul, J, Pearce, CL, Pejovic, T, Pelttari, LM, Pike, MC, Poole, EM, Risch, HA, Rosen, B, Rossing, MA, Rothstein, JH, Rudolph, A, Runnebaum, IB, Rzepecka, IK, Salvesen, HB, Schernhammer, E, Schwaab, I, Shu, XO, Shvetsov, YB, Siddiqui, N, Sieh, W, Song, H, Southey, MC, Spiewankiewicz, B, Sucheston, L, Teo, SH, Terry, KL, Thompson, PJ, Thomsen, L, Tangen, IL, Tworoger, SS, van Altena, AM, Vierkant, RA, Vergote, I, Walsh, CS, Wang-Gohrke, S, Wentzensen, N, Whittemore, AS, Wicklund, KG, Wilkens, LR, Wu, AH, Wu, X, Woo, YL, Yang, H, Zheng, W, Ziogas, A, Hasmad, HN, Berchuck, A, Georgia Chenevix-Trench on behalf of the, Amg, Iversen, ES, Schildkraut, JM, Ramus, SJ, Goode, EL, Monteiro, AN, Gayther, SA, Narod, SA, Pharoah, PD, Sellers, TA, & Phelan, CM. (2015). Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk. PLoS One, 10(6), e0128106.

PRA167. Chauhan, L, Jenkins, GD, Bhise, N, Feldberg, T, Mitra-Ghosh, T, Fridley, BL, & Lamba, JK. (2015). Genome-wide association analysis identified splicing single nucleotide polymorphism in CFLAR predictive of triptolide chemo-sensitivity. BMC Genomics, 16, 483.

PRA168. Lu, Y, Cuellar, G, Painter, JN, Nyholt, D, Australian Ovarian Cancer, S, International Endogene, C, Morris, AP, Fasching, PA, Hein, A, Burghaus, S, Beckmann, MW, Lambrechts, D, Van Nieuwenhuysen, E, Vergote, I, Vanderstichele, A, Doherty, JA, Rossing, MA, Wicklund, KG, Chang-Claude, J, Eilber, U, Rudolph, A, Wang-Gohrke, S, Goodman, MT, Bogdanova, N, Dork, T, Durst, M, Hillemanns, P, Runnebaum, IB, Antonenkova, N, Butzow, R, Leminen, A, Nevanlinna, H, Pelttari, LM, Edwards, RP, Kelley, JL, Modugno, F, Moysich, KB, Ness, RB, Cannioto, R, Hogdall, E, Jensen, A, Giles, GG, Bruinsma, F, Kjaer, SK, Hildebrandt, MA, Liang, D, Lu, KH, Wu, X, Bisogna, M, Dao, F, Levine, DA, Cramer, DW, Terry, KL, Tworoger, SS, Missmer, S, Bjorge, L, Salvesen, HB, Kopperud, RK, Bischof, K, Aben, KK, Kiemeney, LA, Massuger, LF, Brooks-Wilson, A, Olson, SH, McGuire, V, Rothstein, JH, Sieh, W, Whittemore, AS, Cook, LS, Le, ND, Gilks, CB, Gronwald, J, Jakubowska, A, Lubinski, J, Gawelko, J, Song, H, Tyrer, JP, Wentzensen, N, Brinton, L, Trabert, B, Lissowska, J, McLaughlin, JR, Narod, SA, Phelan, C, Anton-Culver, H, Ziogas, A, Eccles, D, Gayther, SA, Gentry-Maharaj, A, Menon, U, Ramus, SJ, Wu, AH, Dansonka-Mieszkowska, A, Kupryjanczyk, J, Timorek, A,



Szafron, L, Cunningham, JM, Fridley, BL, Winham, SJ, Bandera, EV, Poole, EM, Morgan, TK, Risch, HA, Goode, EL, Schildkraut, JM, Webb, PM, Pearce, CL, Berchuck, A, Pharoah, PD, Montgomery, GW, Zondervan, KT, Chenevix-Trench, G, & Macgregor, S. (2015). Shared genetics underlying epidemiological association between endometriosis and ovarian cancer. Hum Mol Genet.

PRA169. Kar, SP, Tyrer, JP, Li, Q, Lawrenson, K, Aben, KK, Anton-Culver, H, Antonenkova, N, Chenevix-Trench, G, Baker, H, Bandera, E, Bean, YT, Beckmann, MW, Berchuck, A, Bisogna, M, Bjorge, L, Bogdanova, N, Brinton, LA, Brooks-Wilson, A, Butzow, R, Campbell, I, Carty, K, Chang-Claude, J, Chen, YA, Chen, Z, Cook, LS, Cramer, D, Cunningham, J, Cybulski, C, Dansonka-Mieszkowska, A, Dennis, J, Dicks, E, Doherty, JA, Dork, T, du Bois, A, Durst, M, Eccles, D, Easton, DF, Edwards, RP, Ekici, AB, Fasching, PA, Fridley, BL, Gao, YT, Gentry-Maharaj, A, Giles, GG, Glasspool, R, Goode, EL, Goodman, MT, Grownwald, J, Harrington, P, Harter, P, Hein, A, Heitz, F, Hildebrandt, MA, Hillemanns, P, Hogdall, E, Hogdall, CK, Hosono, S, Iversen, ES, Jakubowska, A, Paul, J, Jensen, A, Ji, BT, Karlan, BY, Kjaer, SK, Kelemen, LE, Kellar, M, Kelley, J, Kiemeney, LA, Krakstad, C, Kupryjanczyk, J, Lambrechts, D, Lambrechts, S, Le, ND, Lee, AW, Lele, S, Leminen, A, Lester, J, Levine, DA, Liang, D, Lissowska, J, Lu, K, Lubinski, J, Lundvall, L, Massuger, L, Matsuo, K, McGuire, V, McLaughlin, JR, McNeish, IA, Menon, U, Modugno, F, Moysich, KB, Narod, SA, Nedergaard, L, Ness, RB, Nevanlinna, H, Odunsi, K, Olson, SH, Orlow, I, Orsulic, S, Weber, RP, Pearce, CL, Pejovic, T, Pelttari, LM, Permuth-Wey, J, Phelan, CM, Pike, MC, Poole, EM, Ramus, SJ, Risch, HA, Rosen, B, Rossing, MA, Rothstein, JH, Rudolph, A, Runnebaum, IB, Rzepecka, IK, Salvesen, HB, Schildkraut, JM, Schwaab, I, Shu, XO, Shvetsov, YB, Siddiqui, N, Sieh, W, Song, H, Southey, MC, Sucheston-Campbell, LE, Tangen, IL, Teo, SH, Terry, KL, Thompson, PJ, Timorek, A, Tsai, YY, Tworoger, SS, van Altena, AM, Nieuwenhuysen, EV, Vergote, I, Vierkant, RA, Wang-Gohrke, S, Walsh, C, Wentzensen, N, Whittemore, AS, Wicklund, KG, Wilkens, LR, Woo, YL, Wu, X, Wu, A, Yang, H, Zheng, W, Ziogas, A, Sellers, TA, Monteiro, AN, Freedman, ML, Gayther, SA, & Pharoah, PD. (2015). Network-based integration of GWAS and gene expression identifies a HOX-centric network associated with serous ovarian cancer risk. Cancer Epidemiol Biomarkers Prev.

MANUSCRIPTS UNDER REVIEW OR IN PROCESS OF SUBMISSION:

PRA170. Wang, Winterhoff, Kalli, Block, Armasu, Larson, Chen, Visscher, Keeney, Hartmann, Shridhar, Konecny, Goode, and Fridley. “Expression signature distinguishing two tumor transcriptome classes associated with progression free survival among rare histological types of epithelial ovarian cancer", (2015), submitted to JNCI.

PRA171. Fridley, Ghosh, Wang, Raghavan, Goode, and Lamba. “In vitro pharmacogenomic study of ovarian cancer finds novel genetic variants associated with response to platinum and taxane therapies.” (2015), submitted and under review at The Journal of Pharmacogenomics.

PRA172. Chalise, Raghavan, and Fridley. “InterSIM: Simulation of Multiple Integrative ‘Omic Datasets” (2015), submitted and under review at Bioinformatics.

PRA173. Raghavan, Hyter, Chien, Konecny, Wang, Goode, Pathak, and Fridley. “A bioinformatics approach to drug discovery in epithelial ovarian cancer: patient based connectivity mapping” (2015). To be submitted to Drug Discovery Today.

PRA174. Usset and Fridley on behalf of the Ovarian Cancer Association Consortium (OCAC). “Assessment of multifactor gene-environment interactions and ovarian cancer risk: SNPs, obesity, and hormone-related risk factors” (2015). To be submitted to Cancer Epidemiology, Biomarkers and Prevention (CEBP).



EDITORIALS:

ED1. Fridley BL, Koeslter DC, & Godwin AK. (2014). Individualizing Care for Ovarian Cancer Patients Using Big data. J Natl Cancer Inst. Invited Editorial. Impact factor = 14.336

BOOKS OR BOOK CHAPTERS:

BC1. Goode EL, Cicek MS, Phelan CM, Fridley BL. Genetic etiology of sporadic ovarian cancer. In: Deligdisch L, Kase NG, Cohen CJ, editors. Altchek's Diagnosis and Management of Ovarian Disorders. 3rd ed: Cambridge University Press; 2013.

BC2. Biernacka JM, Usset J, Fridley BL, Winham SJ. Study Design and Analysis Considerations in Genome-wide Studies of Gene-Environment Interactions. In: Qi L, editor. Gene-Environment Interactions and its Role in Human Health and Disease. Nova Science Publishers, Inc; In Press.

3. Other evidence of scholarship:

Year Scholarly Activity 2013-2015 Member, The Cancer Genome Atlas (TCGA) Cervical Analysis Working Group 2010-2015 Expert Consultant, PGRN Statistical Analysis Resource

2012-2015 Statistical Lead, Ovarian Genetic Epidemiology Research Group (PI: Ellen Goode), Mayo Clinic, Rochester, MN (10% FTE)

2013-2015 KUCC Ovarian Cancer Research Group

2015 Prostate Cancer DREAM Challenge; All-Stars for rounds 1, 2 & 3. Co-winners for Challenge #1B and #2. (https://www.synapse.org/#!Synapse:syn2813558/wiki/70844)

2015 DREAM ALS Stratification Prize4Life Challenge https://www.synapse.org/#!Synapse:syn2873386/wiki/)

2015 NCI Up for a Challenge (U4C): Stimulating Innovation in Breast Cancer Genetic Epidemiology (https://www.synapse.org/#!Synapse:syn3157598/wiki/232604)

2015 Beta-user for IBM’s Watson Genomics software

4. Presentations:

Below are my scientific presentations that I have presented (first author) at meetings. Following these presentations are presentations by research fellows, students and staff that I have mentored where I was the senior author.

INVITED OR PLATFORM SELECTED PRESENTATIONS AT NATIONAL AND INTERNATIONAL MEETINGS:

Title Conference/ Meeting Year

Pharmacogenetics: Past, Present, and Future Educational Workshop – Pharmacogenomics: When Drug Response Gets Personal; International Genetic Epidemiology Society Annual Meeting, Vienna Austria

2014

Pharmacogenomics: Statistical Challenges and Opportunities on the Journey to Personalized Medicine: Statistical Analysis of Methylation Array Data

Joint Statistical Meeting (JSM), Montreal, Canada. 2013


https://www.synapse.org/%23!Synapse:syn2813558/wiki/70844

https://www.synapse.org/%23!Synapse:syn2873386/wiki/

https://www.synapse.org/%23!Synapse:syn3157598/wiki/232604


Title Conference/ Meeting Year Invited educational session GWAS: The Next Steps: Analytical approaches to uncovering new loci

American Association for Cancer Research, Washington, D.C. 2013

Pharmacogenomics and Drug Interactions: Statistical Challenges and Opportunities on the Journey to Personalized Medicine: Integrative analysis approaches for cancer pharmacogenomics.

International Biometric Society Eastern North American Region Annual Meeting, Orlando 2013

Integrative approaches for understanding the functional relevance of cancer susceptibility loci

AACR Conference: Post-GWAS Horizons in Molecular Epidemiology: Digging Deeper into the Environment, Hollywood, FL.

2012

Lessons learned from analysis of DNA methylation array data

International Genetic Epidemiology Society Annual Meeting, Oregon 2012

Pharmacogenomics in the post-GWAS era: study design and analysis approaches for the next generation of pharmacogenomics

XXth World Congress on Psychiatric Genetics, Hamburg, Germany 2012

Association Testing in Sequencing Studies: A Novel Framework

Statistical Challenges and Biomedical Applications of Deep Sequencing Data, Ascona, Switzerland

2011

Analysis of Pharmacogenomics Studies: Past, Present, Future

Annual Meeting of the Statistical Society of Canada, Nova Scotia 2011

Gene-set analysis: Finding the pathways contributing to complex psychiatric traits

XVIIIth World Congress on Psychiatric Genetics, Athens, Greece 2010

INVITED PRESENTATIONS AT REGIONAL AND CLOSED MEETINGS OR CONTRIBUTED PRESENTATIONS:

Title Conference/Meeting Year

Bioinformatics in Biomedical Research and Precision Medicine

University of Missouri’s Biomedical Innovator's Group (BIG) Seminar and Annual Informatics Institute Symposium

2015

Pharmacogenomics and Precision Medicine: Past, Present, and Future

Kansas – INBRE Annual Research Symposium 2015

Analysis of DNA Methylation Array Data P-Star Analysis Workshop (PGRN Statistical Analysis Resource). 2013

Integrative analysis approaches for cancer genomics and pharmacogenomics

Kansas – Western Missouri Chapter of the ASA: "Innovations in Design, Analysis, and Dissemination: Frontiers in Biostatistical Methods"

2013

Gene set analysis for genome-wide pharmacogenomic studies

Pharmacogenomics Research Network (PGRN): RIKEN Center for Genomic Medicine Strategic Alliance Meeting (NIH)

2011

Integrative Analysis of Genetic and mRNA Expression Variation in the Context of Gene Sets: Application to Platinum Pharmacogenomics

PGRN Analysis Workshop 2011

Pharmacogenomics at Mayo Clinic Iowa-ASA Chapter Meeting 2011



Title Conference/Meeting Year Bioinformatics in Biomedical Research and Precision Medicine

University of Missouri’s Biomedical Innovator's Group (BIG) Seminar and Annual Informatics Institute Symposium

2015

Pharmacogenomics and Precision Medicine: Past, Present, and Future

Kansas – INBRE Annual Research Symposium 2015

Analysis of DNA Methylation Array Data P-Star Analysis Workshop (PGRN Statistical Analysis Resource). 2013

Integrative analysis approaches for cancer genomics and pharmacogenomics

Kansas – Western Missouri Chapter of the ASA: "Innovations in Design, Analysis, and Dissemination: Frontiers in Biostatistical Methods"

2013

Gene set analysis for genome-wide pharmacogenomic studies

Pharmacogenomics Research Network (PGRN): RIKEN Center for Genomic Medicine Strategic Alliance Meeting (NIH)

2011

Integrative Analysis of Genetic and mRNA Expression Variation in the Context of Gene Sets: Application to Platinum Pharmacogenomics


Pharmacogenomics at Mayo Clinic Iowa-ASA Chapter Meeting 2011 Bayesian Path Analysis with Variable Selection for Integration of Multiple Genomic Data Types


Analysis issues related to NextGen DNA sequence data

NIH GARNET Steering Committee Meeting 2010

Investigation of NAPQI - Acetaminophen toxicity utilizing a genome-wide bench to bedside approach


Incorporation of prior knowledge from linkage studies into genetic association studies

International Biometric Society Eastern North American Region Annual Meeting

2009

Bayesian Hierarchical Nonlinear Models for the Analysis Pharmacogenomic Cytotoxicity Studies

Conference on Statistics in Biology; Iowa State University 2008

Repeated Measures Haplotype Analysis PGRN Analysis Workshop 2006 Data Augmentation for the Handling of Censored Spatial Data


2003

Diagnostics Tools in Linkage Analysis for Quantitative Traits


2002

UNIVERSITY (INVITED) SEMINARS:

Title Institution Year

TBD Department of Biostatistics, University of Kentucky Fall 2015

Statistics and Bioinformatics in Biomedical Genomics Research

Department of Health Sciences Research Seminar, Mayo Clinic, Jacksonville, FL

2015



Title Institution Year A Bioinformatics Approach to Drug Discovery: Patient based Connectivity Mapping

Department of Health Sciences Research Seminar, Mayo Clinic, Rochester MN

2015

Population Genetics and Genetic Association Studies for Drug Response Phenotypes

Pediatrics Clinical Pharmacology Seminar, Children’s Mercy Hospital, Kansas City MO

2015

Statistical Analysis of Genome-wide DNA Methylation Array Data with Application to Ovarian Cancer

Biostatistics Seminar, St. Jude, Memphis TN 2013

Genomic Clustering and Signature Development KUCC seminar series 2013 RNA-seq study design and analysis KUMC Kidney Institute seminar series 2013 Statistical Genomics and Bioinformatics in Medical Genomics Research

KUMC Physiology seminar series 2013

Ovarian Cancer Treatment and The University of Minnesota - Mayo Pharmacogenomics Partnership

GYN Seminar Series, Division of Medical Oncology, Mayo Clinic. 2011

Bayesian Methods for Genetic Association Studies Department of Epidemiology, University of Minnesota 2009

Methods, application and limitations of genotype imputation

Genomic Interest Group, Mayo Clinic 2009

Genotype Imputation for Genetic Association Studies

Health Sciences Research Grand Rounds, Mayo Clinic 2009

Analysis of Pharmacogenomic-Cytotoxicity Studies Based on a Cell Line Model System

Institute of Human Genetics, University of Minnesota 2008

POSTER PRESENTATIONS AT REGIONAL, NATIONAL AND INTERNATIONAL MEETINGS:


Clinical outcomes based connectivity mapping for drug discovery with application to ovarian cancer

Translating Cancer Epidemiology: From Cells to Clinic and Population, Huntsman Cancer Institute.

2015

A hierarchical model for differential isoform analysis with application to ovarian cancer

International Genetic Epidemiology Society Annual Meeting 2015

A Bioinformatics Approach to Drug Discovery: Patient based Connectivity Mapping

American Association for Cancer Research Annual Meeting, Philadelphia 2015

Pharmacogenetic study of delayed hyperbilirubinemia in a cohort of 4,000 infants

International Society of Clinical Biostatistics Annual Meeting, Vienna 2014

In vitro pharmacogenomic study of ovarian cancer finds novel genetic variants associated with response to platinum and taxane therapies.

American Association for Cancer Research Annual Meeting, San Diego 2014

Methylation of Leukocyte DNA and Ovarian Cancer: Relationship with Disease Status and Outcome

American Society of Human Genetics Annual Meeting 2013

Integrative Analysis Approaches For the Study of Cancer Pharmacogenomics

K-INBRE annual research symposium 2013

The Gamma Method for gene set analysis of RNA-Seq data: Simulation results and application to a smallpox vaccine study




Title Conference/Meeting Year A Bayesian Latent Model for Prioritization of SNPs for Follow-up Studies


2011

Insights into survival from ovarian cancer revealed by gene set analysis

American Association for Cancer Research Annual Meeting 2011

Integrative analytical approaches for genome-wide pharmacogenomic studies: Application to gemcitabine chemotherapy

Pacific Symposium on Biocomputing 2011

Pooled analysis of GWA studies for survival from clear cell ovarian cancer reveals association at RASGRF2, ANKS1B and KSR2

The International Congress of Human Genetics and the American Society of Human Genetics Annual Meeting

2011

Prioritizing SNPs for Functional Studies using a Bayesian Latent Variable Model


Incorporation of prior knowledge into genetic association studies using Bayesian mixture models

American Association for Cancer Research Annual Meeting *Highly Rated Paper Award

2009

Comparison of self-contained gene set methods for gene expression studies


Comparison of self-contained gene set methods for gene expression studies


Multivariate Models to Detect Genomic Signatures for a Class of Drugs


2008

Combining Linkage Results for Cohorts Genotyped on Different SNP Panels


Analysis of Cytotoxicity Dose-Response Curves for Pharmacogenomic Studies Using Bayesian Hierarchical Nonlinear Models

Conference on Emerging Design and Analysis Issues in Genomic Studies in Population Sciences, Harvard School of Public Health

2007

A comparison of Approaches for Identifying Gene-Gene Interactions in a Study of Genetic and Clinical Predictors of Severe Alcohol Withdrawal


Application of Bayesian Variable Selection Incorporating Linkage Disequilibrium for Genetic Association Studies


2007

Bayesian Hierarchical Nonlinear Models for Analysis of Pharmacogenomic Cytotoxicity Data


Data Augmentation for a Conditionally Specified Gaussian Spatial Model with Censored Observations

Joint Statistical Meetings 2006

Missing Phenotype Data Imputation for Longitudinal Pedigree Analysis


2006

Reproducibility of Genotype Data Using the Affymetrix GeneChip® 100K Human Mapping Array Set


Missing Phenotype Data Imputation in Pedigree Analysis


Missing Phenotype Data Imputation in Pedigree Analysis




Title Conference/Meeting Year Robustness of Data Augmentation for the Analysis of Censored Spatial Data

Joint Statistical Meetings 2005

TALKS AND POSTER PRESENTATIONS BY STUDENTS, POST-DOCTORAL FELLOWS, OR STAFF/LAB MEMBERS AT REGOINAL, NATIONAL, AND INTERNATIONAL MEETINGS WHERE I WAS SENIOR AUTHOR:


Assessment of multifactor gene-environment interactions and ovarian cancer risk: SNPs, obesity, and hormone-related risk factors Presenter: Joseph Usset, PhD

American Association of Cancer Research Annual Meeting; *Selected Platform Presentation 2015

Sequence based gene expression signatures and ovarian cancer histological subtypes Presenter: Junqiang (Eric) Dai, MS Student

Department of Biostatistics Seminar, University of Kansas Medical Center 2015

Assessment of multifactor gene-environment interactions and ovarian cancer risk: SNPs, obesity, and hormone-related risk factors Presenter: Joseph Usset, PhD

Department of Biostatistics Seminar, University of Kansas Medical Center 2015

Recurrent fusion detected involving EEF1DP3 and FRY genes in ovarian cancer Presenter: Rama Raghavan, MS


Sequence based gene expression signatures and ovarian cancer histological subtypes Presenter: Junqiang (Eric) Dai, MS Student

University of Kansas Cancer Center Annual Research Symposium 2014

Standardizing eCRFs and IIT Processes Presenter: Shana Palla

University of Kansas Cancer Center Annual Research Symposium 2014

Correlation of SNPs with Fine Needle Aspiration Cytology and HRT in Postmenopausal Women at High Risk for Breast Cancer. Presenter: Whitney Michaels (MD/PhD Student)

Association for Clinical and Translational (ACTS) Sciences meeting 2014

Opportunity to improve hospital resource allocation: Using the MAX model to reduce 30-day readmission risk Presenter: Maria Iliakova, MS (MD student)

KUMC Student Research Forum (SRF) & American Medical Women’s Association * SRF award winner

2014

Globus Genomics: A Medical Center’s Bioinformatics Core Perspective Presenter: Rama Raghavan, MS

Globus World 2014 Meeting 2014

Power and Sample Sizes for RNA-Seq Studies: Comparison of Proposed Methods Presenter: Milan Bimali (PhD student)


Integrative Connectivity Analysis: Application to Ovarian Cancer Therapies Presenter: Rama Raghavan, MS


Comparison of transcriptome analysis methods for paired tumor-normal RNA-seq data Presenter: Janelle Noel (PhD student)

K-INBRE annual research symposium. 2014

Landscape of Structural Variation in Cancer Presenter: Alice Wang, MS

K-INBRE annual research symposium. 2014



Title Conference/Meeting Year Kernel Canonical Correlation Analysis for Assessing Gene-Gene Interactions Presenter: Nicholas Larson, PhD

International Genetic Epidemiology Society Annual Meeting *Winner of the James V. Neel Young Investigator Award

2012

Bayes-MutSig: A novel approach to determine significantly mutated genes Presenter: Nicholas Larson, PhD


Integrative Methods for Genome-wide Pharmacogenomics Studies with Application to Gemcitabine Therapy Presenter: Prabhakar Chalise, PhD

Statistical, Computational and Visualization methods in Medical Informatics Conference, Clarke University

2011

Association testing in sequencing studies: Accommodating risk and protective variants Presenter: Abra Brisbin, PhD


2011

Identifying the genetic variation of gene expression using gene sets: application towards PharmGKB Gene Sets Presenter: Ryan Abo, PhD


2011

Utilizing gene pathway-based priors in Bayesian association studies Presenter: Abra Brisbin, PhD

Joint Mathematics Meetings 2011

Genetics of gene expression using gene sets Presenter: Ryan Abo, PhD

P-Star Analysis Workshop 2011

Models for incorporating gene pathway priors in Bayesian gene expression association Presenter: Abra Brisbin, PhD


2011

Comparison of Performances of Penalty Functions with Sparse Canonical Correlation Analysis Presenter: Prabhakar Chalise, PhD


2011

Association Testing In Sequencing Studies: Accommodating Risk And Protective Variants Presenter: Abra Brisbin, PhD


Identifying the genetic variation of gene expression using gene sets: application towards PharmGKB Gene Sets Presenter: Ryan Abo, PhD


Sliding-window based testing of rare variant associations Presenter: Abra Brisbin, PhD

The International Congress of Human Genetics and the American Society of Human Genetics Annual Meeting

2011

Comparisons of Integrative Methods for Genomic Data using Sparse Canonical Correlation Analysis Presenter: Prabhakar Chalise, PhD


LD based tagSNP selection using multiple data sources: HapMap, 1000 Genomes Project and Coriell Cell Lines Presenter: Ryan Abo, PhD

P-Star Analysis Workshop

2010


curriculum vitae: brooke l. fridley page | 1 · curriculum vitae: brooke l. fridley page | 1 . ......

Documents